{"PMC7270736": [["In recent decades, many emerging infectious diseases have been occurring at an increasing scale and frequency\u2014i.e. Ebola virus disease, severe acute respiratory syndrome (SARS), avian and pandemic influenza, Middle-East respiratory syndrome (MERS), and the recently emerged coronavirus disease 2019 (COVID-19).", [["infectious diseases", "DISEASE", 33, 52], ["Ebola virus disease", "DISEASE", 115, 134], ["acute respiratory syndrome", "DISEASE", 143, 169], ["SARS", "DISEASE", 171, 175], ["avian and pandemic influenza", "DISEASE", 178, 206], ["Middle-East respiratory syndrome", "DISEASE", 208, 240], ["MERS", "DISEASE", 242, 246], ["coronavirus disease", "DISEASE", 274, 293], ["Ebola virus", "ORGANISM", 115, 126], ["Ebola virus", "SPECIES", 115, 126], ["avian", "SPECIES", 178, 183], ["pandemic influenza", "SPECIES", 188, 206], ["Ebola virus", "SPECIES", 115, 126], ["Middle-East respiratory syndrome (MERS)", "SPECIES", 208, 247], ["many emerging infectious diseases", "PROBLEM", 19, 52], ["an increasing scale", "TREATMENT", 76, 95], ["Ebola virus disease", "PROBLEM", 115, 134], ["severe acute respiratory syndrome", "PROBLEM", 136, 169], ["SARS)", "PROBLEM", 171, 176], ["avian and pandemic influenza", "PROBLEM", 178, 206], ["Middle-East respiratory syndrome", "PROBLEM", 208, 240], ["the recently emerged coronavirus disease", "PROBLEM", 253, 293], ["COVID", "TEST", 300, 305], ["many", "OBSERVATION_MODIFIER", 19, 23], ["emerging", "OBSERVATION_MODIFIER", 24, 32], ["infectious", "OBSERVATION", 33, 43], ["severe", "OBSERVATION_MODIFIER", 136, 142], ["acute", "OBSERVATION_MODIFIER", 143, 148], ["respiratory syndrome", "OBSERVATION", 149, 169], ["pandemic", "OBSERVATION_MODIFIER", 188, 196], ["influenza", "OBSERVATION", 197, 206], ["Middle", "ANATOMY_MODIFIER", 208, 214], ["respiratory syndrome", "OBSERVATION", 220, 240], ["coronavirus", "OBSERVATION", 274, 285]]], ["The outbreaks of these diseases resulted in wide ranging socioeconomic consequences, including loss of lives and disruption to trade and travel.", [["loss of lives", "DISEASE", 95, 108], ["these diseases", "PROBLEM", 17, 31], ["wide ranging socioeconomic consequences", "PROBLEM", 44, 83], ["diseases", "OBSERVATION", 23, 31], ["wide", "OBSERVATION_MODIFIER", 44, 48], ["ranging", "OBSERVATION_MODIFIER", 49, 56]]], ["Preparedness is a crucial investment because its cost is small compared with the unmitigated impact of a health emergency.", [["a crucial investment", "TREATMENT", 16, 36], ["small", "OBSERVATION_MODIFIER", 57, 62]]]], "PMC7497857": [["IntroductionEqual opportunities and representation of all genders in the work force are very important.", [["IntroductionEqual opportunities", "TREATMENT", 0, 31]]], ["This is of course not an exception in the medical society.", [["exception", "OBSERVATION_MODIFIER", 25, 34]]], ["Otolaryngology has been one of the male-dominant surgical branches in Turkey.", [["dominant", "OBSERVATION_MODIFIER", 40, 48], ["surgical", "OBSERVATION", 49, 57], ["branches", "OBSERVATION_MODIFIER", 58, 66]]], ["According to the numbers given at the official website of Turkish Otolaryngology Head and Neck Society, number of male specialists is approximately eight times higher than that of female specialists.IntroductionGender equality in medicine may lead to significant benefits in healthcare system [1].", [["Neck", "ANATOMY", 90, 94]]], ["Gender equality among employees creates a better environment both for staff and patients.", [["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88]]], ["Besides, the patients may prefer to be treated by a specific gendered doctor [1].", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21]]], ["The different approaches for patient treatments by male and female doctors may develop mutual interaction as role models.IntroductionGender discrimination means unequal treatment to a person depending on his or her gender.", [["patient", "ORGANISM", 29, 36], ["patient", "SPECIES", 29, 36], ["person", "SPECIES", 184, 190], ["patient treatments", "TREATMENT", 29, 47]]], ["This unequal treatment may be about proportions, wages, hiring process and laying off, decision-making positions, leadership, giving birth, training, and education.", [["This unequal treatment", "TREATMENT", 0, 22]]], ["The purpose of this study is to gather information about the perceptions of gender discrimination among the male otolaryngologists (MORLs) and their opinions towards gender discrimination.Materials and methodsAn online survey of 46 questions, both close ended and on the 5-point Likert scale, was prepared to obtain MORLs\u2019 feedback about gender discrimination.", [["this study", "TEST", 15, 25]]], ["Upon the approval of this study by the Clinical Research Ethics Committee of Yozgat Bozok University (2017-KAEK-189_2020.02.26_03), a group of ten male residents and specialists who received postgraduate education in the field of otolaryngology was selected to fill the survey to test its validity and clarity of the questions.", [["this study", "TEST", 21, 31], ["postgraduate education", "TREATMENT", 191, 213]]], ["The total number of MORLs was 1574 according to membership roaster of the forum.", [["total", "OBSERVATION_MODIFIER", 4, 9]]], ["Only 161 MORLs completed the online survey within 3 months during March\u2013May 2020 under the unfavorable conditions of COVID-19 pandemic.", [["COVID", "TEST", 117, 122], ["pandemic", "PROBLEM", 126, 134]]], ["Then, the responses were compared with those of FORLs on a 5-point Likert scale.Statistical analysisChi square method of the SSPS 18 is used for statistical analysis.", [["SSPS 18", "DNA", 125, 132], ["Statistical analysis", "TEST", 80, 100], ["the SSPS", "TEST", 121, 129], ["statistical analysis", "TEST", 145, 165]]], ["P < 0.05 significance level is accepted as statistically significant.Marital status ::: Results65.8% of the respondents are married with working wives.", [["P < 0.05 significance level", "TEST", 0, 27]]], ["25.5% has no children, 31.7% one child, 36% two, 6.2% three, 0.6% four or more.Institutions, titles, and experience ::: Results40.4% of the participants completed their residency at a training and research hospital, 57.1% at a state university and 2.5% at a private university.Institutions, titles, and experience ::: Results15.5% of the participants are residents, 9.9% assistant professors, 6.7% associate professor, 14.3% professors, 12.4% instructors at training and research hospitals and the remaining is nonacademic MORLs.", [["children", "ORGANISM", 13, 21], ["participants", "ORGANISM", 338, 350], ["children", "SPECIES", 13, 21], ["participants", "SPECIES", 140, 152], ["participants", "SPECIES", 338, 350], ["no", "UNCERTAINTY", 10, 12]]], ["43.3% of them occupies an academic position.Institutions, titles, and experience ::: Results21.7% of MORLs has less than 5 year experience in the field of otolaryngology, 13% 5\u201310 years, 20.5% 10\u201320 years, 29.2% more than 20 years at the time surveying.", [["MORLs", "CANCER", 101, 106], ["academic position", "OBSERVATION", 26, 43]]], ["15.5% of them are residents.Maternity leave and breastfeeding breaks ::: Results8.7% of MORLs has positive opinion towards FORLs having a child during their residency; 24.2% approves FORLs to have a child after residency and 67.1% is neutral about such specific timing.", [["MORLs", "CANCER", 88, 93]]], ["The remaining 14.9% states non-surgical clinical branches (56.7%), basic sciences (40%) and other surgical branches (3.3%) are more suitable for female doctors.Work life ::: Results26.7% of MORLs worked with only one female resident or none during their residency, 27.3% with two, 16.1% with three and 29.8% with four or more.", [["MORLs", "CANCER", 190, 195], ["basic sciences", "TEST", 67, 81], ["14.9%", "OBSERVATION_MODIFIER", 14, 19], ["branches", "ANATOMY_MODIFIER", 49, 57], ["surgical", "OBSERVATION", 98, 106], ["branches", "ANATOMY_MODIFIER", 107, 115]]], ["9.3% of participants worked under a female administrator, i.e. a department head or an academic advisor during their residency.", [["participants", "ORGANISM", 8, 20], ["head", "ORGANISM_SUBDIVISION", 76, 80], ["participants", "SPECIES", 8, 20]]], ["Even though the majority of MORLs (73.9%) thinks gender doesn\u2019t matter to be eligible for a department head or academic advisor, 1.2% of them thinks a female could fulfill those roles, and 24.8% thinks a male is eligible.", [["MORLs", "CANCER", 28, 33], ["head", "ORGANISM_SUBDIVISION", 103, 107]]], ["9.3% of MORLs claims that they have been bullied by their female colleagues who don\u2019t hold any administrative positions.Gender discrimination ::: Results83.2% of the participants doesn\u2019t claim witnessing any kind of negative gender discrimination against FORLs, whereas 14.3% admits witnessing it.", [["participants", "ORGANISM", 166, 178], ["participants", "SPECIES", 166, 178], ["Gender discrimination", "TEST", 120, 141], ["Results", "TEST", 146, 153]]], ["While 49.1% claims that there is positive gender discrimination against FORLs, 44.1% disagrees about it.Gender discrimination ::: Results53.4% of MORLs states there is not any negative gender discrimination against FORLs when asked about their view on whom they see responsible for it.", [["FORLs", "DISEASE", 72, 77], ["Gender discrimination", "TEST", 104, 125], ["Results", "TEST", 130, 137]]], ["The remaining 46.6% believes there is discrimination, and they attribute such discrimination done by patients by 18.6%, female colleagues by 14.3%, male associates by 6.8% and their superiors by 6.8%.", [["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109]]], ["Based on our previous survey [2], gender discrimination against FORLs was committed mainly, in descending order, by senior MORLs, colleagues, patients and hospital staff.Gender discrimination ::: Results70.2% of MORLs responds that there is no gender discrimination when asked about which areas they think FORLs are exposed to gender discrimination.", [["patients", "ORGANISM", 142, 150], ["MORLs", "CANCER", 212, 217], ["patients", "SPECIES", 142, 150], ["Gender discrimination", "TEST", 170, 191], ["Results", "TEST", 196, 203], ["descending", "ANATOMY_MODIFIER", 95, 105], ["no", "UNCERTAINTY", 241, 243]]], ["The distribution of remaining answers is as follows: 19.3% family responsibilities, 8.1% performing lesser number of operations, 5.6% being allowed to attend scientific meetings, 2.5% examining higher number of patients daily.", [["patients", "ORGANISM", 211, 219], ["patients", "SPECIES", 211, 219], ["distribution", "OBSERVATION_MODIFIER", 4, 16]]], ["MORLs think there is no discrimination at all on the income level.", [["discrimination", "PROBLEM", 24, 38], ["no", "UNCERTAINTY", 21, 23], ["discrimination", "OBSERVATION_MODIFIER", 24, 38]]], ["71.4% also states FORLs\u2019 promotions are not gender dependent.", [["gender dependent", "PROBLEM", 44, 60]]], ["Nearly 20% thinks that FORLs use their gender in their advantage for academic promotions.Gender discrimination ::: ResultsThe responses to the 13 questions on the 5-point Likert scale were found statistically significant.", [["Likert scale", "TEST", 171, 183], ["significant", "OBSERVATION_MODIFIER", 209, 220]]], ["Similarly, our previous study was conducted among FORLs [2] to document the female\u2019s perception of gender discrimination.", [["our previous study", "TEST", 11, 29]]], ["Therefore, to diminish the bias, this survey is conducted as a follow-up study using the same methodology among MORLs.", [["a follow-up study", "TEST", 61, 78]]], ["Even though MORLs outnumber FORLs in Otolaryngology, unfortunately the participation rate to this follow-up study stayed at 10.2%.DiscussionIn parallel to increasing number of women in otolaryngology over the past few decades, academic productivity gap has been closing between the both genders.", [["women", "ORGANISM", 176, 181], ["women", "SPECIES", 176, 181], ["this follow-up study", "TEST", 93, 113], ["academic productivity gap", "PROBLEM", 227, 252], ["increasing", "OBSERVATION_MODIFIER", 155, 165], ["number", "OBSERVATION_MODIFIER", 166, 172]]], ["The discrimination may be in different forms, for example, marginalization of female residents; FORLs being assigned to more work compared to their MORLs counterparts on the same seniority level, but to lesser number of operations; unfavorable working conditions; facing difficulties for maternity leaves, breastfeeding breaks and in pursuing an academic career; being seen as having less physical strength and capability; patients\u2019 preference for male surgeons and patients\u2019 less respectful attitudes towards female surgeons [2].", [["patients", "ORGANISM", 423, 431], ["patients", "ORGANISM", 466, 474], ["patients", "SPECIES", 423, 431], ["patients", "SPECIES", 466, 474], ["unfavorable working conditions", "PROBLEM", 232, 262], ["may be", "UNCERTAINTY", 19, 25]]], ["Such observations have also been documented in several previously published studies in surgical fields [4, 5].DiscussionThe family medical leave act, short-term disability, and official vacation rights are used as basis for parental leave in the US.", [["disability", "DISEASE", 161, 171]]], ["Some program directors still have negative attitudes towards maternity leave because of increased workload on co-residents on duty and delayed training of female residents during their maternity leaves [6].", [["increased workload", "PROBLEM", 88, 106]]], ["Additionally, working mothers have an option for a long-term unpaid maternity leave up to 24 months.", [["mothers", "ORGANISM", 22, 29]]], ["The majority of MORLs are very positive towards both short-term leave of 3 months by 93.4% and long term leave by 80%.", [["MORLs", "CANCER", 16, 21], ["very positive", "PROBLEM", 26, 39], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["very", "OBSERVATION_MODIFIER", 26, 30], ["positive", "OBSERVATION", 31, 39]]], ["The variation in perceptions between males and females may be due to MORLs being less sincere in their responses about such sensitive subject like motherhood.DiscussionAnother discrepancy occurs in representations of FORLs by lesser numbers on the boards of otolaryngology associations even though MORLs support FORLs\u2019 assignments by 98% including the neutral responds.", [["variation", "OBSERVATION_MODIFIER", 4, 13]]], ["The dominance of MORLs in this respect is not the country specific issue.", [["dominance", "OBSERVATION_MODIFIER", 4, 13]]], ["Number of females in such societies should be more balanced in an attempt to assure a gender diversity both in surgical branches and in subspecialties [7].", [["females", "OBSERVATION", 10, 17], ["surgical branches", "ANATOMY", 111, 128]]], ["Additionally, the representation of females on the boards of societies and sub-societies should be constantly monitored as the number of senior female otolaryngologists increase overtime [8].DiscussionPerceptions of MORLs and FORLs on specific gender discrimination issues noticeably show a contrast.", [["females", "OBSERVATION", 36, 43]]], ["Even though 83% of MORLs claims that they didn\u2019t witness any negative gender discrimination towards FORLs, only 53.4% of them actually thinks there is no gender discrimination at all when asked to collect their opinion on the same subject with a different question, \u201cwho do you think discriminate your female colleagues based on their gender?\u201d", [["MORLs", "CANCER", 19, 24], ["no", "UNCERTAINTY", 151, 153]]], ["The replies to this indirect question is consistent with that of FORLs who experienced gender discrimination.", [["consistent with", "UNCERTAINTY", 41, 56]]], ["In this case, 30% of MORLs could probably witness gender discrimination towards their female colleagues but they may deny confessing it.", [["MORLs", "CANCER", 21, 26]]], ["Interestingly, MORLs mainly consider patients and female colleagues as part of the reason of negative discrimination towards FORLs who, in fact, point to their superiors and male colleagues responsible for negative discrimination towards themselves.", [["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45]]], ["Furthermore, MORLs think that FORLs are subject to negative discrimination, in the order of frequency, in the areas of family responsibilities, attendance to operations, attendance to conferences and examining higher number of patients daily.", [["patients", "ORGANISM", 227, 235], ["patients", "SPECIES", 227, 235]]], ["Interestingly, 49% of the MORLs claims there is positive gender discrimination towards FORLs, which is confirmed only by 5% of FORLs.DiscussionEven though some studies refer to a gender-based salary scale among otolaryngologists [9\u201311], some other studies don\u2019t report such income inequality [12, 13].", [["FORLs", "PATHOLOGICAL_FORMATION", 87, 92], ["FORLs", "CANCER", 127, 132], ["some studies", "TEST", 155, 167], ["positive", "OBSERVATION_MODIFIER", 48, 56]]], ["In our study, MORLs also don\u2019t assert the existence of such inequality.", [["our study", "TEST", 3, 12]]], ["This perception may be explained with the fixed pay scale used in the public hospitals in Turkey.", [["the fixed pay scale", "TREATMENT", 38, 57]]], ["On the other hand, the wage gap could be due to performance-based salary system used especially in the private sector.DiscussionAnother comparative study conducted among the non-medical academicians in Spain and the UK demonstrated that women perceived more gender inequality in areas of invitation to conferences as speakers, receiving scientific awards, representation on editorial boards of scientific publications, receiving citations, invitation to be a reviewer, promotions and leadership positions, whereas men did not perceive such extensive discrimination [14].", [["women", "ORGANISM", 237, 242], ["men", "ORGANISM", 514, 517], ["women", "SPECIES", 237, 242], ["men", "SPECIES", 514, 517], ["Another comparative study", "TEST", 128, 153]]], ["Similarly, Handley et al. documented that men didn\u2019t admit the existence of gender bias in science as women did [15].", [["men", "ORGANISM", 42, 45], ["women", "ORGANISM", 102, 107], ["men", "SPECIES", 42, 45], ["women", "SPECIES", 102, 107]]], ["This is an indication of unwillingness of men to acknowledge it, and the results of this study also support this conclusion.DiscussionWhen the Likert scale responses of MORLs are classified and compared to those of FORLs (Table 2), statistically significant opposing views are observed for 1) finding female surgeons more patient and punctual while doing their jobs (Fig. 1, 2) primarily taking men\u2019s words into consideration (Fig. 2, 3) FORLs being much more exposed to disturbing behaviors by the opposite gender.", [["men", "ORGANISM", 42, 45], ["patient", "ORGANISM", 322, 329], ["men", "ORGANISM", 395, 398], ["men", "SPECIES", 42, 45], ["patient", "SPECIES", 322, 329], ["men", "SPECIES", 395, 398], ["this study", "TEST", 84, 94]]], ["In reference to the question, \u201cmen\u2019s words are taken into consideration more compared to women\u2019s words in my department\u201d, 77.6% of MORLs\u2019 \u201cagree\u201d responses may be interpreted as an indication of their perception about their dominance over FORLs in the workplace which is acknowledged by only 7% of FORLs.", [["men", "ORGANISM", 31, 34], ["women", "ORGANISM", 89, 94], ["FORLs", "CANCER", 298, 303], ["men", "SPECIES", 31, 34], ["women", "SPECIES", 89, 94]]], ["On contrary, 52.6% of FORLs disagree that men\u2019 worlds are more valued in decision-making.", [["FORLs", "PATHOLOGICAL_FORMATION", 22, 27], ["men", "ORGANISM", 42, 45], ["men", "SPECIES", 42, 45]]], ["On the other hand, MORLs\u2019 answers to follow-up cross-questioning about MORLs being prioritized in pursuing an academic career may show a contradiction where MORLs don\u2019t really accept such preeminence (Fig. 3).DiscussionMoreover, the majority of MORLs and FORLs mutually agree that the offerings of academic opportunities are not gender dependent.", [["MORLs", "CANCER", 245, 250]]], ["This may be due to the stereotype about male\u2019s being held responsible for financial matters in the society.DiscussionIn regards to (1) specialties requiring intensive workings hours and call duties are more suitable for males, (2) males being more successful in specialties requiring physical strength, MORLs agree that males certainly have an advantage over females.", [["may be due to", "UNCERTAINTY", 5, 18]]], ["MORLs agree to the latter view about FORLs falling behind in their academic careers with some degree of ambiguity due to considerable number of replies on the disagreement scale side.DiscussionThe responses of MORLs in regards to (1) patients taking MORLs more seriously and relying more on them, (2) patients\u2019 preference for their doctor\u2019s gender as a criterion, are generally scattered.", [["patients", "ORGANISM", 234, 242], ["patients", "ORGANISM", 301, 309], ["patients", "SPECIES", 234, 242], ["patients", "SPECIES", 301, 309], ["scattered", "OBSERVATION_MODIFIER", 378, 387]]], ["Even though both MORLs and FORLs mostly agree on patients having confidence to MORLs and their preference for male surgeons, there is a noticeable divergence in the higher numbers of neutral answers of FORLs and the higher numbers in MORLs\u2019 disagreement (Table 2).", [["patients", "ORGANISM", 49, 57], ["MORLs", "CELL_TYPE", 17, 22], ["patients", "SPECIES", 49, 57]]], ["As a matter of fact, patients\u2019 gender preference may differ depending on subspecialty; for example, head and neck oncology patients prefer males, while females are more preferred in pediatric otolaryngology [18].", [["head", "ANATOMY", 100, 104], ["neck", "ANATOMY", 109, 113], ["patients", "ORGANISM", 21, 29], ["head", "ORGANISM_SUBDIVISION", 100, 104], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 123, 131], ["neck", "ANATOMY", 109, 113]]], ["On contrary, potential impact of physician\u2019s gender on patients\u2019 preference is not demonstrated in a study by Tracy LF et al. [19].DiscussionThe limitation of our current study is the lesser number of MORLs\u2019 participation in spite of sending out the survey to quite a large sample group.", [["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["a study", "TEST", 99, 106], ["our current study", "TEST", 159, 176]]], ["Thus, the results of this study may fall short in reflecting the views of MORLs in much wider range.ConclusionMORLs do not usually have any confrontation with FORLs in regards to the roles of women in the society such as their motherhood role.", [["women", "ORGANISM", 192, 197], ["women", "SPECIES", 192, 197], ["this study", "TEST", 21, 31]]]], "9b462593f722ce41b9e429f8ebea6e57f2e84e9a": [["Its further integration into the global financial system is strengthened due to the financialization process in commodity markets (Zhang and Ji, 2019) .", [["the financialization process", "PROBLEM", 80, 108], ["global", "OBSERVATION_MODIFIER", 33, 39]]], ["According to Tang and Xiong (2012) , the total value of the market transactions of institutional investors increases on a large scale, and a large amount of funds flow into commodity market, giving commodity prices clearly new features.", [["a large scale", "TREATMENT", 120, 133], ["large", "OBSERVATION_MODIFIER", 141, 146], ["amount", "OBSERVATION_MODIFIER", 147, 153], ["funds flow", "OBSERVATION", 157, 167], ["new", "OBSERVATION_MODIFIER", 223, 226]]], ["The recent trend, especially after the 2008 global financial crisis, has revealed a very different scenario.", [["the 2008 global financial crisis", "PROBLEM", 35, 67], ["a very different scenario", "PROBLEM", 82, 107], ["trend", "OBSERVATION_MODIFIER", 11, 16]]], ["Extreme price dynamics, higher short-term volatility, and increasing level of co-movement in commodity prices are far beyond the explanatory power of the standard demand and supply framework .", [["Extreme price dynamics", "PROBLEM", 0, 22], ["higher short-term volatility", "PROBLEM", 24, 52], ["increasing level of co-movement", "PROBLEM", 58, 89], ["higher short-term volatility", "OBSERVATION_MODIFIER", 24, 52], ["increasing", "OBSERVATION_MODIFIER", 58, 68]]], ["As a consequence, factors that may affect commodity price movement have becoming more complicated.IntroductionIn the financialization process, investors in commodity market are more vulnerable to nonconventional shocks such as market sentiments, policy uncertainties and other unexpected events.", [["IntroductionIn the financialization process", "TREATMENT", 98, 141], ["other unexpected events", "PROBLEM", 271, 294]]], ["For example, with a large number of investors entering commodity futures market in the recent years, market friction and investor sentiment have caused dramatic fluctuations in commodity prices, which also lead to deviations between commodity prices and economic fundamentals (Masters, 2008; Tang and Xiong, 2012) .", [["dramatic fluctuations in commodity prices", "PROBLEM", 152, 193], ["large", "OBSERVATION_MODIFIER", 20, 25], ["number", "OBSERVATION_MODIFIER", 26, 32], ["friction", "OBSERVATION_MODIFIER", 108, 116], ["dramatic", "OBSERVATION_MODIFIER", 152, 160], ["fluctuations", "OBSERVATION_MODIFIER", 161, 173], ["commodity prices", "OBSERVATION", 177, 193]]], ["Global economic uncertainties and rising systemic risks in the international financial system have also spill over to commodity markets.IntroductionTaking financialization and a broad category of factors (other than traditional supply and demand) into commodity pricing models has become a booming research direction .", [["Global economic uncertainties", "PROBLEM", 0, 29], ["rising systemic risks", "PROBLEM", 34, 55], ["traditional supply and demand)", "TREATMENT", 216, 246], ["economic uncertainties", "OBSERVATION", 7, 29], ["rising", "OBSERVATION_MODIFIER", 34, 40], ["systemic", "OBSERVATION_MODIFIER", 41, 49]]], ["Studies have separately investigated the driving factors behind commodity prices from the perspectives of supply-demand and macroeconomic fundamentals (Trostle, 2008; Akram, 2009; Matesanz et al., 2014) , uncertainty, geopolitical risk and extreme events (Balcilar et al., 2016; Jo\u00ebts et al., 2017; Bilgin et al., 2018; Antonakakis et al., 2017; Gkillas et al., 2019) , and commodity financialization Laroque, 1992, 1996; Masters, 2008; Tang and Xiong, 2012) .IntroductionIn terms of supply-demand and macroeconomic fundamentals, Mackey (1989) , Deaton and Laroque (1996) , and Chambers and Bailey (1996) find that resource commodity market is usually an oligopoly market, and sellers mostly control the quality and quantity of supply, which has a great influence on commodity pricing.", [["extreme events", "PROBLEM", 240, 254]]], ["However, Jacks and Stuermer (2020) argue that the impact of commodity supply on commodity prices gradually decreases over time, while demand factors have increased their influence.", [["decreases", "OBSERVATION_MODIFIER", 107, 116], ["increased", "OBSERVATION_MODIFIER", 154, 163]]], ["Trostle (2008) , Kilian (2009) , and Cevik and Sedik (2011) also suggest that the rapid growth of commodity demand is the main reason for the overall rise in commodity prices.", [["the rapid growth of commodity demand", "PROBLEM", 78, 114], ["rapid", "OBSERVATION_MODIFIER", 82, 87], ["growth", "OBSERVATION_MODIFIER", 88, 94]]], ["The reason behind the price linkage is complicated.", [["complicated", "OBSERVATION", 39, 50]]], ["Baffes (2007) believes that the linkage between agricultural products and fossil energy is the mutual substitution between them.", [["agricultural products", "TREATMENT", 48, 69], ["fossil energy", "PROBLEM", 74, 87], ["fossil energy", "OBSERVATION", 74, 87]]], ["For example, the high price of oil increases the demand for agricultural products as the sources of bioenergy, leading to the increase in agricultural product prices.", [["oil", "ANATOMY", 31, 34], ["oil", "ORGANISM_SUBSTANCE", 31, 34], ["agricultural products", "TREATMENT", 60, 81], ["agricultural product prices", "TREATMENT", 138, 165], ["high", "OBSERVATION_MODIFIER", 17, 21], ["increase", "OBSERVATION_MODIFIER", 126, 134], ["agricultural", "OBSERVATION_MODIFIER", 138, 150], ["product prices", "OBSERVATION", 151, 165]]], ["Among them, the world's GDP, mine production and stock-keeping are the top three most important factors.", [["GDP", "CHEMICAL", 24, 27], ["GDP", "CHEMICAL", 24, 27], ["GDP", "SIMPLE_CHEMICAL", 24, 27], ["the world's GDP", "TEST", 12, 27]]], ["Kagraoka (2016) uses generalized dynamic factor model to study the driving factors of the monthly prices of commodities, and finds that the U.S. inflation rate, the world industrial production, the world stock index and the price of crude oil are four common dynamic factors that determine commodity prices.", [["oil", "ORGANISM_SUBSTANCE", 239, 242]]], ["Bhardwaj et al. (2015) use default spread (DEF) as a proxy of business cycle to explore whether macroeconomic risks will lead to commodity risk premiums, and the results show that there are obvious business cycle components in the correlation between the commodity prices.", [["macroeconomic risks", "PROBLEM", 96, 115], ["obvious business cycle components", "PROBLEM", 190, 223], ["obvious", "OBSERVATION_MODIFIER", 190, 197], ["business cycle", "OBSERVATION", 198, 212]]], ["They conclude that macroeconomic factors have a spillover effect on precious metal price fluctuations.", [["macroeconomic factors", "PROBLEM", 19, 40], ["a spillover effect", "PROBLEM", 46, 64], ["spillover effect", "OBSERVATION", 48, 64]]], ["Recently, some researchers argue that the exchange rate of the US dollar as well as interest rates (Akram, 2009; Gruber and Vigfusson, 2018) , economic activity (Klotz et al., 2014) and other macroeconomic factors (Smiech and PapiezaDabrowski, 2015; are also important sources to drive commodity price fluctuations.IntroductionEntering the new century, extreme events happen more frequently together with a clearly rising geopolitical risks across the world.", [["the US dollar", "TREATMENT", 59, 72], ["extreme events", "PROBLEM", 353, 367], ["new", "OBSERVATION_MODIFIER", 340, 343]]], ["The global financial crisis in 2008 has changed the global economic condition and raised worldwide economic uncertainties.", [["The global financial crisis", "PROBLEM", 0, 27], ["the global economic condition", "PROBLEM", 48, 77], ["global", "OBSERVATION_MODIFIER", 4, 10], ["financial crisis", "OBSERVATION", 11, 27]]], ["And then the world has seen the European sovereign debt crisis, the Ukraine-Russia conflict, turmoils in the Middle East, and now the pandemic of coronavirus (Zhang et al., 2020; Ji et al., 2020a) .", [["coronavirus", "DISEASE", 146, 157], ["coronavirus", "ORGANISM", 146, 157], ["coronavirus", "PROBLEM", 146, 157], ["debt crisis", "OBSERVATION", 51, 62], ["Middle", "ANATOMY_MODIFIER", 109, 115]]], ["All of these have profound impacts on commodity markets and thus lead to a number of empirical studies.", [["empirical studies", "TEST", 85, 102], ["profound", "OBSERVATION_MODIFIER", 18, 26], ["impacts", "OBSERVATION_MODIFIER", 27, 34]]], ["They find that the agricultural and industrial markets are more sensitive to changes in macroeconomic uncertainty, whereas the sensitivity of precious metals markets is relatively low.", [["the agricultural and industrial markets", "PROBLEM", 15, 54], ["macroeconomic uncertainty", "OBSERVATION", 88, 113], ["relatively", "OBSERVATION_MODIFIER", 169, 179], ["low", "OBSERVATION_MODIFIER", 180, 183]]], ["Balcilar et al. (2016) use a nonparametric causality-in-quantiles test to examine the relationship between various uncertainty measures and gold returns.", [["a nonparametric causality", "TEST", 27, 52]]], ["Bilgin et al. (2018) explore the impact of the volatility index (VIX), skewness (SKEW), global economic policy uncertainty (EPU), and the partisan conflict indexes (PC) on gold prices.", [["the volatility index", "TEST", 43, 63], ["gold prices", "TREATMENT", 172, 183]]], ["Their results show that gold prices exhibit a positive response to negative changes in the VIX index and positive changes in the EPU index.", [["the VIX index", "TEST", 87, 100], ["positive changes in the EPU index", "PROBLEM", 105, 138], ["positive response", "OBSERVATION", 46, 63], ["positive changes", "OBSERVATION", 105, 121]]], ["Antonakakis et al. (2017) and Gkillas et al. (2019) confirm the predictive power of geopolitical risk in crude oil and gold price fluctuations, respectively.", [["oil", "ANATOMY", 111, 114], ["oil", "ORGANISM_SUBSTANCE", 111, 114]]], ["Furthermore, some researches, such as Tzeng and Shieh (2016) , Vercammen (2020) and Yousef (2020) , examine the performance of commodity markets in extreme cases, and find clear differences of commodity markets in normal periods.IntroductionStudies on commodity financialization have also found some interesting results.", [["normal periods", "OBSERVATION", 214, 228]]], ["Laroque (1992, 1996) show that an influx of speculators in commodity markets will significantly increase the volatility and autocorrelation of commodity prices.", [["an influx of speculators in commodity markets", "PROBLEM", 31, 76]]], ["They show that there is a high positive correlation between movements in open interest and commodity prices, and one standard deviation increase in commodity market interest will lead to a 0.73% increase in expected commodity returns per month.", [["a high positive correlation between movements", "PROBLEM", 24, 69], ["increase", "OBSERVATION_MODIFIER", 136, 144]]], ["Basu and Miffre (2013) construct factor mimicking portfolios to capture the correlation between commodity futures risk premiums and investor' hedging pressure.", [["investor' hedging pressure", "TREATMENT", 132, 158]]], ["B\u00fcy\u00fck\u015fahin and Robe (2014) study the relationship between commodities and stock returns using a non-public trader position dataset of 17 commodity futures markets, and they suggest that the link between commodities and stock returns grows as the financialization of commodities strengthens.", [["a non-public trader position", "TREATMENT", 94, 122]]], ["Furthermore, Mensi et al. (2017a,b) , Bouri et al. (2017) and Ji et al., 2018a Ji et al., , 2018b examine the dependence structure between energy and agricultural commodity price fluctuations from the perspective of risk management.", [["risk management", "TREATMENT", 216, 231]]], ["They find that the existence of risk spillovers from energy to agricultural commodities, and the dependent structure between them is not only time-varying, but also sensitive to time horizons.IntroductionMost of the existing literature focuses on a single dimension of factors, while the evidence of commodity financialization shows the importance of financialization and news factors in the commodity market, as well as the multidimensional nature of the problem.", [["risk spillovers", "PROBLEM", 32, 47]]], ["These three dimensions discussed above are not necessarily separated from each other, instead, they are intrinsically linked in a complex system.", [["not necessarily", "UNCERTAINTY", 43, 58], ["complex", "OBSERVATION_MODIFIER", 130, 137]]], ["Without synthetically including all dimensions into the analytical framework, empirical results may be biased or partial.", [["partial", "OBSERVATION_MODIFIER", 113, 120]]], ["To overcome this problem, and extend from these existing knowledge, this paper focus on the aspects of financialization and macro news, explicitly takes all three dimensions into consideration, and empirically investigates how the broad macro factors contribute to fluctuations in commodity markets.", [["the broad macro factors", "PROBLEM", 227, 250]]], ["Specifically, we use economic policy uncertainty (EPU), the economic surprise index (ESI), default spread (DEF), the investor sentiment index (SI), the volatility index (VIX), and the geopolitical risk index (GPR) to identify the main information transmission channels and drivers that affect commodity price fluctuations, and provide investors and policymakers with implications of commodity investment or management that respond to rapidly changing macro situation.", [["default spread (DEF)", "PROBLEM", 91, 111], ["the volatility index", "TEST", 148, 168], ["management", "TREATMENT", 407, 417]]], ["Second, soybeans, gold, and crude oil are selected as the representatives of three major commodity markets, namely, agricultural, metal, and energy products.", [["oil", "ANATOMY", 34, 37], ["gold", "CHEMICAL", 18, 22], ["soybeans", "ORGANISM_SUBDIVISION", 8, 16], ["gold", "SIMPLE_CHEMICAL", 18, 22], ["oil", "ORGANISM_SUBSTANCE", 34, 37], ["soybeans", "SPECIES", 8, 16], ["soybeans", "SPECIES", 8, 16], ["energy products", "TREATMENT", 141, 156]]], ["And these three commodities are the most typical commodities verified in most existing literature.", [["most typical", "OBSERVATION_MODIFIER", 36, 48]]], ["This approach overcomes the endogeneity problems in time series analysis and is robust to variable ordering, and also allows us to analyze interactions among variables in a systemic way.", [["the endogeneity problems", "PROBLEM", 24, 48], ["series analysis", "TEST", 57, 72]]], ["The network perspective provides an effective way to describe underlying mechanisms from system-wide level to pairwise level, and thus avoids controversial issues related to \"contagion\" or \"herding behaviour\".", [["controversial issues", "PROBLEM", 142, 162]]], ["The last section concludes.", [["The last section", "TREATMENT", 0, 16]]], ["The accuracy of RV depends on sampling frequency.", [["RV", "ANATOMY", 16, 18]]], ["A higher sampling frequency can better capture volatility information, but with the increase in sampling frequency, the noise of the market microstructure also increases, which leads to a decrease in the measurement accuracy of the high-frequency RV.", [["A higher sampling frequency", "PROBLEM", 0, 27], ["the increase in sampling frequency", "PROBLEM", 80, 114], ["increase", "OBSERVATION_MODIFIER", 84, 92], ["market", "OBSERVATION_MODIFIER", 133, 139], ["microstructure", "OBSERVATION_MODIFIER", 140, 154], ["increases", "OBSERVATION_MODIFIER", 160, 169], ["decrease", "OBSERVATION_MODIFIER", 188, 196], ["high", "OBSERVATION_MODIFIER", 232, 236]]], ["Andersen et al. (2001) suggest that 5-min is the optimal sampling interval for a liquid market to balance the advantages of using high-frequency data and the disadvantages of microstructure noises.", [["a liquid market", "TREATMENT", 79, 94], ["high-frequency data", "TREATMENT", 130, 149], ["microstructure noises", "PROBLEM", 175, 196]]], ["Hence, this paper also 5-min high-frequency data to construct the realized volatility.Connectedness networkDiebold and Yilmaz's (2014) connectedness network approach is a simple and very powerful method to describe systemic interactions based on the vector autoregressive (VAR) model and the generalized variance decomposition (GVD) method.", [["Connectedness networkDiebold", "TREATMENT", 86, 114], ["Yilmaz's", "TREATMENT", 119, 127], ["systemic interactions", "PROBLEM", 215, 236], ["the vector autoregressive (VAR) model", "TREATMENT", 246, 283], ["the generalized variance decomposition (GVD) method", "TREATMENT", 288, 339]]], ["It has been widely used in the analysis of cross-market risk contagion (Maghyereh et al., 2016; Zhang, 2017; Mensi et al., 2017a,b; Rehman et al., 2018; Ji et al., 2018a Ji et al., , 2018b and systemic risk analysis (Alter and Beyer, 2014; Diebold and Yilmaz, 2014; Fernando et al., 2016) .", [["systemic risk analysis", "TEST", 193, 215], ["widely", "OBSERVATION_MODIFIER", 12, 18]]], ["Compared with traditional measurement approaches (such as cointegration, causality analysis, etc.), this approach can provide more intuitive descriptions of the direction and intensity of information spillovers occurring between multivariable.Connectedness networkFirst, a VAR(p) model is constructed:Connectedness networkwhere y m t is an N \u00d7 1 vector, including the realized volatilities of commodity m (m = soybeans, gold, and crude oil, respectively) and the macro factors.", [["oil", "ANATOMY", 436, 439], ["gold", "SIMPLE_CHEMICAL", 420, 424], ["oil", "ORGANISM_SUBSTANCE", 436, 439], ["traditional measurement approaches", "TEST", 14, 48], ["causality analysis", "TEST", 73, 91], ["a VAR(p) model", "TREATMENT", 271, 285]]], ["The VAR model can be converted into the vector moving average (VMA) representation:Connectedness networkwhere the N \u00d7 N matrices A m j can be calculated by the recursive formulaConnectedness networkAfter estimating the model, the generalized variance decomposition method proposed by Pesaran and Shin (1998) can be constructed.", [["The VAR model", "TREATMENT", 0, 13], ["the N \u00d7 N matrices", "TREATMENT", 110, 128], ["the generalized variance decomposition method", "TREATMENT", 226, 271], ["Shin", "ANATOMY", 296, 300]]], ["Equation (4) calculates the H-step ahead generalized forecast error variance decomposition:Connectedness networkwhere \u03b8 H ij measures the variance contribution of the innovations in variable j to variable i at the H-step ahead. e j is a selection vector with one as its jth entry and zeros elsewhere.", [["Equation", "TEST", 0, 8], ["H ij", "TREATMENT", 120, 124], ["a selection vector", "TREATMENT", 235, 253], ["ij", "ANATOMY", 122, 124], ["zeros", "OBSERVATION", 284, 289]]], ["A h is the h-lagged coefficient matrix in the moving-average representation of the VAR model.", [["the h-lagged coefficient matrix", "TREATMENT", 7, 38], ["the VAR model", "TREATMENT", 79, 92]]], ["\u03a3 m is the covariance matrix of the error vector in the VAR model, and \u03c3 jj is the jth diagonal entry of \u03a3.", [["VAR model", "ANATOMY", 56, 65]]], ["Due to the non-orthogonalized shocks in the GVD environment, the row sums of the generalized forecast error variance decomposition matrix are not unity in general.", [["matrix", "CELLULAR_COMPONENT", 131, 137], ["the non-orthogonalized shocks in the GVD environment", "PROBLEM", 7, 59], ["the generalized forecast error variance decomposition matrix", "PROBLEM", 77, 137], ["GVD environment", "OBSERVATION", 44, 59]]], ["Hence, we normalize equation (4) as the following function to ensure the row sum equals one:Connectedness networkThe generalized variance decomposition matrix can be constructued Diebold and Yilmaz (2014) further propose several connectedness measures and construct the connectedness network.Connectedness networkGiven that the pairwise directional connectedness from j to i is \u03b8 H ij , then the net pairwise directional connectedness between i and j can be written asConnectedness networkThen, the total directional connectedness from others to i (From) and the total directional connectedness to others from i (To) are defined asConnectedness networkIn order to measure the net information spillover contribution between variable i and the other variables in the system, the net total directional connectedness of variable i is defined asConnectedness networkFinally, in order to measure the total spillovers in the system, the total connectedness for the system is constructed asDataSoybeans futures, gold futures, and WTI Light Sweet Crude Oil futures data from the Chicago Mercantile Exchange (CME) are used to represent agricultural, metal, and energy products for comparative analysis, respectively, which is dictated by the availability of highfrequency data for commodities.", [["The generalized variance decomposition matrix", "PROBLEM", 113, 158], ["Yilmaz", "TREATMENT", 191, 197], ["several connectedness measures", "TREATMENT", 221, 251], ["the total directional connectedness", "TREATMENT", 559, 594], ["variable i and the other variables in the system", "PROBLEM", 723, 771], ["the net total directional connectedness", "TREATMENT", 773, 812], ["the Chicago Mercantile Exchange (CME)", "TREATMENT", 1066, 1103], ["comparative analysis", "TEST", 1171, 1191], ["generalized", "OBSERVATION_MODIFIER", 117, 128], ["ij", "ANATOMY", 382, 384]]], ["Although we only obtained highfrequency data for three commodities, these three commodities are the most typical commodities.", [["most typical", "OBSERVATION_MODIFIER", 100, 112]]], ["All high-frequency data for commodity markets is collected from the Datastream database.DataWith the development of commodity financialization, the volatility of commodities is more vulnerable to news-based factors rather than fundamental factors.", [["fundamental factors", "PROBLEM", 227, 246]]], ["Thus six factors are selected from macroeconomics and capital markets to a broader geopolitical dimension which can capture the different responses of commodity volatility to the changes of these factors.", [["capital markets", "OBSERVATION", 54, 69], ["commodity volatility", "OBSERVATION", 151, 171]]], ["According to existing literature, six macro factors are chosen including economic policy uncertainty (EPU; Balcilar et al., 2016; Bilgin et al., 2018) , the economic surprise index (ESI; Mave\u00e9 et al., 2016) , default spread (DEF; Bhardwaj et al., 2015; Ordu et al., 2018) , the investor sentiment index (SI; Bahloul, 2018; Ji et al., 2020b) , the volatility index (VIX; Silvennoinen and Thorp, 2013; Bilgin et al., 2018) , and the geopolitical risk index (GPR; Antonakakis et al., 2017; Plakandaras et al., 2019) .", [["six macro factors", "PROBLEM", 34, 51], ["default spread", "PROBLEM", 209, 223], ["Bahloul", "TEST", 308, 315], ["the volatility index", "TEST", 343, 363], ["the geopolitical risk index", "TEST", 427, 454], ["GPR", "TEST", 456, 459]]], ["They are from three dimensions, namely, macroeconomics, capital market, and geopolitical risk.", [["capital market", "OBSERVATION", 56, 70]]], ["Since futures are not continuously traded, we exclude all data on soybeans futures trading between 13:15 CST on Friday and 20:30 CST on Sunday as well as all data on gold and crude oil futures trading between 17:15 EST on Friday and Sunday 18:00 EST on Sunday, following Andersen et al. (2001 Andersen et al. ( , 2003 Andersen et al. ( , 2007 .", [["soybeans", "ORGANISM_SUBDIVISION", 66, 74], ["gold", "SIMPLE_CHEMICAL", 166, 170]]], ["Moreover, we define the daily trading hours of soybeans futures and gold/crude oil futures on a certain day as the period from 20:30 CST and 18:00 EST of the previous day to 13:15 CST and 17:15 EST that day, respectively.", [["oil", "ANATOMY", 79, 82], ["gold", "CHEMICAL", 68, 72], ["gold", "SIMPLE_CHEMICAL", 68, 72], ["oil", "ORGANISM_SUBSTANCE", 79, 82], ["soybeans", "SPECIES", 47, 55]]], ["In addition, we also exclude any data from inactive trading days and certain holidays, such as Christmas, Thanksgiving, etc. Finally, as the data frequency of the investor sentiment index is weekly, we replace the realized volatility of the commodities with weekly data, which consisted of 204, 230, and 230 observations for soybeans, gold, and crude oil futures, respectively.", [["gold", "SIMPLE_CHEMICAL", 335, 339], ["oil", "ORGANISM_SUBSTANCE", 351, 354]]], ["Table 2 reports the descriptive statistics of the realized volatility of the commodity futures and macro factors.", [["macro factors", "PROBLEM", 99, 112]]], ["Panel A of Table 2 shows that the mean values of the realized volatility of the three commodity futures are around 0.018, of which gold is the largest, and soybeans is the smallest.", [["soybeans", "ORGANISM_SUBDIVISION", 156, 164], ["soybeans", "SPECIES", 156, 164], ["Panel A of Table 2", "TEST", 0, 18], ["the mean values", "TEST", 30, 45], ["volatility", "OBSERVATION_MODIFIER", 62, 72], ["three", "OBSERVATION_MODIFIER", 80, 85], ["commodity", "OBSERVATION_MODIFIER", 86, 95], ["gold", "OBSERVATION_MODIFIER", 131, 135], ["largest", "OBSERVATION_MODIFIER", 143, 150], ["smallest", "OBSERVATION_MODIFIER", 172, 180]]], ["However, based on the median, the realized volatility of gold futures has the smallest median value of 0.010, while the realized volatility of crude oil futures has the largest median value of 0.015.", [["oil", "ORGANISM_SUBSTANCE", 149, 152], ["smallest", "OBSERVATION_MODIFIER", 78, 86], ["largest", "OBSERVATION_MODIFIER", 169, 176]]], ["This means that the intraday returns of gold futures are more stable, and the intraday returns of crude oil has higher uncertainty most of the time.", [["oil", "ORGANISM_SUBSTANCE", 104, 107], ["crude oil", "TREATMENT", 98, 107], ["stable", "OBSERVATION_MODIFIER", 62, 68]]], ["In addition, the realized volatility of the three commodity futures shows positive skewness, excess kurtosis, and fat tails, and the realized volatility of soybeans futures has the largest skewness and kurtosis.", [["fat", "ANATOMY", 114, 117], ["soybeans", "ORGANISM_SUBDIVISION", 156, 164], ["soybeans", "SPECIES", 156, 164], ["positive skewness", "PROBLEM", 74, 91], ["excess kurtosis, and fat tails", "PROBLEM", 93, 123], ["positive skewness", "OBSERVATION", 74, 91], ["excess kurtosis", "OBSERVATION", 93, 108], ["fat tails", "ANATOMY", 114, 123], ["largest", "OBSERVATION_MODIFIER", 181, 188], ["skewness", "OBSERVATION", 189, 197]]], ["The results in the last three columns indicate that the realized volatility series of all the commodity futures significantly differ from the normal distribution; these variables are all stationary.DataPanel B of Table 2 presents the statistical characteristics of the first difference of the macro information indicators.", [["normal", "OBSERVATION", 142, 148], ["distribution", "OBSERVATION_MODIFIER", 149, 161]]], ["1 The results show that the mean of GPR is the largest, its positive value indicates an upward trend of global geopolitical risk.", [["GPR", "PROTEIN", 36, 39], ["GPR", "TEST", 36, 39], ["global geopolitical risk", "PROBLEM", 104, 128], ["largest", "OBSERVATION_MODIFIER", 47, 54], ["upward", "OBSERVATION_MODIFIER", 88, 94], ["trend", "OBSERVATION_MODIFIER", 95, 100], ["global", "OBSERVATION_MODIFIER", 104, 110], ["geopolitical risk", "OBSERVATION", 111, 128]]], ["GPR has the largest range and volatility, followed by EPU.", [["GPR", "PROTEIN", 0, 3], ["GPR", "TEST", 0, 3], ["largest", "OBSERVATION_MODIFIER", 12, 19], ["volatility", "OBSERVATION_MODIFIER", 30, 40]]], ["Moreover, similar to the realized volatility of commodity futures, all series significantly differ from the normal distribution but all stationary.Empirical results and analysisThe network approach proposed by Diebold and Yilmaz (2014) will be used to construct three information spillover networks between the macro information factors and soybeans, gold, and crude oil futures.", [["soybeans", "ORGANISM_SUBDIVISION", 341, 349], ["gold", "SIMPLE_CHEMICAL", 351, 355], ["oil", "ORGANISM_SUBSTANCE", 367, 370], ["macro information factors", "PROTEIN", 311, 336], ["Empirical results", "TEST", 147, 164], ["analysis", "TEST", 169, 177], ["normal", "OBSERVATION", 108, 114], ["distribution", "OBSERVATION_MODIFIER", 115, 127]]], ["Following Diebold and Yilmaz (2012) , this paper constructs generalized variance decomposition matrices using the VAR(4) model and a 10-step ahead generalized forecast error variance decomposition.Static analysisIn this section, we use the full sample to study the information spillover networks between commodity markets and macro information, and the results are shown in Table 3 .", [["this paper constructs generalized variance decomposition matrices", "TREATMENT", 38, 103], ["the VAR(4) model", "TREATMENT", 110, 126], ["generalized forecast error variance decomposition", "PROBLEM", 147, 196]]], ["From the table, we can see that the total connectedness between the realized volatility of the three commodities and the macro information indicators are quite similar.", [["similar", "OBSERVATION_MODIFIER", 160, 167]]], ["The system of crude oil futures and macro information has the largest systemic spillover effect (14.9%), followed by the system of soybeans futures and macro information, with total connectedness of 13.1%; the spillover effect of the system of gold futures and macro information is the smallest (12.6%).", [["oil", "ANATOMY", 20, 23], ["oil", "ORGANISM_SUBSTANCE", 20, 23], ["soybeans", "SPECIES", 131, 139], ["soybeans", "SPECIES", 131, 139], ["crude oil", "TREATMENT", 14, 23], ["largest", "OBSERVATION_MODIFIER", 62, 69], ["systemic", "OBSERVATION_MODIFIER", 70, 78], ["spillover", "OBSERVATION", 79, 88], ["smallest", "OBSERVATION_MODIFIER", 286, 294]]], ["It is interesting to see that the contribution of each commodity market to the system are also very similar ranging from 11.7% for gold to 12.9% for soybeans.", [["soybeans", "SPECIES", 149, 157], ["gold", "TEST", 131, 135]]], ["For the whole sample period, the similarity found here, to some extent, verifies the long-term co-movement occurring among commodity markets.", [["long-term", "OBSERVATION_MODIFIER", 85, 94]]], ["This finding is consistent with Pindyck and Rotemberg (1990) and Fernandez (2015) that commodity markets exhibit persistent co-movements beyond the explanation of fundamentals.", [["persistent co-movements", "PROBLEM", 113, 136], ["consistent with", "UNCERTAINTY", 16, 31], ["Pindyck", "OBSERVATION", 32, 39], ["persistent", "OBSERVATION_MODIFIER", 113, 123], ["co-movements", "OBSERVATION", 124, 136]]], ["This excess co-movement is often due to the extensive flow of speculative investments across different markets (Le Pen and S\u00e9vi, 2018) .Static analysisDespite the similarity of systemic connectedness in these three systems, there are clear differences in the information spillovers from the systems to each commodities.", [["systemic connectedness in these three systems", "PROBLEM", 177, 222], ["extensive", "OBSERVATION_MODIFIER", 44, 53], ["flow", "OBSERVATION", 54, 58], ["systemic", "OBSERVATION_MODIFIER", 177, 185], ["connectedness", "OBSERVATION", 186, 199], ["clear", "OBSERVATION_MODIFIER", 234, 239], ["differences", "OBSERVATION_MODIFIER", 240, 251]]], ["Soybeans for example, can gain 14.3% of information from the macro factors, whereas the number for gold is only 11.6%.", [["Soybeans", "CHEMICAL", 0, 8], ["macro factors", "PROTEIN", 61, 74]]], ["Crude oil futures behave even more differently as its variation gains over 32.8% from the system.", [["oil", "ANATOMY", 6, 9], ["oil", "ORGANISM_SUBSTANCE", 6, 9], ["Crude oil futures", "TREATMENT", 0, 17]]], ["In other words, variations in the crude oil futures are much more sensitive to macro factors relative to other commodities.Static analysisMoreover, the spillover effects from each macro information indicator to commodity volatility are also significantly different in three commodity-macro information systems.", [["oil", "ORGANISM_SUBSTANCE", 40, 43], ["macro factors", "PROBLEM", 79, 92], ["the spillover effects", "PROBLEM", 148, 169]]], ["In the soybeans-macro information system, the default spread has the largest explanatory power to soybeans volatility, explaining 4.3% of the variations in soybean RV.", [["soybeans", "ORGANISM_SUBDIVISION", 98, 106], ["soybean", "SPECIES", 156, 163], ["the default spread", "PROBLEM", 42, 60], ["the variations in soybean RV", "PROBLEM", 138, 166], ["soybean RV", "ANATOMY", 156, 166]]], ["The second contributor is the investor sentiment index, with an explanatory power of 2.7%.", [["an explanatory power", "TEST", 61, 81]]], ["In the gold-macro information system, VIX and SI has the top two factors in terms of explanatory power to gold volatility, contributing to 4.2% and 2.5% of its variations.", [["gold volatility", "OBSERVATION", 106, 121]]], ["The strong information gains for crude oil futures from the system are due to VIX.", [["oil", "ORGANISM_SUBSTANCE", 39, 42], ["crude oil", "TREATMENT", 33, 42]]], ["The volatility index explains 21.7% of crude oil futures' RV variations alone.Static analysisIf we come back to the concept that the first three factors (EPU, ESI and DEF) are macroeconomic factors, a clear pattern can be found through comparing these systems.", [["oil", "ANATOMY", 45, 48], ["oil", "ORGANISM_SUBSTANCE", 45, 48], ["The volatility index", "TEST", 0, 20], ["Static analysis", "TEST", 78, 93], ["EPU", "TEST", 154, 157], ["macroeconomic factors", "PROBLEM", 176, 197]]], ["For soybeans, macroeconomic factors take the leading role.", [["soybeans", "ORGANISM_SUBDIVISION", 4, 12], ["soybeans", "SPECIES", 4, 12], ["soybeans", "SPECIES", 4, 12], ["macroeconomic factors", "PROBLEM", 14, 35]]], ["Whereas for gold and crude oil, financial factors take over that position.", [["oil", "ANATOMY", 27, 30], ["gold", "CHEMICAL", 12, 16], ["gold", "SIMPLE_CHEMICAL", 12, 16], ["oil", "ORGANISM_SUBSTANCE", 27, 30], ["gold and crude oil", "TREATMENT", 12, 30], ["financial factors", "TREATMENT", 32, 49]]], ["This is especially obvious for crude oil when VIX contributes over one fifth of the variations.", [["oil", "ANATOMY", 37, 40], ["VIX", "CHEMICAL", 46, 49], ["oil", "ORGANISM_SUBSTANCE", 37, 40]]], ["The findings here are consistent with Zhang (2017) that crude oil has shown stronger characteristics of financialization in recent years and its price movements are more affected by the conditions in financial markets.Static analysisIn addition, the results show that these commodities do not contribute much additional information to the system.", [["oil", "ANATOMY", 62, 65], ["oil", "ORGANISM_SUBSTANCE", 62, 65], ["consistent with", "UNCERTAINTY", 22, 37], ["stronger characteristics", "OBSERVATION_MODIFIER", 76, 100]]], ["Only gold futures are a net information transmitter, and its net contribution power is less than 1%; whereas soybeans and crude oil futures are net information receivers.", [["soybeans", "ORGANISM_SUBDIVISION", 109, 117], ["oil", "ORGANISM_SUBSTANCE", 128, 131], ["soybeans", "SPECIES", 109, 117]]], ["Meanwhile, the net information gain for soybeans is only 1.5%.", [["soybeans", "SPECIES", 40, 48]]], ["The situation is much different for crude oil as it has a much larger net gain (20.9%) from the system.", [["oil", "ANATOMY", 42, 45], ["oil", "ORGANISM_SUBSTANCE", 42, 45]]], ["This result supports that the crude oil market is more sensitive to changes in external information, and thus should be treated very differently in commodity markets.Static analysisFinally, a comparative analysis of the contribution of the different macro information indicators in the system reveals that the volatility index is the largest information receiver in each system from the perspective of information inflow, with values ranging from 16.6% to 21.2%.", [["oil", "ANATOMY", 36, 39], ["oil", "ORGANISM_SUBSTANCE", 36, 39], ["Static analysis", "TEST", 166, 181], ["a comparative analysis", "TEST", 190, 212], ["the volatility index", "TEST", 306, 326], ["values", "TEST", 427, 433], ["volatility index", "OBSERVATION", 310, 326], ["largest", "OBSERVATION_MODIFIER", 334, 341]]], ["From the perspective of information outflow, although there is no single largest information transmitter in the three systems, the economic policy uncertainty index is ranking the top three information transmitter of the six macro information indicators.", [["no", "UNCERTAINTY", 63, 65]]], ["In other words, the volatility index is most affected by changes in the system, while economic policy uncertainty is an important factor for system volatility.", [["the volatility index", "TEST", 16, 36]]], ["In terms of net contribution of the macro information to the system, the economic policy uncertainty index, investor sentiment index, and geopolitical risk index are net information transmitters for all systems, while the economic surprise index is a net information receiver for all systems.", [["sentiment index", "TEST", 117, 132], ["geopolitical risk index", "PROBLEM", 138, 161], ["all systems", "TEST", 199, 210]]], ["In addition, the results also show that the volatility index exhibits different performances in different systems.", [["the volatility index", "TEST", 40, 60], ["different performances in different systems", "PROBLEM", 70, 113]]], ["This is because crude oil futures are more sensitive to changes in the panic index than soybeans and gold futures.", [["oil", "ANATOMY", 22, 25], ["panic", "DISEASE", 71, 76], ["oil", "ORGANISM_SUBSTANCE", 22, 25], ["soybeans", "ORGANISM_SUBDIVISION", 88, 96], ["soybeans", "SPECIES", 88, 96], ["the panic index", "PROBLEM", 67, 82]]], ["Fig. 1 uses a coloured chord graph for this purpose.", [["a coloured chord graph", "TREATMENT", 12, 34]]], ["In the graph, coloured bands represent the net information flow between different indicators, and the larger width of the bands represents a higher level of net information flow.", [["coloured bands", "PROBLEM", 14, 28], ["the bands", "PROBLEM", 118, 127], ["coloured bands", "OBSERVATION", 14, 28], ["net", "OBSERVATION_MODIFIER", 43, 46], ["larger", "OBSERVATION_MODIFIER", 102, 108], ["width", "OBSERVATION_MODIFIER", 109, 114]]], ["As can be seen in Fig. 1 , the total level of net information flow between the crude oil futures and the system is the largest, followed by soybeans and gold.", [["oil", "ANATOMY", 85, 88], ["oil", "ORGANISM_SUBSTANCE", 85, 88], ["soybeans", "ORGANISM_SUBDIVISION", 140, 148], ["gold", "SIMPLE_CHEMICAL", 153, 157], ["soybeans", "SPECIES", 140, 148], ["soybeans", "SPECIES", 140, 148], ["Fig", "OBSERVATION", 18, 21], ["largest", "OBSERVATION_MODIFIER", 119, 126]]], ["In the soybeans-macro information system, the default spread, volatility index, and geopolitical risk index are net information transmitters of soybeans volatility.", [["soybeans", "ORGANISM_SUBDIVISION", 144, 152], ["soybeans", "SPECIES", 7, 15], ["volatility index", "TEST", 62, 78], ["geopolitical risk index", "PROBLEM", 84, 107]]], ["In contrast, the economic policy uncertainty index, economic surprise index, and investor sentiment index are net information receivers, where the default spread and soybeans volatility have the largest differences in their mutual explanatory power.", [["soybeans", "ORGANISM_SUBDIVISION", 166, 174], ["economic surprise index", "TEST", 52, 75], ["largest", "OBSERVATION_MODIFIER", 195, 202]]], ["Unlike the gold-macro information system, the share of the total level of the net pairwise directional connectedness between crude oil and each macro information indicator accounts for a quarter of the total level of the net pairwise directional connectedness in the system, especially the net information flow from the volatility index to crude oil volatility, which is the most noticeable net information flow.Dynamic analysisThe static analysis of full-sample connectedness provides a good description of the connectedness between commodity futures volatility and macro information indicators throughout the full sample period, but the situation may change over time.", [["oil", "ANATOMY", 131, 134], ["oil", "ANATOMY", 346, 349], ["oil", "ORGANISM_SUBSTANCE", 131, 134], ["oil", "ORGANISM_SUBSTANCE", 346, 349], ["Dynamic analysis", "TEST", 412, 428], ["The static analysis", "TEST", 428, 447], ["oil volatility", "OBSERVATION", 346, 360]]], ["2 Fig. 2 show the total connectedness in the commodity-macro information system, and the red dashed line in the figure shows the mean value of the dynamic total connectedness of each commodity-macro information system.", [["red dashed line", "CELL_LINE", 89, 104], ["the red dashed line", "TREATMENT", 85, 104]]], ["As a whole, the mean value of the dynamic total connectedness of each system is about 60%, which reveals that there is a high degree of integration between the volatility of the commodity market and macro information in the short term.", [["the mean value", "TEST", 12, 26], ["high degree", "OBSERVATION_MODIFIER", 121, 132], ["volatility", "OBSERVATION_MODIFIER", 160, 170]]], ["The range of the total Note: SI = investor sentiment index, VIX = volatility index, DEF = default spread, EPU = US economic policy uncertainty Index, ESI = Citi economic surprise index, GPR = geopolitical risk index.", [["sentiment index", "TEST", 43, 58], ["VIX", "TEST", 60, 63], ["DEF = default spread", "PROBLEM", 84, 104], ["EPU", "TEST", 106, 109], ["Index", "TEST", 143, 148], ["ESI", "TEST", 150, 153], ["GPR", "TEST", 186, 189], ["geopolitical risk index", "PROBLEM", 192, 215]]], ["2 We also use 60, 70 and 80 weeks as three alternative window size, and the results are robust.", [["size", "OBSERVATION_MODIFIER", 62, 66]]], ["Hence, we only present the results of the window size of 50 weeks. connectedness of the soybeans-macro information system is concentrated between 50% and 70%, while the range of the total connectedness of the gold-and crude oil-macro information systems are relatively large, ranging from 47% to 78%.", [["the gold-and crude oil", "TREATMENT", 205, 227], ["relatively", "OBSERVATION_MODIFIER", 258, 268], ["large", "OBSERVATION", 269, 274], ["ranging", "OBSERVATION_MODIFIER", 276, 283]]], ["This indicates that the total connectedness of the gold-and crude oil-macro information systems have stronger time-varying characteristics.", [["the gold-and crude oil", "TREATMENT", 47, 69]]], ["In particular, the total connectedness of the soybeans-and gold -macro information systems can be divided into three periods.", [["the soybeans", "TREATMENT", 42, 54], ["gold -macro information systems", "TREATMENT", 59, 90]]], ["From 2012, in response to the global economic downturn, a series of policy actions, such as quantitative easing, have been used across the world.", [["policy actions", "TREATMENT", 68, 82]]], ["These policies had a positive impact on the markets, but also increased the linkage between macro information and the commodity markets.", [["positive", "OBSERVATION_MODIFIER", 21, 29], ["impact", "OBSERVATION_MODIFIER", 30, 36], ["increased", "OBSERVATION_MODIFIER", 62, 71]]], ["This peak can be explained by investor panic caused by the US stock market's plunge on August 24, 2015.", [["panic", "DISEASE", 39, 44], ["investor panic", "PROBLEM", 30, 44]]], ["In most periods, the dynamic net total directional connectedness of commodity futures is between \u2212 30% and 30%, the change of the explanatory power of gold and crude oil futures to the system is much higher than that of soybeans to the system.", [["gold", "CHEMICAL", 151, 155], ["gold", "SIMPLE_CHEMICAL", 151, 155], ["oil", "ORGANISM_SUBSTANCE", 166, 169], ["soybeans", "ORGANISM_SUBDIVISION", 220, 228], ["soybeans", "SPECIES", 220, 228], ["gold and crude oil", "TREATMENT", 151, 169], ["most periods", "OBSERVATION_MODIFIER", 3, 15]]], ["In addition, similar to the static connectedness networks, gold futures play a dominant role in the information transmissions, while soybeans and crude oil futures are net information receivers.Dynamic analysisFurthermore, combining Figs.", [["soybeans", "ORGANISM_SUBDIVISION", 133, 141], ["oil", "ORGANISM_SUBSTANCE", 152, 155], ["soybeans", "SPECIES", 133, 141]]], ["2 and 3, we find that in most periods, the change of the dynamic total connectedness is not caused by the net information flow from commodity futures to the systems.", [["not caused", "UNCERTAINTY", 88, 98]]], ["The only exception is the significant increase in the total connectedness in the crude oil-macro information system at the end of 2014, which is caused by the substantial increase in the information outflow from crude oil futures.", [["oil", "ORGANISM_SUBSTANCE", 218, 221], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["increase", "OBSERVATION_MODIFIER", 38, 46], ["total", "OBSERVATION_MODIFIER", 54, 59], ["connectedness", "OBSERVATION_MODIFIER", 60, 73], ["substantial", "OBSERVATION_MODIFIER", 159, 170], ["increase", "OBSERVATION_MODIFIER", 171, 179]]], ["Moreover, changes in the influence of each macro information on soybeans volatility is relatively small, where the default spread and the investor sentiment index account for a relatively large proportion.", [["soybeans", "ORGANISM_SUBDIVISION", 64, 72], ["the default spread", "PROBLEM", 111, 129], ["the investor sentiment index", "TEST", 134, 162], ["relatively", "OBSERVATION_MODIFIER", 87, 97], ["small", "OBSERVATION_MODIFIER", 98, 103], ["large", "OBSERVATION_MODIFIER", 188, 193]]], ["For gold futures, the fluctuation of the information inflow mainly stems from the investor sentiment index and the volatility index.", [["the investor sentiment index", "TEST", 78, 106], ["the volatility index", "TEST", 111, 131], ["volatility index", "OBSERVATION", 115, 131]]], ["Together, the mean of the information outflow from the investor sentiment index and the volatility index are about 11%.", [["the investor sentiment index", "TEST", 51, 79], ["the volatility index", "TEST", 84, 104], ["volatility", "OBSERVATION_MODIFIER", 88, 98], ["index", "OBSERVATION_MODIFIER", 99, 104]]], ["For crude oil futures, the prices fluctuation mainly stems from the default spread and the volatility index.", [["oil", "ORGANISM_SUBSTANCE", 10, 13], ["crude oil futures", "TREATMENT", 4, 21], ["the prices fluctuation", "TEST", 23, 45], ["the volatility index", "TEST", 87, 107], ["default spread", "OBSERVATION", 68, 82]]], ["In other words, the business cycle and the investors panic are the main risk sources for crude oil futures volatility.", [["oil", "ANATOMY", 95, 98], ["panic", "DISEASE", 53, 58], ["oil", "ORGANISM_SUBSTANCE", 95, 98], ["panic", "PROBLEM", 53, 58]]], ["Moreover, in the short term, the volatility of crude oil futures is more affected by geopolitical risk than gold futures.", [["oil", "ORGANISM_SUBSTANCE", 53, 56], ["short term", "OBSERVATION_MODIFIER", 17, 27]]], ["It is worth noting that when the total connectedness and the net directional connectedness increased significantly at the end of 2014, the information outflow from macro information to crude oil volatility did not significantly increase.", [["oil", "ANATOMY", 191, 194], ["oil", "ORGANISM_SUBSTANCE", 191, 194], ["the net directional connectedness", "PROBLEM", 57, 90]]], ["This finding confirms Maghyereh et al. (2016) who claim the fall in crude oil prices in 2014 was not caused by an increase in information inflow from external information to crude oil, but rather by an increase in the production of shale oils.", [["oil", "ANATOMY", 74, 77], ["oil", "ANATOMY", 180, 183], ["oil", "ORGANISM_SUBSTANCE", 74, 77], ["oil", "ORGANISM_SUBSTANCE", 180, 183], ["the production of shale oils", "TREATMENT", 214, 242], ["increase", "OBSERVATION_MODIFIER", 202, 210], ["shale oils", "OBSERVATION", 232, 242]]], ["In other words, it is driven by the fundamentals of crude oil, or the oversupply in the global market.", [["oil", "ANATOMY", 58, 61], ["oil", "ORGANISM_SUBSTANCE", 58, 61]]], ["In addition, the increase in information outflow from the volatility index to each commodity futures volatility in August 2015 also confirms that the investor panic caused by the US stock market's plunge is responsible for the sudden increase in the total connectedness.ConclusionTaking soybeans, gold and crude oil futures as representatives of three main types of commodities in the international market, we study how macro factors affect their price fluctuations.", [["panic", "DISEASE", 159, 164], ["gold", "SIMPLE_CHEMICAL", 297, 301], ["oil", "ORGANISM_SUBSTANCE", 312, 315], ["the investor panic", "PROBLEM", 146, 164], ["the sudden increase", "PROBLEM", 223, 242], ["increase", "OBSERVATION_MODIFIER", 17, 25], ["increase", "OBSERVATION_MODIFIER", 234, 242]]], ["Extended from the existing literature, we consider three dimensions of macro factors, namely, macroeconomics, capital market and geopolitical risks in a systemic framework to evaluate their interactions with each commodities.", [["a systemic framework", "TREATMENT", 151, 171]]], ["We also use high-frequency data to calculate realized volatility for each commodity and the Diebold and Yilmaz (2014) approach to evaluate both static and dynamic connectedness.ConclusionThe empirical results show certain similarities in three networks (one for each commodity), which is consistent with the strong co-movement among commodities found in the existing literature.", [["high-frequency data", "TREATMENT", 12, 31], ["the Diebold and Yilmaz", "TREATMENT", 88, 110], ["consistent with", "UNCERTAINTY", 288, 303]]], ["There are however, some clear differences.", [["some", "OBSERVATION_MODIFIER", 19, 23], ["clear", "OBSERVATION", 24, 29]]], ["First, the role of each commodities in their own networks differs: gold plays a dominant role in its network and is a net information contributor, whereas soybeans and crude oil futures are net information receivers.", [["gold", "CHEMICAL", 67, 71], ["soybeans", "ORGANISM_SUBDIVISION", 155, 163]]], ["Second, crude oil futures volatility is more sensitive to changes in macro information than soybeans and gold futures.", [["oil", "ANATOMY", 14, 17], ["oil", "ORGANISM_SUBSTANCE", 14, 17], ["soybeans", "ORGANISM_SUBDIVISION", 92, 100], ["soybeans", "SPECIES", 92, 100]]], ["In particular, investor panic has the greatest impact on the realized volatility of crude oil and gold futures, while the business cycle contributes the most to the realized volatility of soybeans futures.", [["oil", "ANATOMY", 90, 93], ["panic", "DISEASE", 24, 29], ["oil", "ORGANISM_SUBSTANCE", 90, 93], ["soybeans", "ORGANISM_SUBDIVISION", 188, 196], ["soybeans", "SPECIES", 188, 196], ["investor panic", "PROBLEM", 15, 29], ["greatest", "OBSERVATION_MODIFIER", 38, 46]]], ["Third, our results show that the volatility index is the largest information receiver in each system, while economic policy uncertainty is an important source for systemic volatility.ConclusionInterestingly, the total connectedness of the gold-and crude oilmacro information systems present significant time-varying characteristics, while the total connectedness of the soybeans-macro information systems is relatively stable.", [["the volatility index", "TEST", 29, 49], ["systemic volatility", "PROBLEM", 163, 182], ["largest", "OBSERVATION_MODIFIER", 57, 64], ["significant", "OBSERVATION_MODIFIER", 291, 302], ["relatively", "OBSERVATION_MODIFIER", 408, 418], ["stable", "OBSERVATION_MODIFIER", 419, 425]]], ["It reflects that gold and crude oil are special in the sense of dynamic process.ConclusionThere are also some interesting differences for each commodity.", [["oil", "ANATOMY", 32, 35], ["gold", "CHEMICAL", 17, 21], ["gold", "SIMPLE_CHEMICAL", 17, 21], ["oil", "ORGANISM_SUBSTANCE", 32, 35], ["gold and crude oil", "TREATMENT", 17, 35], ["gold", "OBSERVATION_MODIFIER", 17, 21]]], ["The main driving forces for each time varying total network connectedness differ across commodities.", [["main", "OBSERVATION_MODIFIER", 4, 8], ["driving forces", "OBSERVATION", 9, 23]]], ["In particular, the fluctuation in the total connectedness in the soybeans-macro information system mainly stems from default spread and the investor sentiment index, while the fluctuation in the total connectedness in the gold-macro information system mainly stems from the investor sentiment index and the volatility index.", [["default spread", "PROBLEM", 117, 131], ["the investor sentiment index", "TEST", 136, 164], ["the investor sentiment index", "TEST", 270, 298], ["the volatility index", "TEST", 303, 323], ["fluctuation", "OBSERVATION_MODIFIER", 19, 30], ["default spread", "OBSERVATION", 117, 131], ["volatility index", "OBSERVATION", 307, 323]]], ["Additionally, the fluctuation in the total connectedness in the crude oilmacro information system mainly stems from default spread and the volatility index.", [["the fluctuation", "PROBLEM", 14, 29], ["default spread", "PROBLEM", 116, 130], ["the volatility index", "TEST", 135, 155], ["fluctuation", "OBSERVATION_MODIFIER", 18, 29], ["default spread", "OBSERVATION", 116, 130], ["volatility index", "OBSERVATION", 139, 155]]], ["Specifically, market regulators should strengthen the monitoring of speculation in the financial and commodity markets and stabilize investor sentiment in the capital markets.", [["capital", "ANATOMY_MODIFIER", 159, 166]]], ["Specific regulatory measures should be applied to different commodity types in order to achieve the optimal regulatory effects.", [["Specific regulatory measures", "TREATMENT", 0, 28]]], ["Investors can also diversify their investment portfolios according to the different characteristics of information spillovers between commodity futures and macro factors, so as to minimize the risk of their investment.", [["macro factors", "PROBLEM", 156, 169]]], ["For example, in addition to paying attention to the impact of market sentiment on all commodity markets, the impact of business cycles on soybean and crude oil price fluctuations and the impact of geopolitical risk on crude oil price fluctuations should be specifically considered.", [["oil", "ANATOMY", 156, 159], ["oil", "ANATOMY", 224, 227], ["soybean", "ORGANISM_SUBDIVISION", 138, 145], ["oil", "ORGANISM_SUBSTANCE", 224, 227], ["soybean", "SPECIES", 138, 145], ["soybean", "SPECIES", 138, 145], ["business cycles", "TREATMENT", 119, 134], ["soybean and crude oil price fluctuations", "TREATMENT", 138, 178], ["crude oil price", "TREATMENT", 218, 233]]], ["More importantly, investors and market regulators should dynamically adjust investment portfolios or commodity market management strategies in response to changes in the correlation between commodity markets and macro factors over time.ConclusionWhile this paper shows some interesting implications that macro- factors can play very critical roles in commodity markets, it is important to note the fundamental reasons remain unclear and worth for further investigation.", [["investment portfolios", "TREATMENT", 76, 97], ["commodity market management strategies", "TREATMENT", 101, 139], ["further investigation", "TEST", 447, 468]]], ["The time series approach used here can potentially combine with standard econometric analysis, which could be an interesting direction of future research.", [["standard econometric analysis", "TEST", 64, 93]]]], "PMC7323832": [["Statistical Analysis ::: METHODSDemographic data were summarized using mean and standard deviation (SD) for continuous data.", [["METHODSDemographic data", "TEST", 25, 48], ["mean", "TEST", 71, 75], ["continuous data", "TEST", 108, 123]]], ["Percentages were listed for categorical data.", [["Percentages", "TEST", 0, 11], ["categorical data", "TEST", 28, 44]]], ["Given the small sample size, Fisher exact test was used to evaluate the association between body mass index (BMI) and gender and QLFT results.RESULTSOf the 92 HCWs screened (79 via email and 13 in person), 29 HCWs (24 women, 5 men) agreed to participate (Figure 1; Table 1).", [["body", "ANATOMY", 92, 96], ["body", "ORGANISM_SUBDIVISION", 92, 96], ["women", "ORGANISM", 218, 223], ["men", "ORGANISM", 227, 230], ["person", "SPECIES", 197, 203], ["women", "SPECIES", 218, 223], ["men", "SPECIES", 227, 230], ["the small sample size", "PROBLEM", 6, 27], ["Fisher exact test", "TEST", 29, 46], ["body mass index", "TEST", 92, 107], ["small", "OBSERVATION_MODIFIER", 10, 15], ["sample", "OBSERVATION_MODIFIER", 16, 22], ["size", "OBSERVATION_MODIFIER", 23, 27]]], ["Three participants were excluded from the study, 2 because of abnormal facial anatomy and the other due to claustrophobia.", [["facial", "ANATOMY", 71, 77], ["abnormal facial anatomy", "DISEASE", 62, 85], ["claustrophobia", "DISEASE", 107, 121], ["facial", "ORGAN", 71, 77], ["participants", "SPECIES", 6, 18], ["the study", "TEST", 38, 47], ["abnormal facial anatomy", "PROBLEM", 62, 85], ["claustrophobia", "PROBLEM", 107, 121], ["facial", "ANATOMY", 71, 77], ["anatomy", "OBSERVATION", 78, 85]]], ["Twenty-six participants (23 women, 3 men) were retested (Table 2).", [["participants", "ORGANISM", 11, 23], ["women", "ORGANISM", 28, 33], ["men", "ORGANISM", 37, 40], ["participants", "SPECIES", 11, 23], ["women", "SPECIES", 28, 33], ["men", "SPECIES", 37, 40]]], ["Mean BMI was 24 (women = 24, SD = 5.2; men = 25, SD = 4.38) (Table 1).RESULTSSixteen women and 2 men, 68% of the participants, passed with an MAR.", [["women", "ORGANISM", 85, 90], ["men", "ORGANISM", 97, 100], ["participants", "ORGANISM", 113, 125], ["women", "SPECIES", 17, 22], ["men", "SPECIES", 39, 42], ["women", "SPECIES", 85, 90], ["men", "SPECIES", 97, 100], ["participants", "SPECIES", 113, 125], ["Mean BMI", "TEST", 0, 8], ["women", "TEST", 17, 22], ["SD", "TEST", 29, 31], ["men", "TEST", 39, 42], ["SD", "TEST", 49, 51]]], ["There were 9 failures (35%) despite the modification (Tables 2 and 3).", [["9 failures", "PROBLEM", 11, 21], ["9 failures", "OBSERVATION_MODIFIER", 11, 21]]], ["Of the 9 HCWs who failed the MAR fit test, 5 later passed with a Safelite respirator (Columbus, OH) and 3 passed with a 3M 8210 respirator.", [["the MAR fit test", "TEST", 25, 41], ["a 3M 8210 respirator", "TREATMENT", 118, 138]]], ["One failed with each of the respirator models available to us (3M, Safelite, and Kimberly-Clark respirators [Kimberly-Clark, Irving, TX]).RESULTSOf the 26 personnel who participated in the study, 14 participants had a BMI between 18 and 25 and 12 had a BMI >25.", [["participants", "ORGANISM", 199, 211], ["participants", "SPECIES", 199, 211], ["the study", "TEST", 185, 194], ["a BMI", "TEST", 216, 221], ["a BMI", "TEST", 251, 256]]], ["Mean BMI was 24 (women = 24, SD = 5.2; men = 25, SD = 4.38) (Table 1).", [["women", "SPECIES", 17, 22], ["men", "SPECIES", 39, 42], ["Mean BMI", "TEST", 0, 8], ["women", "TEST", 17, 22], ["SD", "TEST", 29, 31], ["men", "TEST", 39, 42], ["SD", "TEST", 49, 51]]], ["Although the BMI of those who failed fit testing with an MAR was slightly lower than those who did not fail (mean, 24 vs 25), no significant relationship of fit to an MAR and BMI was observed (P = .59) (Table 2).RESULTSWe also looked back at the original cohort (N = 63) of HCWs who failed their fit tests but did not participate in our study.", [["fit testing", "TEST", 37, 48], ["an MAR", "TEST", 54, 60], ["mean", "TEST", 109, 113], ["BMI", "TEST", 175, 178], ["P", "TEST", 193, 194], ["their fit tests", "TEST", 290, 305], ["our study", "TEST", 333, 342]]], ["In that group, 73% of HCWs (46 women, 17 men) who failed were women.", [["HCWs", "ORGANISM", 22, 26], ["women", "ORGANISM", 31, 36], ["men", "ORGANISM", 41, 44], ["women", "ORGANISM", 62, 67], ["women", "SPECIES", 31, 36], ["men", "SPECIES", 41, 44], ["women", "SPECIES", 62, 67]]], ["However, we found no relationship between fit with an MAR and sex, likely due to the small participant group (P = .227) (Table 2).RESULTSOf the 63 HCWs in the original cohort, 16 (46%) passed with a 3M 8210 respirator, 14 (40%) passed with a Safelite SM respirator, and 5 (14%) passed with a Kimberly-Clark SM/R respirator.", [["an MAR and sex", "TEST", 51, 65], ["respirator", "TEST", 207, 217], ["a Safelite SM respirator", "TREATMENT", 240, 264], ["a Kimberly-Clark SM/R respirator", "TREATMENT", 290, 322], ["likely due to", "UNCERTAINTY", 67, 80], ["small", "OBSERVATION_MODIFIER", 85, 90]]], ["Twenty-eight HCWS did not follow-up with occupational health.DiscussionThe results of this study are in accordance with data suggesting that for high-efficacy respirators, the greatest contributing factor to inward leakage is the face seal.5 An MAR eliminated face seal leakage in 68% of the participants who had previously failed.", [["face seal", "ANATOMY", 260, 269], ["HCWS", "DISEASE", 13, 17], ["participants", "SPECIES", 292, 304], ["this study", "TEST", 86, 96], ["high-efficacy respirators", "PROBLEM", 145, 170], ["inward leakage", "PROBLEM", 208, 222], ["the face seal", "TREATMENT", 226, 239], ["An MAR eliminated face seal leakage", "PROBLEM", 242, 277], ["inward", "OBSERVATION_MODIFIER", 208, 214], ["leakage", "OBSERVATION", 215, 222], ["face seal", "OBSERVATION", 230, 239], ["seal", "OBSERVATION_MODIFIER", 265, 269], ["leakage", "OBSERVATION", 270, 277]]], ["During manufacturing, total inward leakage can be tested using sulfur hexafluoride gas, but this testing is not a part of National Institute for Occupational Safety and Health standards.", [["sulfur hexafluoride", "CHEMICAL", 63, 82], ["sulfur hexafluoride", "CHEMICAL", 63, 82], ["sulfur hexafluoride", "SIMPLE_CHEMICAL", 63, 82], ["total inward leakage", "PROBLEM", 22, 42], ["sulfur hexafluoride gas", "TEST", 63, 86], ["this testing", "TEST", 92, 104]]], ["Also, even if the respirator originally fit well, the face seal may be breached during use.7 Factors including physical activity, ventilatory rate, and head and body movements influence particle entry through face seal leaks.2 Some studies have also suggested that N95 respirators fail to protect HCWs during strenuous activities such as performing chest compressions.8,9DiscussionIn line with studies by Lee et al10 and McMahon et al,11 women had higher fit failure rates compared with men.", [["head", "ANATOMY", 152, 156], ["body", "ANATOMY", 161, 165], ["chest", "ANATOMY", 349, 354], ["head", "ORGANISM_SUBDIVISION", 152, 156], ["body", "ORGANISM_SUBDIVISION", 161, 165], ["chest", "ORGANISM_SUBDIVISION", 349, 354], ["women", "ORGANISM", 438, 443], ["men", "ORGANISM", 487, 490], ["women", "SPECIES", 438, 443], ["men", "SPECIES", 487, 490], ["the face seal", "TREATMENT", 50, 63], ["physical activity", "TEST", 111, 128], ["ventilatory rate", "TEST", 130, 146], ["head and body movements", "TEST", 152, 175], ["face seal leaks", "PROBLEM", 209, 224], ["Some studies", "TEST", 227, 239], ["N95 respirators", "TREATMENT", 265, 280], ["performing chest compressions", "TREATMENT", 338, 367], ["higher fit failure rates", "PROBLEM", 448, 472], ["head", "ANATOMY", 152, 156], ["seal leaks", "OBSERVATION", 214, 224], ["chest", "ANATOMY", 349, 354], ["failure", "OBSERVATION", 459, 466]]], ["We observed a similar pattern with fit testing of standard respirators.", [["fit testing", "TEST", 35, 46]]], ["Due to small sample size, we were unable to test for sex differences with the MAR.DiscussionConsistent with studies by Harber et al12 and Roberge et al,13 our study participants reported that the leaks were most prominent at the nasal bridge.", [["nasal", "ANATOMY", 229, 234], ["participants", "ORGANISM", 165, 177], ["nasal", "ORGAN", 229, 234], ["MAR", "DNA", 78, 81], ["participants", "SPECIES", 165, 177], ["small sample size", "PROBLEM", 7, 24], ["the leaks", "PROBLEM", 192, 201], ["small", "OBSERVATION_MODIFIER", 7, 12], ["sample", "OBSERVATION_MODIFIER", 13, 19], ["size", "OBSERVATION_MODIFIER", 20, 24], ["leaks", "OBSERVATION", 196, 201], ["most prominent", "OBSERVATION_MODIFIER", 207, 221], ["nasal bridge", "ANATOMY", 229, 241]]], ["We observed that the metal nose clip on the 3M respirator hindered the adhesive tape from conforming to the nasal bridge.DiscussionThis study had limitations.", [["nasal", "ANATOMY", 108, 113], ["nasal", "ORGAN", 108, 113], ["the metal nose clip", "TREATMENT", 17, 36], ["the 3M respirator", "TREATMENT", 40, 57], ["the adhesive tape", "TREATMENT", 67, 84], ["the nasal bridge", "TREATMENT", 104, 120], ["This study", "TEST", 131, 141], ["clip", "OBSERVATION", 32, 36], ["adhesive tape", "OBSERVATION", 71, 84], ["nasal", "ANATOMY", 108, 113]]], ["First, the overall response rate was low because 55% (35 of the 63 in the original cohort) of HCWs were offered other respirator models and passed the fit test with those.", [["the overall response rate", "TEST", 7, 32], ["the fit test", "TEST", 147, 159]]], ["Our results may be biased in that those who responded were those who had been unable to find a respirator that passed the fit test.", [["the fit test", "TEST", 118, 130]]], ["Second, the modification we applied to the respirator was nonstandard and has not been tested or validated before.", [["the modification", "TREATMENT", 8, 24], ["the respirator", "TREATMENT", 39, 53]]], ["This modification can be inadequate because the MAR did not undergo vigorous quality tests as a commercial respirator would.", [["vigorous quality tests", "TEST", 68, 90], ["a commercial respirator", "TREATMENT", 94, 117]]], ["Third, we only tested a small number of HCWs due to scarcity of resources.", [["small", "OBSERVATION_MODIFIER", 24, 29]]], ["More studies are needed to test the efficacy of adhesive-sealed respirators.ConclusionsA successful respirator fit test is important for the safety of HCWs and should be an essential component of a respirator program.", [["adhesive-sealed respirators", "TREATMENT", 48, 75], ["A successful respirator fit test", "TEST", 87, 119], ["a respirator program", "TREATMENT", 196, 216]]], ["Sex is an important consideration because the failure rate is much higher in women than in men.", [["women", "ORGANISM", 77, 82], ["men", "ORGANISM", 91, 94], ["women", "SPECIES", 77, 82], ["men", "SPECIES", 91, 94], ["the failure rate", "PROBLEM", 42, 58], ["important consideration", "UNCERTAINTY", 10, 33], ["failure", "OBSERVATION", 46, 53]]], ["Respirator manufacturers should consider fit characteristics and focus on minimizing face seal leakage.", [["Respirator manufacturers", "TREATMENT", 0, 24], ["minimizing face seal leakage", "TREATMENT", 74, 102], ["leakage", "OBSERVATION", 95, 102]]], ["We further recommend that an adhesive modification be considered to protect HCWs during strenuous work activities, even if a passing fit is initially achieved.DISCLOSURESName: Richa Wardhan, MD.DISCLOSURESContribution: This author helped with study design, literature search, manuscript preparation, and tables.DISCLOSURESName: Meghan M. Brennan, MD.DISCLOSURESContribution: This author helped with data analysis, data analysis interpretation, and manuscript preparation.DISCLOSURESName: Holden L. Brown, MD.DISCLOSURESContribution: This author helped with data collection, study design, and manuscript preparation.DISCLOSURESName: Trey B. Creech, MD.DISCLOSURESContribution: This author helped with data collection, study design, and manuscript preparation.DISCLOSURESThis manuscript was handled by: BobbieJean Sweitzer, MD, FACP.", [["an adhesive modification", "TREATMENT", 26, 50], ["data analysis", "TEST", 399, 412], ["data analysis interpretation", "TEST", 414, 442], ["data collection", "TEST", 557, 572], ["manuscript preparation", "TREATMENT", 592, 614], ["manuscript preparation", "TREATMENT", 735, 757]]]], "472612fa7100a706e3f38c291e900e4402b92f06": [["HOLOCAUST SURVIVORS' REACTIONS TO COVID-19Letter to the Editor: Suffering from Infectious Diseases during the HolocaustRelates to Amplified Psychological Reactions during the COVID-19 PandemicOlder adults are more susceptible to coronavirus disease 2019 health complications and are likely to remain in stricter self-isolation than other age groups (Shahid et al., 2020) .", [["Infectious Diseases", "DISEASE", 79, 98], ["coronavirus disease", "DISEASE", 229, 248], ["coronavirus", "ORGANISM", 229, 240], ["Infectious Diseases", "PROBLEM", 79, 98], ["Amplified Psychological Reactions", "PROBLEM", 130, 163], ["the COVID-19 PandemicOlder adults", "TREATMENT", 171, 204], ["coronavirus disease", "PROBLEM", 229, 248], ["Infectious", "OBSERVATION", 79, 89]]], ["Therefore, COVID-19 related anxiety and the effects of isolation and ensuing loneliness may be especially severe for them (Vahia et al., 2020) .", [["anxiety", "DISEASE", 28, 35], ["loneliness", "DISEASE", 77, 87], ["COVID", "TEST", 11, 16], ["anxiety", "PROBLEM", 28, 35], ["isolation", "TREATMENT", 55, 64]]], ["Therefore, a critical goal is to map risk assessment: who is more psychologically vulnerable and who is relatively resilient vis-\u00e0-vis the COVID-19 pandemic.Relates to Amplified Psychological Reactions during the COVID-19 PandemicOne potentially in-risk group may be that of older adults suffering from longterm effects of traumatic events.", [["the COVID", "TEST", 135, 144], ["pandemic", "PROBLEM", 148, 156], ["Amplified Psychological Reactions", "PROBLEM", 168, 201], ["the COVID", "TREATMENT", 209, 218], ["traumatic events", "PROBLEM", 323, 339]]], ["Relatedly, the psychological consequences of massive traumatic events such as World War II (WWII) may persist for decades (Rzeszutek et al., 2020) .", [["massive traumatic events", "PROBLEM", 45, 69], ["massive", "OBSERVATION_MODIFIER", 45, 52], ["traumatic", "OBSERVATION", 53, 62]]], ["Many of them not only cope with posttraumatic stress disorder (PTSD) symptoms and other impairments (Barel et al., 2010) , they may also suffer the resurface of Holocaust memories due to COVID-19 threats.Relates to Amplified Psychological Reactions during the COVID-19 PandemicAccording to memory-based theories of PTSD (Brewin, 2014), present circumstances akin to past traumatic conditions can trigger involuntary retrieval and reliving of intense trauma-related memories and images.", [["posttraumatic stress disorder", "DISEASE", 32, 61], ["PTSD", "DISEASE", 63, 67], ["Holocaust memories", "DISEASE", 161, 179], ["PTSD", "DISEASE", 315, 319], ["trauma", "DISEASE", 450, 456], ["posttraumatic stress disorder", "PROBLEM", 32, 61], ["PTSD) symptoms", "PROBLEM", 63, 77], ["other impairments", "PROBLEM", 82, 99], ["COVID", "TEST", 187, 192], ["Amplified Psychological Reactions", "PROBLEM", 215, 248], ["the COVID", "TREATMENT", 256, 265], ["PTSD", "PROBLEM", 315, 319], ["past traumatic conditions", "PROBLEM", 366, 391], ["involuntary retrieval", "TREATMENT", 404, 425], ["intense trauma", "PROBLEM", 442, 456], ["images", "TEST", 478, 484]]], ["Similarly, the current pandemic is reminiscent of various adverse conditions that have existed during the Holocaust, among them the prolonged isolation, the separation from family members J o u r n a l P r e -p r o o f due to COVID-19 health policy, but mostly the omnipresent risk of an infectious disease (Cohn-Schwartz et al., 2020) .Relates to Amplified Psychological Reactions during the COVID-19 PandemicWe, therefore, hypothesized that survivors, especially those who contracted infectious diseases during the Holocaust, would report higher levels of PTSD symptoms, COVID-19 worries, and loneliness relative to comparisons.MethodThe sample included 127 older adult Jewish Israelis born before 1945 divided into three groups: 26 survivors who reported having contracted infectious diseases (e.g., tuberculosis, dysentery, etc.) during the Holocaust, 70 survivors who reported not having contracted such diseases, and 31 Jews of European descent who did not live in Nazi or pro-Nazi dominated countries.", [["infectious disease", "DISEASE", 288, 306], ["infectious diseases", "DISEASE", 486, 505], ["PTSD", "DISEASE", 558, 562], ["infectious diseases", "DISEASE", 776, 795], ["tuberculosis", "DISEASE", 803, 815], ["dysentery", "DISEASE", 817, 826], ["various adverse conditions", "PROBLEM", 50, 76], ["the prolonged isolation", "TREATMENT", 128, 151], ["COVID", "TEST", 226, 231], ["an infectious disease", "PROBLEM", 285, 306], ["Amplified Psychological Reactions", "PROBLEM", 348, 381], ["PTSD symptoms", "PROBLEM", 558, 571], ["contracted infectious diseases", "PROBLEM", 765, 795], ["tuberculosis", "PROBLEM", 803, 815], ["dysentery", "PROBLEM", 817, 826], ["contracted such diseases", "PROBLEM", 893, 917], ["infectious", "OBSERVATION", 288, 298], ["infectious", "OBSERVATION", 486, 496], ["infectious", "OBSERVATION", 776, 786], ["tuberculosis", "OBSERVATION", 803, 815], ["dysentery", "OBSERVATION", 817, 826]]], ["Eligible participants were located through contact lists provided by organizations related to older adults and survivors, and were interviewed face-to-face, by phone, or were requested to complete web-based questionnaire when possible, all on a voluntary basis.", [["participants", "SPECIES", 9, 21]]], ["Participants provided verbal informed consent to procedures approved by the ethics committee in Bar-Ilan University.MethodParticipants reported background characteristics and exposure to the Holocaust and to other traumatic events.", [["traumatic", "DISEASE", 214, 223], ["Participants", "SPECIES", 0, 12], ["other traumatic events", "PROBLEM", 208, 230]]], ["They noted whether they had chronic medical conditions suspected to increase the risk of death due to COVID-19 complications (i.e., cardiovascular disease, hypertension, diabetes, chronic respiratory disease, and cancer), and noted exposure to six COVID-19 pandemic-related events (Shrira et al., 2020) .", [["cardiovascular", "ANATOMY", 132, 146], ["respiratory", "ANATOMY", 188, 199], ["cancer", "ANATOMY", 213, 219], ["death", "DISEASE", 89, 94], ["COVID", "DISEASE", 102, 107], ["cardiovascular disease", "DISEASE", 132, 154], ["hypertension", "DISEASE", 156, 168], ["diabetes", "DISEASE", 170, 178], ["chronic respiratory disease", "DISEASE", 180, 207], ["cancer", "DISEASE", 213, 219], ["pandemic", "DISEASE", 257, 265], ["cancer", "CANCER", 213, 219], ["chronic medical conditions", "PROBLEM", 28, 54], ["death", "PROBLEM", 89, 94], ["COVID-19 complications", "PROBLEM", 102, 124], ["cardiovascular disease", "PROBLEM", 132, 154], ["hypertension", "PROBLEM", 156, 168], ["diabetes", "PROBLEM", 170, 178], ["chronic respiratory disease", "PROBLEM", 180, 207], ["cancer", "PROBLEM", 213, 219], ["cardiovascular", "ANATOMY", 132, 146], ["disease", "OBSERVATION", 147, 154], ["hypertension", "OBSERVATION", 156, 168], ["chronic", "OBSERVATION_MODIFIER", 180, 187], ["respiratory disease", "OBSERVATION", 188, 207], ["cancer", "OBSERVATION", 213, 219]]], ["Respondents further completed the 6-item ICD-11 PTSD questionnaire (Cloitre Relative to the comparison group, Holocaust survivor groups had a lower percentage of women, a lower percentage of those who completed secondary education, and reported having more medical conditions.", [["PTSD", "DISEASE", 48, 52], ["women", "ORGANISM", 162, 167], ["women", "SPECIES", 162, 167], ["ICD", "TREATMENT", 41, 44]]], ["The groups did not differ in other background characteristics or exposure to COVID-19 events.ResultsSurvivors with Holocaust-related diseases reported higher PTSD symptoms and loneliness than comparisons.", [["Holocaust-related diseases", "DISEASE", 115, 141], ["PTSD", "DISEASE", 158, 162], ["loneliness", "DISEASE", 176, 186], ["related diseases", "PROBLEM", 125, 141], ["higher PTSD symptoms", "PROBLEM", 151, 171], ["loneliness", "PROBLEM", 176, 186]]], ["Survivors without Holocaust-related diseases did not significantly differ from the other groups.", [["related diseases", "PROBLEM", 28, 44]]], ["Moreover, survivors with Holocaust-related diseases reported higher COVID-19 worries than both survivors without Holocaustrelated diseases and comparisons.", [["related diseases", "PROBLEM", 35, 51], ["Holocaustrelated diseases", "PROBLEM", 113, 138]]], ["Controlling for gender and medical conditions, group differences remained significant (for more details see Table 1 ).", [["gender and medical conditions", "PROBLEM", 16, 45]]], ["Study limitations include a convenience sample, symptoms based on self-report rather on psychiatric evaluation, and cross-sectional design.", [["psychiatric", "DISEASE", 88, 99], ["a convenience sample", "TEST", 26, 46], ["symptoms", "PROBLEM", 48, 56], ["psychiatric evaluation", "TEST", 88, 110]]], ["Despite limitations, to the best of our knowledge, this is the first study assessing Holocaust survivors' psychological reactions during the COVID-19 pandemic.", [["the first study", "TEST", 59, 74], ["psychological reactions", "PROBLEM", 106, 129], ["the COVID", "TEST", 137, 146], ["pandemic", "PROBLEM", 150, 158]]], ["Our preliminary findings can inform mental health professionals and policy makers in their efforts to minimize psychological damage among older adults.", [["psychological damage", "DISEASE", 111, 131], ["psychological damage", "PROBLEM", 111, 131]]], ["Tailored interventions aiming to mitigate distress and loneliness should be developed for Holocaust survivors, especially for those whose focal trauma is reactivated in the context of the current pandemic.", [["loneliness", "DISEASE", 55, 65], ["trauma", "DISEASE", 144, 150], ["Tailored interventions", "TREATMENT", 0, 22], ["distress", "PROBLEM", 42, 50], ["loneliness", "PROBLEM", 55, 65], ["those whose focal trauma", "PROBLEM", 126, 150], ["focal", "OBSERVATION_MODIFIER", 138, 143], ["trauma", "OBSERVATION", 144, 150], ["pandemic", "OBSERVATION", 196, 204]]], ["Future studies should assess whether the current findings generalize to other populations of older adults suffering from the long-term effects of WWII.ReferencesJ o u r n a l P r e -p r o o f The sum of exposure to the following experiences: currently in isolation, was in isolation, and contracted the coronavirus.", [["coronavirus", "DISEASE", 303, 314], ["coronavirus", "ORGANISM", 303, 314], ["Future studies", "TEST", 0, 14], ["WWII", "TREATMENT", 146, 150], ["the coronavirus", "PROBLEM", 299, 314], ["long-term effects", "OBSERVATION_MODIFIER", 125, 142]]], ["3 The sum of exposure to the following experiences: know people close to me, who have been in isolation, know people who have contracted the coronavirus, and know people who died of the coronavirus.", [["coronavirus", "DISEASE", 141, 152], ["coronavirus", "DISEASE", 186, 197], ["people", "ORGANISM", 57, 63], ["people", "ORGANISM", 110, 116], ["coronavirus", "ORGANISM", 141, 152], ["people", "ORGANISM", 163, 169], ["coronavirus", "ORGANISM", 186, 197], ["people", "SPECIES", 57, 63], ["people", "SPECIES", 110, 116], ["people", "SPECIES", 163, 169], ["the coronavirus", "PROBLEM", 182, 197]]], ["4 The sum of medical conditions reported from a list: cardiovascular disease, hypertension, diabetes, chronic respiratory disease, and cancer.", [["cardiovascular", "ANATOMY", 54, 68], ["respiratory", "ANATOMY", 110, 121], ["cancer", "ANATOMY", 135, 141], ["cardiovascular disease", "DISEASE", 54, 76], ["hypertension", "DISEASE", 78, 90], ["diabetes", "DISEASE", 92, 100], ["chronic respiratory disease", "DISEASE", 102, 129], ["cancer", "DISEASE", 135, 141], ["cancer", "CANCER", 135, 141], ["cardiovascular disease", "PROBLEM", 54, 76], ["hypertension", "PROBLEM", 78, 90], ["diabetes", "PROBLEM", 92, 100], ["chronic respiratory disease", "PROBLEM", 102, 129], ["cancer", "PROBLEM", 135, 141], ["cardiovascular", "ANATOMY", 54, 68], ["disease", "OBSERVATION", 69, 76], ["hypertension", "OBSERVATION", 78, 90], ["diabetes", "OBSERVATION", 92, 100], ["chronic", "OBSERVATION_MODIFIER", 102, 109], ["respiratory disease", "OBSERVATION", 110, 129], ["cancer", "OBSERVATION", 135, 141]]], ["5 Score was computed as sum of symptoms rated as at least moderately severe (\u22652 on a 5-point scale).", [["symptoms", "PROBLEM", 31, 39], ["moderately severe", "PROBLEM", 58, 75], ["moderately", "OBSERVATION_MODIFIER", 58, 68], ["severe", "OBSERVATION", 69, 75]]], ["6 Although education level also significantly differed across the study groups we did not control for it in the analyses of covariance, as we considered this difference to be a direct effect of the Holocaust.ReferencesNevertheless, in additional analyses group differences in PTSD symptoms, COVID-19 worries and loneliness remained significant even J o u r n a l P r e -p r o o f", [["PTSD", "DISEASE", 276, 280], ["loneliness", "DISEASE", 312, 322], ["education level", "TEST", 11, 26], ["PTSD symptoms", "PROBLEM", 276, 289], ["COVID", "TEST", 291, 296], ["loneliness", "PROBLEM", 312, 322]]]], "PMC6634972": [["IntroductionViral infection of the CNS can cause permanent neurologic damage and psychiatric disorders (Bergmann et al., 2006; Koyuncu et al., 2013; van den Pol, 2009).", [["CNS", "ANATOMY", 35, 38], ["neurologic", "ANATOMY", 59, 69], ["infection", "DISEASE", 18, 27], ["neurologic damage", "DISEASE", 59, 76], ["psychiatric disorders", "DISEASE", 81, 102], ["CNS", "ANATOMICAL_SYSTEM", 35, 38], ["IntroductionViral infection of the CNS", "PROBLEM", 0, 38], ["permanent neurologic damage", "PROBLEM", 49, 76], ["psychiatric disorders", "PROBLEM", 81, 102], ["infection", "OBSERVATION", 18, 27], ["CNS", "ANATOMY", 35, 38]]], ["Indeed, multiple viruses including Zika and West Nile virus have been associated with Guillain-Barre syndrome and memory deficits, respectively (Carson et al., 2006; Parra et al., 2016; Vasek et al., 2016).", [["Guillain-Barre syndrome", "DISEASE", 86, 109], ["memory deficits", "DISEASE", 114, 129], ["Zika", "GENE_OR_GENE_PRODUCT", 35, 39], ["West Nile virus", "ORGANISM", 44, 59], ["West Nile virus", "SPECIES", 44, 59], ["West Nile virus", "SPECIES", 44, 59], ["multiple viruses", "PROBLEM", 8, 24], ["Zika", "PROBLEM", 35, 39], ["West Nile virus", "PROBLEM", 44, 59], ["Barre syndrome", "PROBLEM", 95, 109], ["memory deficits", "PROBLEM", 114, 129], ["multiple", "OBSERVATION_MODIFIER", 8, 16], ["viruses", "OBSERVATION", 17, 24], ["Barre syndrome", "OBSERVATION", 95, 109]]], ["Moreover, while Parkinson\u2019s disease, multiple sclerosis, Alzheimer\u2019s disease, narcolepsy and other chronic neurologic diseases have unknown etiologies, initiation by CNS viral infection has been implicated (Itzhaki et al., 2016; Kakalacheva et al., 2011; Stoessl, 1999; Tesoriero et al., 2016; Virtanen and Jacobson, 2012).", [["neurologic", "ANATOMY", 107, 117], ["CNS", "ANATOMY", 166, 169], ["Parkinson\u2019s disease", "DISEASE", 16, 35], ["multiple sclerosis", "DISEASE", 37, 55], ["Alzheimer\u2019s disease", "DISEASE", 57, 76], ["narcolepsy", "DISEASE", 78, 88], ["chronic neurologic diseases", "DISEASE", 99, 126], ["viral infection", "DISEASE", 170, 185], ["CNS viral", "ORGANISM", 166, 175], ["Parkinson\u2019s disease", "PROBLEM", 16, 35], ["multiple sclerosis", "PROBLEM", 37, 55], ["Alzheimer\u2019s disease", "PROBLEM", 57, 76], ["narcolepsy", "PROBLEM", 78, 88], ["other chronic neurologic diseases", "PROBLEM", 93, 126], ["CNS viral infection", "PROBLEM", 166, 185], ["multiple", "OBSERVATION_MODIFIER", 37, 45], ["sclerosis", "OBSERVATION", 46, 55], ["chronic", "OBSERVATION_MODIFIER", 99, 106], ["neurologic diseases", "OBSERVATION", 107, 126]]], ["Viral infection of the CNS presents unique challenges to the immune system with regard to controlling and eliminating the invading pathogen.", [["CNS", "ANATOMY", 23, 26], ["immune system", "ANATOMY", 61, 74], ["Viral infection", "DISEASE", 0, 15], ["CNS", "ANATOMICAL_SYSTEM", 23, 26], ["immune system", "ANATOMICAL_SYSTEM", 61, 74], ["Viral infection of the CNS", "PROBLEM", 0, 26], ["the invading pathogen", "PROBLEM", 118, 139], ["infection", "OBSERVATION", 6, 15], ["CNS", "ANATOMY", 23, 26], ["invading", "OBSERVATION_MODIFIER", 122, 130], ["pathogen", "OBSERVATION", 131, 139]]], ["Resident cells of the CNS are often targets for infection and are critical in induction of distinct pro-inflammatory signatures that function to attract virus-specific lymphocytes into the CNS.", [["cells", "ANATOMY", 9, 14], ["CNS", "ANATOMY", 22, 25], ["lymphocytes", "ANATOMY", 168, 179], ["CNS", "ANATOMY", 189, 192], ["infection", "DISEASE", 48, 57], ["cells", "CELL", 9, 14], ["CNS", "ANATOMICAL_SYSTEM", 22, 25], ["lymphocytes", "CELL", 168, 179], ["CNS", "ANATOMICAL_SYSTEM", 189, 192], ["Resident cells", "CELL_TYPE", 0, 14], ["lymphocytes", "CELL_TYPE", 168, 179], ["infection", "PROBLEM", 48, 57], ["distinct pro-inflammatory signatures", "PROBLEM", 91, 127], ["CNS", "ANATOMY", 22, 25], ["infection", "OBSERVATION", 48, 57], ["CNS", "ANATOMY", 189, 192]]], ["Consequently, a significant hurdle encountered by infiltrating antigen-specific lymphocytes is to eliminate virus from infected cells while limiting damage that may have long-term detrimental consequences to the host.", [["lymphocytes", "ANATOMY", 80, 91], ["cells", "ANATOMY", 128, 133], ["antigen", "GENE_OR_GENE_PRODUCT", 63, 70], ["lymphocytes", "CELL", 80, 91], ["cells", "CELL", 128, 133], ["infiltrating antigen-specific lymphocytes", "CELL_TYPE", 50, 91], ["infected cells", "CELL_TYPE", 119, 133], ["infiltrating antigen", "PROBLEM", 50, 70], ["specific lymphocytes", "PROBLEM", 71, 91], ["virus", "PROBLEM", 108, 113], ["infected cells", "PROBLEM", 119, 133], ["long-term detrimental consequences", "PROBLEM", 170, 204], ["significant", "OBSERVATION_MODIFIER", 16, 27], ["infiltrating", "OBSERVATION", 50, 62], ["infected cells", "OBSERVATION", 119, 133], ["long-term detrimental", "OBSERVATION_MODIFIER", 170, 191]]], ["Therefore, defining antiviral host defense mechanisms within the CNS might highlight novel therapeutic interventions to prevent or treat many of these viral-induced neurologic disorders.IntroductionMicroglia are resident tissue phagocytes of the CNS that function in host defense and tissue homeostasis.", [["CNS", "ANATOMY", 65, 68], ["neurologic", "ANATOMY", 165, 175], ["Microglia", "ANATOMY", 198, 207], ["tissue phagocytes", "ANATOMY", 221, 238], ["CNS", "ANATOMY", 246, 249], ["tissue", "ANATOMY", 284, 290], ["neurologic disorders", "DISEASE", 165, 185], ["CNS", "ANATOMICAL_SYSTEM", 65, 68], ["Microglia", "CELL", 198, 207], ["tissue phagocytes", "CELL", 221, 238], ["CNS", "ANATOMICAL_SYSTEM", 246, 249], ["tissue", "TISSUE", 284, 290], ["Microglia", "CELL_TYPE", 198, 207], ["antiviral host defense mechanisms", "TREATMENT", 20, 53], ["novel therapeutic interventions", "TREATMENT", 85, 116], ["these viral-induced neurologic disorders", "PROBLEM", 145, 185], ["antiviral host", "OBSERVATION", 20, 34], ["viral", "OBSERVATION", 151, 156], ["CNS", "ANATOMY", 246, 249], ["host defense", "OBSERVATION", 267, 279], ["tissue homeostasis", "OBSERVATION", 284, 302]]], ["Recent studies have shown that despite their location within the CNS, microglia are impacted by the gut microbiota (Erny et al., 2015; Matcovitch-Natan et al., 2016; Sampson et al., 2016).", [["CNS", "ANATOMY", 65, 68], ["microglia", "ANATOMY", 70, 79], ["gut", "ANATOMY", 100, 103], ["CNS", "ANATOMICAL_SYSTEM", 65, 68], ["microglia", "CELL", 70, 79], ["gut", "ORGANISM_SUBDIVISION", 100, 103], ["microglia", "CELL_TYPE", 70, 79], ["Recent studies", "TEST", 0, 14], ["CNS", "ANATOMY", 65, 68], ["microglia", "ANATOMY", 70, 79]]], ["This is consistent with the known function of the microbiota on both immune cell composition and functionality (Belkaid and Hand, 2014; Hooper et al., 2012).", [["immune cell", "ANATOMY", 69, 80], ["immune cell", "CELL", 69, 80], ["consistent with", "UNCERTAINTY", 8, 23], ["immune cell composition", "OBSERVATION", 69, 92]]], ["Several studies have shown that resident commensal species can instruct the development of regulatory and inflammatory immune cell subsets that aid to limit viral replication at mucosal sites (Abt et al., 2012; Robinson and Pfeiffer, 2014).", [["immune cell", "ANATOMY", 119, 130], ["mucosal sites", "ANATOMY", 178, 191], ["inflammatory immune cell subsets", "CELL", 106, 138], ["mucosal sites", "MULTI-TISSUE_STRUCTURE", 178, 191], ["regulatory and inflammatory immune cell subsets", "CELL_TYPE", 91, 138], ["Several studies", "TEST", 0, 15], ["regulatory and inflammatory immune cell subsets", "TREATMENT", 91, 138], ["inflammatory immune cell subsets", "OBSERVATION", 106, 138]]], ["However, while the microbiota inhibits infection by some viruses, it can also enhance the infectivity of other viruses (Robinson and Pfeiffer, 2014).", [["infection", "DISEASE", 39, 48], ["infection", "PROBLEM", 39, 48], ["some viruses", "PROBLEM", 52, 64], ["infection", "OBSERVATION", 39, 48], ["viruses", "OBSERVATION", 57, 64]]], ["Thus, the contribution of the microbiota during viral infection may be distinct for each virus and might be determined by the location of infection.", [["viral infection", "DISEASE", 48, 63], ["infection", "DISEASE", 138, 147], ["viral infection", "PROBLEM", 48, 63], ["each virus", "PROBLEM", 84, 94], ["infection", "PROBLEM", 138, 147], ["infection", "OBSERVATION", 54, 63], ["infection", "OBSERVATION", 138, 147]]], ["Despite advancements in this area, it remains unclear if microbial commensals impact either host defense and/or disease in response to CNS viral infection.The microbiota protects from neurologic damage associated with viral infection ::: ResultsTo characterize the role of the microbiota in a model of viral-induced neurologic disease, 6- to 8-week-old C57BL/6 specific-pathogen-free (SPF) or germ-free (GF) mice were infected intracranially (i.c.) with the neurotropic JHM strain of mouse hepatitis virus (JHMV).", [["neurologic", "ANATOMY", 184, 194], ["neurologic", "ANATOMY", 316, 326], ["germ", "ANATOMY", 393, 397], ["intracranially", "ANATOMY", 427, 441], ["viral infection", "DISEASE", 139, 154], ["neurologic damage", "DISEASE", 184, 201], ["viral infection", "DISEASE", 218, 233], ["neurologic disease", "DISEASE", 316, 334], ["JHM", "CHEMICAL", 470, 473], ["mouse hepatitis virus", "DISEASE", 484, 505], ["CNS viral", "ORGANISM", 135, 144], ["C57BL/6 specific-pathogen", "ORGANISM", 353, 378], ["SPF", "ORGANISM", 385, 388], ["germ-free (GF)", "ORGANISM", 393, 407], ["mice", "ORGANISM", 408, 412], ["JHM strain", "ORGANISM", 470, 480], ["mouse hepatitis virus", "ORGANISM", 484, 505], ["JHMV", "CANCER", 507, 511], ["mice", "SPECIES", 408, 412], ["mouse", "SPECIES", 484, 489], ["hepatitis virus", "SPECIES", 490, 505], ["mice", "SPECIES", 408, 412], ["mouse hepatitis virus", "SPECIES", 484, 505], ["JHMV", "SPECIES", 507, 511], ["microbial commensals", "PROBLEM", 57, 77], ["disease", "PROBLEM", 112, 119], ["CNS viral infection", "PROBLEM", 135, 154], ["neurologic damage", "PROBLEM", 184, 201], ["viral infection", "PROBLEM", 218, 233], ["viral-induced neurologic disease", "PROBLEM", 302, 334], ["the neurotropic JHM strain", "TREATMENT", 454, 480], ["mouse hepatitis virus", "PROBLEM", 484, 505], ["host defense", "OBSERVATION", 92, 104], ["CNS", "ANATOMY", 135, 138], ["viral infection", "OBSERVATION", 139, 154], ["viral", "OBSERVATION_MODIFIER", 218, 223], ["infection", "OBSERVATION", 224, 233], ["neurologic disease", "OBSERVATION", 316, 334]]], ["JHMV infection results in an acute encephalomyelitis characterized by viral replication in astrocytes, microglia, and oligodendrocytes (Bergmann et al., 2006) (Greenberg et al., 2014) (Blanc et al., 2014; Carbajal et al., 2010; Marro et al., 2016; Schrauf et al., 2008; Stiles et al., 2006; Chen et al., 2014).", [["astrocytes", "ANATOMY", 91, 101], ["microglia", "ANATOMY", 103, 112], ["oligodendrocytes", "ANATOMY", 118, 134], ["JHMV infection", "DISEASE", 0, 14], ["encephalomyelitis", "DISEASE", 35, 52], ["astrocytes", "CELL", 91, 101], ["microglia", "CELL", 103, 112], ["oligodendrocytes", "CELL", 118, 134], ["astrocytes", "CELL_TYPE", 91, 101], ["microglia", "CELL_TYPE", 103, 112], ["oligodendrocytes", "CELL_TYPE", 118, 134], ["JHMV", "SPECIES", 0, 4], ["JHMV infection", "PROBLEM", 0, 14], ["an acute encephalomyelitis", "PROBLEM", 26, 52], ["viral replication in astrocytes", "PROBLEM", 70, 101], ["infection", "OBSERVATION", 5, 14], ["acute", "OBSERVATION_MODIFIER", 29, 34], ["encephalomyelitis", "OBSERVATION", 35, 52], ["viral replication", "OBSERVATION", 70, 87], ["astrocytes", "ANATOMY", 91, 101]]], ["Virus-specific T cells control viral replication through secretion of anti-viral cytokines and cytolytic activity.", [["T cells", "ANATOMY", 15, 22], ["Virus", "ORGANISM", 0, 5], ["T cells", "CELL", 15, 22], ["T cells", "CELL_TYPE", 15, 22], ["anti-viral cytokines", "PROTEIN", 70, 90], ["Virus", "PROBLEM", 0, 5], ["specific T cells", "TREATMENT", 6, 22], ["viral replication", "TREATMENT", 31, 48], ["anti-viral cytokines", "TREATMENT", 70, 90], ["cytolytic activity", "TREATMENT", 95, 113]]], ["Sterile immunity is not achieved and virus persists within white matter tracts in surviving mice that subsequently develop an immune-mediated demyelinating disease (Bender and Weiss, 2010; Bergmann et al., 2006; Cheng et al., 2018; Lane and Hosking, 2010; Libbey et al., 2014).", [["white matter tracts", "ANATOMY", 59, 78], ["demyelinating disease", "DISEASE", 142, 163], ["matter tracts", "PATHOLOGICAL_FORMATION", 65, 78], ["mice", "ORGANISM", 92, 96], ["mice", "SPECIES", 92, 96], ["mice", "SPECIES", 92, 96], ["Sterile immunity", "TREATMENT", 0, 16], ["virus", "PROBLEM", 37, 42], ["an immune-mediated demyelinating disease", "PROBLEM", 123, 163], ["immunity", "OBSERVATION", 8, 16], ["demyelinating disease", "OBSERVATION", 142, 163]]], ["As is typical in this model, infected SPF mice reach peak clinical disease by day 10\u201311 post-infection (p.i.) followed by a reduction of symptoms that plateaus around day 15\u201316 p.i.", [["infection", "DISEASE", 93, 102], ["SPF mice", "ORGANISM", 38, 46], ["mice", "SPECIES", 42, 46], ["SPF", "SPECIES", 38, 41], ["mice", "SPECIES", 42, 46], ["peak clinical disease", "PROBLEM", 53, 74], ["infection", "PROBLEM", 93, 102], ["symptoms", "PROBLEM", 137, 145], ["infected", "OBSERVATION_MODIFIER", 29, 37], ["infection", "OBSERVATION", 93, 102], ["plateaus", "OBSERVATION_MODIFIER", 151, 159]]], ["In contrast, GF mice developed worsened clinical disease that peaks at day 13 and is maintained through 21 days p.i.", [["GF mice", "ORGANISM", 13, 20], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 16, 20], ["worsened clinical disease", "PROBLEM", 31, 56], ["worsened", "OBSERVATION_MODIFIER", 31, 39]]], ["While GF mice had slightly lower titers of virus within the brain at 7 days p.i., control of viral replication was impaired at 14-days p.i. and virus was still present in GF mice at 21 days p.i., a time point where SPF animals have almost undetectable levels of infectious viral particles (Figure 1B).", [["brain", "ANATOMY", 60, 65], ["GF mice", "ORGANISM", 6, 13], ["brain", "ORGAN", 60, 65], ["GF mice", "ORGANISM", 171, 178], ["SPF animals", "ORGANISM", 215, 226], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 174, 178], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 174, 178], ["SPF", "SPECIES", 215, 218], ["slightly lower titers of virus within the brain", "PROBLEM", 18, 65], ["viral replication", "PROBLEM", 93, 110], ["virus", "PROBLEM", 144, 149], ["SPF animals", "TEST", 215, 226], ["infectious viral particles", "PROBLEM", 262, 288], ["slightly", "OBSERVATION_MODIFIER", 18, 26], ["lower titers", "OBSERVATION_MODIFIER", 27, 39], ["brain", "ANATOMY", 60, 65], ["viral replication", "OBSERVATION", 93, 110], ["infectious", "OBSERVATION_MODIFIER", 262, 272]]], ["Importantly, GF mice displayed enhanced neurologic damage, as there was significantly more demyelination in the spinal cord when compared to SPF animals (Figure 1C,D).", [["neurologic", "ANATOMY", 40, 50], ["spinal cord", "ANATOMY", 112, 123], ["neurologic damage", "DISEASE", 40, 57], ["demyelination", "DISEASE", 91, 104], ["GF mice", "ORGANISM", 13, 20], ["spinal cord", "ORGAN", 112, 123], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 16, 20], ["enhanced neurologic damage", "PROBLEM", 31, 57], ["significantly more demyelination in the spinal cord", "PROBLEM", 72, 123], ["enhanced", "OBSERVATION_MODIFIER", 31, 39], ["neurologic damage", "OBSERVATION", 40, 57], ["more", "OBSERVATION_MODIFIER", 86, 90], ["demyelination", "OBSERVATION", 91, 104], ["spinal cord", "ANATOMY", 112, 123]]], ["Immune cells traffic to the CNS in response to JHMV infection and viral clearance is dependent on both CD4 and CD8 T cells.", [["Immune cells", "ANATOMY", 0, 12], ["CNS", "ANATOMY", 28, 31], ["CD4", "ANATOMY", 103, 106], ["CD8 T cells", "ANATOMY", 111, 122], ["infection", "DISEASE", 52, 61], ["Immune cells", "CELL", 0, 12], ["CNS", "ANATOMICAL_SYSTEM", 28, 31], ["JHMV", "GENE_OR_GENE_PRODUCT", 47, 51], ["CD4", "GENE_OR_GENE_PRODUCT", 103, 106], ["CD8", "GENE_OR_GENE_PRODUCT", 111, 114], ["Immune cells", "CELL_TYPE", 0, 12], ["CD4 and CD8 T cells", "CELL_TYPE", 103, 122], ["JHMV", "SPECIES", 47, 51], ["Immune cells", "PROBLEM", 0, 12], ["JHMV infection", "PROBLEM", 47, 61], ["viral clearance", "TEST", 66, 81], ["CNS", "ANATOMY", 28, 31], ["infection", "OBSERVATION", 52, 61], ["viral clearance", "OBSERVATION", 66, 81]]], ["Fewer total cells were recovered from the CNS of GF mice during peak viral infection (day 7) (Figure 1E).", [["cells", "ANATOMY", 12, 17], ["CNS", "ANATOMY", 42, 45], ["viral infection", "DISEASE", 69, 84], ["cells", "CELL", 12, 17], ["CNS", "ANATOMICAL_SYSTEM", 42, 45], ["GF mice", "ORGANISM", 49, 56], ["mice", "SPECIES", 52, 56], ["mice", "SPECIES", 52, 56], ["Fewer total cells", "PROBLEM", 0, 17], ["peak viral infection", "PROBLEM", 64, 84], ["infection", "OBSERVATION", 75, 84]]], ["Moreover, there was a reduced frequency of total CNS-infiltrating CD4+ and CD8+ T cells (Figure 1F,G) and fewer viral-specific CD4+ and CD8+ T cells in GF mice at day 7 p.i.", [["CNS-infiltrating CD4+ and CD8+ T cells", "ANATOMY", 49, 87], ["T cells", "ANATOMY", 141, 148], ["CD4", "GENE_OR_GENE_PRODUCT", 66, 69], ["CD8", "GENE_OR_GENE_PRODUCT", 75, 78], ["G", "GENE_OR_GENE_PRODUCT", 99, 100], ["CD4", "GENE_OR_GENE_PRODUCT", 127, 130], ["CD8", "GENE_OR_GENE_PRODUCT", 136, 139], ["T cells", "CELL", 141, 148], ["GF mice", "ORGANISM", 152, 159], ["CD4", "PROTEIN", 66, 69], ["CD8", "PROTEIN", 75, 78], ["T cells", "CELL_TYPE", 80, 87], ["CD4", "PROTEIN", 127, 130], ["CD8", "PROTEIN", 136, 139], ["T cells", "CELL_TYPE", 141, 148], ["mice", "SPECIES", 155, 159], ["total CNS", "TEST", 43, 52], ["infiltrating CD4", "TEST", 53, 69], ["CD8", "TEST", 75, 78], ["Figure", "TEST", 89, 95], ["G", "TEST", 99, 100], ["viral", "TEST", 112, 117], ["specific CD4", "TEST", 118, 130], ["CD8", "TEST", 136, 139]]], ["These differences are diminished at a chronic timepoint (day 21), as reductions in only total CD8+ and viral-specific CD8+ T cells are observed (Figure 1G\u2013I).", [["CD8+ T cells", "ANATOMY", 118, 130], ["CD8", "GENE_OR_GENE_PRODUCT", 94, 97], ["CD8", "GENE_OR_GENE_PRODUCT", 118, 121], ["CD8", "PROTEIN", 94, 97], ["CD8+ T cells", "CELL_TYPE", 118, 130], ["total CD8", "TEST", 88, 97], ["viral", "TEST", 103, 108], ["T cells", "PROBLEM", 123, 130], ["diminished", "OBSERVATION_MODIFIER", 22, 32], ["chronic", "OBSERVATION_MODIFIER", 38, 45]]], ["Inflammation is controlled by the presence of CD4+, FoxP3+ T regulatory (Tregs) cells and previous reports have shown a critical role for these cells in controlling neuroinflammation in response to JHMV infection (Anghelina et al., 2009).", [["CD4+, FoxP3+ T regulatory (Tregs) cells", "ANATOMY", 46, 85], ["cells", "ANATOMY", 144, 149], ["Inflammation", "DISEASE", 0, 12], ["neuroinflammation", "DISEASE", 165, 182], ["infection", "DISEASE", 203, 212], ["CD4", "GENE_OR_GENE_PRODUCT", 46, 49], ["FoxP3", "GENE_OR_GENE_PRODUCT", 52, 57], ["cells", "CELL", 144, 149], ["JHMV", "ORGANISM", 198, 202], ["CD4", "PROTEIN", 46, 49], ["FoxP3", "PROTEIN", 52, 57], ["T regulatory (Tregs) cells", "CELL_TYPE", 59, 85], ["JHMV", "SPECIES", 198, 202], ["Inflammation", "PROBLEM", 0, 12], ["CD4", "TEST", 46, 49], ["these cells", "PROBLEM", 138, 149], ["JHMV infection", "PROBLEM", 198, 212], ["infection", "OBSERVATION", 203, 212]]], ["GF mice have increased CNS infiltrating Tregs during the acute phase of infection (7 p.i); however, there is a paucity of Tregs in infected GF mice during the chronic demyelinating phase of disease (Figure 1J).The microbiota protects from neurologic damage associated with viral infection ::: ResultsThe gut microbiota can be significantly reduced in the presence of antibiotics and is often used to validate findings in GF mice.", [["CNS infiltrating Tregs", "ANATOMY", 23, 45], ["Tregs", "ANATOMY", 122, 127], ["neurologic", "ANATOMY", 239, 249], ["gut microbiota", "ANATOMY", 304, 318], ["infection", "DISEASE", 72, 81], ["chronic demyelinating phase of disease", "DISEASE", 159, 197], ["neurologic damage", "DISEASE", 239, 256], ["viral infection", "DISEASE", 273, 288], ["GF mice", "ORGANISM", 0, 7], ["CNS infiltrating Tregs", "CELL", 23, 45], ["Tregs", "CELL", 122, 127], ["GF mice", "ORGANISM", 140, 147], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 304, 318], ["GF mice", "ORGANISM", 421, 428], ["CNS infiltrating Tregs", "CELL_TYPE", 23, 45], ["Tregs", "CELL_TYPE", 122, 127], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 143, 147], ["mice", "SPECIES", 424, 428], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 143, 147], ["mice", "SPECIES", 424, 428], ["increased CNS infiltrating Tregs", "PROBLEM", 13, 45], ["infection", "PROBLEM", 72, 81], ["the chronic demyelinating phase of disease", "PROBLEM", 155, 197], ["neurologic damage", "PROBLEM", 239, 256], ["viral infection", "PROBLEM", 273, 288], ["antibiotics", "TREATMENT", 367, 378], ["increased", "OBSERVATION_MODIFIER", 13, 22], ["CNS", "ANATOMY", 23, 26], ["infiltrating Tregs", "OBSERVATION", 27, 45], ["acute phase", "OBSERVATION_MODIFIER", 57, 68], ["infection", "OBSERVATION", 72, 81], ["paucity", "OBSERVATION_MODIFIER", 111, 118], ["Tregs", "OBSERVATION", 122, 127], ["infected", "OBSERVATION_MODIFIER", 131, 139], ["chronic", "OBSERVATION_MODIFIER", 159, 166], ["demyelinating", "OBSERVATION_MODIFIER", 167, 180], ["viral", "OBSERVATION_MODIFIER", 273, 278], ["infection", "OBSERVATION", 279, 288], ["gut", "ANATOMY", 304, 307], ["microbiota", "OBSERVATION", 308, 318], ["significantly", "OBSERVATION_MODIFIER", 326, 339], ["reduced", "OBSERVATION_MODIFIER", 340, 347]]], ["To this end, progeny from breeder pairs of SPF mice that were orally treated with antibiotics, and remained on antibiotics after weaning, were subsequently infected i.c. with JHMV at 6\u20137 weeks of age.", [["JHMV", "CHEMICAL", 175, 179], ["SPF", "ORGANISM", 43, 46], ["mice", "ORGANISM", 47, 51], ["mice", "SPECIES", 47, 51], ["SPF", "SPECIES", 43, 46], ["mice", "SPECIES", 47, 51], ["JHMV", "SPECIES", 175, 179], ["SPF mice", "TREATMENT", 43, 51], ["antibiotics", "TREATMENT", 82, 93], ["antibiotics", "TREATMENT", 111, 122]]], ["The same antibiotic regimen was performed previously, and qRT-PCR of bacterial 16S sequences demonstrated a reduction of fecal bacteria by approximately 100-fold (Soto et al., 2017).", [["bacterial 16S sequences", "DNA", 69, 92], ["The same antibiotic regimen", "TREATMENT", 0, 27], ["qRT", "TEST", 58, 61], ["bacterial 16S sequences", "TEST", 69, 92], ["fecal bacteria", "PROBLEM", 121, 135], ["reduction", "OBSERVATION_MODIFIER", 108, 117], ["fecal bacteria", "OBSERVATION", 121, 135]]], ["Similar to what was observed in GF mice, lifelong antibiotic-treated infected animals developed worsened chronic disease when compared to animals with an intact microbiota (Figure 1\u2014figure supplement 1A) and were unable to control viral replication (Figure 1\u2014figure supplement 1B).", [["chronic disease", "DISEASE", 105, 120], ["GF mice", "ORGANISM", 32, 39], ["animals", "ORGANISM", 78, 85], ["mice", "SPECIES", 35, 39], ["mice", "SPECIES", 35, 39], ["lifelong antibiotic", "TREATMENT", 41, 60], ["worsened chronic disease", "PROBLEM", 96, 120], ["viral replication", "TREATMENT", 231, 248], ["worsened", "OBSERVATION_MODIFIER", 96, 104], ["chronic", "OBSERVATION_MODIFIER", 105, 112], ["disease", "OBSERVATION", 113, 120]]], ["These data provide further support for the microbiota in functioning to coordinate disease following CNS viral infection.T cell-extrinsic defects from GF mice are responsible for worsened disease ::: ResultsNumerous reports have demonstrated a critical role for the microbiota in maturation of the immune response (Belkaid and Hand, 2014; Hooper et al., 2012).", [["CNS", "ANATOMY", 101, 104], ["T cell", "ANATOMY", 121, 127], ["viral infection", "DISEASE", 105, 120], ["CNS viral", "ORGANISM", 101, 110], ["T cell", "CELL", 121, 127], ["GF mice", "ORGANISM", 151, 158], ["mice", "SPECIES", 154, 158], ["mice", "SPECIES", 154, 158], ["further support", "TREATMENT", 19, 34], ["CNS viral infection", "PROBLEM", 101, 120], ["extrinsic defects", "PROBLEM", 128, 145], ["worsened disease", "PROBLEM", 179, 195], ["viral", "OBSERVATION_MODIFIER", 105, 110], ["infection", "OBSERVATION", 111, 120], ["extrinsic defects", "OBSERVATION", 128, 145], ["responsible for", "UNCERTAINTY", 163, 178], ["worsened", "OBSERVATION_MODIFIER", 179, 187], ["disease", "OBSERVATION", 188, 195]]], ["In particular, commensal microbes promote CD4+ T helper cell responses both within and outside of the intestine (Atarashi et al., 2011; Ivanov et al., 2009; Lee et al., 2011; Mazmanian et al., 2005).", [["CD4+ T helper cell", "ANATOMY", 42, 60], ["intestine", "ANATOMY", 102, 111], ["CD4", "GENE_OR_GENE_PRODUCT", 42, 45], ["intestine", "ORGAN", 102, 111], ["CD4", "PROTEIN", 42, 45], ["intestine", "ANATOMY", 102, 111]]], ["To determine whether increased disease in JHMV-infected GF mice is due to T cell-intrinsic or-extrinsic effects, either CD4+ or CD8+ T cells from immunized SPF or GF mice were adoptively transferred into JHMV infected Rag1-/- mice.", [["T cell", "ANATOMY", 74, 80], ["CD4+", "ANATOMY", 120, 124], ["CD8+ T cells", "ANATOMY", 128, 140], ["JHMV-infected GF mice", "ORGANISM", 42, 63], ["T cell", "CELL", 74, 80], ["CD4", "GENE_OR_GENE_PRODUCT", 120, 123], ["CD8", "GENE_OR_GENE_PRODUCT", 128, 131], ["GF mice", "ORGANISM", 163, 170], ["JHMV", "GENE_OR_GENE_PRODUCT", 204, 208], ["Rag1", "GENE_OR_GENE_PRODUCT", 218, 222], ["-/- mice", "ORGANISM", 222, 230], ["CD4", "PROTEIN", 120, 123], ["CD8+ T cells", "CELL_TYPE", 128, 140], ["Rag1", "PROTEIN", 218, 222], ["mice", "SPECIES", 59, 63], ["mice", "SPECIES", 166, 170], ["mice", "SPECIES", 226, 230], ["JHMV", "SPECIES", 42, 46], ["mice", "SPECIES", 59, 63], ["SPF", "SPECIES", 156, 159], ["mice", "SPECIES", 166, 170], ["JHMV", "SPECIES", 204, 208], ["mice", "SPECIES", 226, 230], ["increased disease in JHMV", "PROBLEM", 21, 46], ["T cell", "PROBLEM", 74, 80], ["extrinsic effects", "PROBLEM", 94, 111], ["CD4", "TEST", 120, 123], ["CD8", "PROBLEM", 128, 131], ["T cells", "PROBLEM", 133, 140], ["immunized SPF", "TREATMENT", 146, 159], ["increased", "OBSERVATION_MODIFIER", 21, 30], ["disease", "OBSERVATION", 31, 38]]], ["SPF or GF mice were infected intraperitoneally (i.p.) with mouse hepatitis virus strain DM (MHV-DM) to generate virus-specific T cells (Bergmann et al., 2004; Glass and Lane, 2003).", [["intraperitoneally", "ANATOMY", 29, 46], ["T cells", "ANATOMY", 127, 134], ["hepatitis virus", "DISEASE", 65, 80], ["GF mice", "ORGANISM", 7, 14], ["mouse", "ORGANISM", 59, 64], ["hepatitis virus strain DM", "ORGANISM", 65, 90], ["MHV-DM", "ORGANISM", 92, 98], ["T cells", "CELL", 127, 134], ["T cells", "CELL_TYPE", 127, 134], ["mice", "SPECIES", 10, 14], ["mouse", "SPECIES", 59, 64], ["hepatitis virus", "SPECIES", 65, 80], ["mice", "SPECIES", 10, 14], ["mouse hepatitis virus", "SPECIES", 59, 80], ["MHV", "SPECIES", 92, 95], ["mouse hepatitis virus strain DM", "PROBLEM", 59, 90], ["DM", "PROBLEM", 96, 98], ["generate virus", "PROBLEM", 103, 117], ["Glass", "TEST", 159, 164]]], ["Splenic CD4+ or CD8+ T cells were purified and stained with tetramers to enumerate viral-specific T cells; subsequently, equal numbers of viral-specific T cells were separately transferred into JHMV infected Rag1-/- mice (Figure 2A).", [["Splenic CD4+ or CD8+", "ANATOMY", 0, 20], ["T cells", "ANATOMY", 21, 28], ["T cells", "ANATOMY", 98, 105], ["T cells", "ANATOMY", 153, 160], ["CD4", "GENE_OR_GENE_PRODUCT", 8, 11], ["CD8", "GENE_OR_GENE_PRODUCT", 16, 19], ["T cells", "CELL", 21, 28], ["T cells", "CELL", 98, 105], ["T cells", "CELL", 153, 160], ["JHMV", "GENE_OR_GENE_PRODUCT", 194, 198], ["Rag1", "GENE_OR_GENE_PRODUCT", 208, 212], ["-/- mice", "ORGANISM", 212, 220], ["CD4", "PROTEIN", 8, 11], ["CD8", "PROTEIN", 16, 19], ["T cells", "CELL_TYPE", 21, 28], ["T cells", "CELL_TYPE", 98, 105], ["T cells", "CELL_TYPE", 153, 160], ["Rag1", "PROTEIN", 208, 212], ["mice", "SPECIES", 216, 220], ["JHMV", "SPECIES", 194, 198], ["mice", "SPECIES", 216, 220], ["Splenic CD4", "TEST", 0, 11], ["CD8", "PROBLEM", 16, 19], ["T cells", "TEST", 21, 28], ["tetramers", "TEST", 60, 69], ["viral-specific T cells", "PROBLEM", 83, 105], ["viral", "TEST", 138, 143], ["CD4", "OBSERVATION", 8, 11], ["CD8+", "OBSERVATION", 16, 20]]], ["Consistent with published reports using other viruses, we observed slight systemic immune deficiencies in the response to i.p. infection with MHV-DM in GF mice in both total T cells and virus-specific T cells; only the number of viral-specific CD8+ T cells reached statistical significance (Figure 2\u2014figure supplement 1A\u2013D) (Abt et al., 2012; Ichinohe et al., 2011).", [["T cells", "ANATOMY", 174, 181], ["T cells", "ANATOMY", 201, 208], ["CD8+ T cells", "ANATOMY", 244, 256], ["infection", "DISEASE", 127, 136], ["MHV-DM", "ORGANISM", 142, 148], ["GF mice", "ORGANISM", 152, 159], ["T cells", "CELL", 174, 181], ["T cells", "CELL", 201, 208], ["CD8", "GENE_OR_GENE_PRODUCT", 244, 247], ["T cells", "CELL_TYPE", 174, 181], ["virus-specific T cells", "CELL_TYPE", 186, 208], ["CD8+ T cells", "CELL_TYPE", 244, 256], ["mice", "SPECIES", 155, 159], ["MHV", "SPECIES", 142, 145], ["mice", "SPECIES", 155, 159], ["other viruses", "PROBLEM", 40, 53], ["slight systemic immune deficiencies", "PROBLEM", 67, 102], ["i.p. infection", "PROBLEM", 122, 136], ["MHV", "PROBLEM", 142, 145], ["DM", "PROBLEM", 146, 148], ["virus", "PROBLEM", 186, 191], ["specific T cells", "PROBLEM", 192, 208], ["viral", "TEST", 229, 234], ["T cells", "PROBLEM", 249, 256], ["Figure", "TEST", 291, 297], ["slight", "OBSERVATION_MODIFIER", 67, 73], ["systemic immune deficiencies", "OBSERVATION", 74, 102], ["infection", "OBSERVATION", 127, 136]]], ["Importantly, there were no differences observed in the recruitment of either CD4+ or CD8+ T cells derived from either GF or SPF mice to the CNS of JHMV-infected Rag1-/- mice, nor were there differences in CNS viral burden (Figure 2B\u2013G).", [["CD4+ or CD8+", "ANATOMY", 77, 89], ["T cells", "ANATOMY", 90, 97], ["CNS", "ANATOMY", 140, 143], ["CNS", "ANATOMY", 205, 208], ["CD4", "GENE_OR_GENE_PRODUCT", 77, 80], ["CD8", "GENE_OR_GENE_PRODUCT", 85, 88], ["T cells", "CELL", 90, 97], ["SPF mice", "ORGANISM", 124, 132], ["CNS", "ANATOMICAL_SYSTEM", 140, 143], ["JHMV", "GENE_OR_GENE_PRODUCT", 147, 151], ["Rag1", "GENE_OR_GENE_PRODUCT", 161, 165], ["-/- mice", "ORGANISM", 165, 173], ["CNS", "ANATOMICAL_SYSTEM", 205, 208], ["CD4", "PROTEIN", 77, 80], ["CD8", "PROTEIN", 85, 88], ["T cells", "CELL_TYPE", 90, 97], ["Rag1", "PROTEIN", 161, 165], ["mice", "SPECIES", 128, 132], ["mice", "SPECIES", 169, 173], ["mice", "SPECIES", 128, 132], ["mice", "SPECIES", 169, 173], ["CD8", "PROBLEM", 85, 88], ["T cells", "PROBLEM", 90, 97], ["JHMV", "TEST", 147, 151], ["CNS viral burden", "PROBLEM", 205, 221], ["no", "UNCERTAINTY", 24, 26]]], ["Collectively, these data show that neither CD4+ or CD8+ T cells from GF mice are intrinsically deficient in their ability to respond to JHMV or traffic to the CNS.", [["CD4+ or CD8+", "ANATOMY", 43, 55], ["T cells", "ANATOMY", 56, 63], ["CNS", "ANATOMY", 159, 162], ["CD4", "GENE_OR_GENE_PRODUCT", 43, 46], ["CD8", "GENE_OR_GENE_PRODUCT", 51, 54], ["T cells", "CELL", 56, 63], ["GF mice", "ORGANISM", 69, 76], ["JHMV", "GENE_OR_GENE_PRODUCT", 136, 140], ["CNS", "ANATOMICAL_SYSTEM", 159, 162], ["CD4", "PROTEIN", 43, 46], ["CD8", "PROTEIN", 51, 54], ["T cells", "CELL_TYPE", 56, 63], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 72, 76], ["JHMV", "SPECIES", 136, 140], ["these data", "TEST", 14, 24], ["CD4", "TEST", 43, 46], ["CD8", "PROBLEM", 51, 54], ["intrinsically deficient", "PROBLEM", 81, 104], ["CNS", "ANATOMY", 159, 162]]], ["Thus, these data suggest that the microbiota exerts effects on alternate cell types to protect from viral infection within the CNS.The microbiota upregulates antigen presentation in microglia ::: ResultsMicroglia are the resident innate immune cells of the brain and are important for diverse processes including maintaining neuronal homeostasis, regulating brain development, and mounting immunity against pathogenic organisms.", [["cell", "ANATOMY", 73, 77], ["CNS", "ANATOMY", 127, 130], ["microglia", "ANATOMY", 182, 191], ["immune cells", "ANATOMY", 237, 249], ["brain", "ANATOMY", 257, 262], ["neuronal", "ANATOMY", 325, 333], ["brain", "ANATOMY", 358, 363], ["viral infection", "DISEASE", 100, 115], ["cell", "CELL", 73, 77], ["CNS", "ANATOMICAL_SYSTEM", 127, 130], ["microglia", "CELL", 182, 191], ["innate immune cells", "CELL", 230, 249], ["brain", "ORGAN", 257, 262], ["neuronal", "CELL", 325, 333], ["brain", "ORGAN", 358, 363], ["microglia", "CELL_TYPE", 182, 191], ["resident innate immune cells", "CELL_TYPE", 221, 249], ["these data", "TEST", 6, 16], ["alternate cell types", "TREATMENT", 63, 83], ["viral infection", "PROBLEM", 100, 115], ["diverse processes", "PROBLEM", 285, 302], ["neuronal homeostasis", "TREATMENT", 325, 345], ["pathogenic organisms", "PROBLEM", 407, 427], ["viral", "OBSERVATION_MODIFIER", 100, 105], ["infection", "OBSERVATION", 106, 115], ["brain", "ANATOMY", 257, 262], ["neuronal homeostasis", "OBSERVATION", 325, 345], ["brain", "ANATOMY", 358, 363]]], ["Commensal microbes are necessary for proper microglia maturation, with gene expression and morphological analysis suggesting that microglia isolated from GF mice have an immature phenotype (Erny et al., 2015; Matcovitch-Natan et al., 2016; Sampson et al., 2016).", [["microglia", "ANATOMY", 44, 53], ["microglia", "ANATOMY", 130, 139], ["microglia", "CELL", 44, 53], ["microglia", "CELL", 130, 139], ["GF mice", "ORGANISM", 154, 161], ["microglia", "CELL_TYPE", 44, 53], ["microglia", "CELL_TYPE", 130, 139], ["mice", "SPECIES", 157, 161], ["Commensal microbes", "PROBLEM", 0, 18], ["proper microglia maturation", "PROBLEM", 37, 64], ["morphological analysis", "TEST", 91, 113], ["microglia", "PROBLEM", 130, 139], ["microbes", "OBSERVATION", 10, 18], ["microglia maturation", "OBSERVATION", 44, 64], ["immature", "OBSERVATION_MODIFIER", 170, 178]]], ["Yet, the effect of commensal microbes on microglial responses to CNS viral infection has yet to be well-tested.", [["microglial", "ANATOMY", 41, 51], ["CNS", "ANATOMY", 65, 68], ["viral infection", "DISEASE", 69, 84], ["microglial", "CELL", 41, 51], ["CNS viral", "ORGANISM", 65, 74], ["commensal microbes", "PROBLEM", 19, 37], ["microglial responses", "TEST", 41, 61], ["CNS viral infection", "PROBLEM", 65, 84], ["infection", "OBSERVATION", 75, 84]]], ["Flow cytometric analysis from homogenized brains followed by percoll gradient purification did not demonstrate significant differences in the frequencies of microglia from GF and SPF mice under homeostatic conditions (Figure 3\u2014figure supplement 1A\u2013C).", [["brains", "ANATOMY", 42, 48], ["microglia", "ANATOMY", 157, 166], ["microglia", "CELL", 157, 166], ["GF", "CELL", 172, 174], ["SPF mice", "ORGANISM", 179, 187], ["microglia", "CELL_TYPE", 157, 166], ["mice", "SPECIES", 183, 187], ["mice", "SPECIES", 183, 187], ["Flow cytometric analysis", "TEST", 0, 24], ["homogenized brains", "PROBLEM", 30, 48], ["percoll gradient purification", "TEST", 61, 90], ["Figure 3\u2014figure supplement", "TREATMENT", 218, 244], ["significant", "OBSERVATION_MODIFIER", 111, 122], ["differences", "OBSERVATION", 123, 134]]], ["One role for microglia is to activate antigen-specific T cell responses through presentation of antigens via MHC molecules (Mack et al., 2003).", [["microglia", "ANATOMY", 13, 22], ["T cell", "ANATOMY", 55, 61], ["microglia", "CELL", 13, 22], ["antigen", "GENE_OR_GENE_PRODUCT", 38, 45], ["T cell", "CELL", 55, 61], ["microglia", "CELL_TYPE", 13, 22], ["antigens", "PROTEIN", 96, 104], ["MHC molecules", "PROTEIN", 109, 122], ["antigen", "TEST", 38, 45]]], ["We identified a lower frequency of MHC class II + microglia in uninfected GF mice (Figure 3A,B).", [["MHC class II + microglia", "ANATOMY", 35, 59], ["MHC class II", "GENE_OR_GENE_PRODUCT", 35, 47], ["GF mice", "ORGANISM", 74, 81], ["B", "CELL", 93, 94], ["MHC class II", "PROTEIN", 35, 47], ["microglia", "CELL_TYPE", 50, 59], ["mice", "SPECIES", 77, 81], ["mice", "SPECIES", 77, 81], ["lower frequency", "OBSERVATION_MODIFIER", 16, 31], ["microglia", "ANATOMY", 50, 59]]], ["Disruption to the microbiota with antibiotics decreases both the percentage of total microglia and the number of MHC expressing microglia in uninfected animals (Figure 3C\u2013F).", [["microglia", "ANATOMY", 85, 94], ["microglia", "ANATOMY", 128, 137], ["microglia", "CELL", 85, 94], ["microglia", "CELL", 128, 137], ["microglia", "CELL_TYPE", 85, 94], ["MHC expressing microglia", "CELL_TYPE", 113, 137], ["antibiotics", "TREATMENT", 34, 45], ["total microglia", "PROBLEM", 79, 94], ["percentage", "OBSERVATION_MODIFIER", 65, 75], ["total microglia", "OBSERVATION", 79, 94], ["microglia", "OBSERVATION_MODIFIER", 128, 137]]], ["Presentation of antigens requires co-stimulatory molecules such as CD86 and CD40 which are significantly reduced in expression on microglia from uninfected GF mice (Figure 3G and Figure 3\u2014figure supplement 1H).", [["microglia", "ANATOMY", 130, 139], ["1H", "CHEMICAL", 206, 208], ["CD86", "GENE_OR_GENE_PRODUCT", 67, 71], ["CD40", "GENE_OR_GENE_PRODUCT", 76, 80], ["microglia", "CELL", 130, 139], ["GF mice", "ORGANISM", 156, 163], ["co-stimulatory molecules", "PROTEIN", 34, 58], ["CD86", "PROTEIN", 67, 71], ["CD40", "PROTEIN", 76, 80], ["microglia", "CELL_TYPE", 130, 139], ["mice", "SPECIES", 159, 163], ["mice", "SPECIES", 159, 163], ["co-stimulatory molecules", "PROBLEM", 34, 58], ["CD86", "TEST", 67, 71], ["Figure 3G and Figure 3\u2014figure supplement", "TREATMENT", 165, 205], ["significantly", "OBSERVATION_MODIFIER", 91, 104], ["reduced", "OBSERVATION_MODIFIER", 105, 112]]], ["CIITA is a transcription factor that is critical to the expression of MHCII expression (Mach et al., 1996).", [["CIITA", "GENE_OR_GENE_PRODUCT", 0, 5], ["MHCII", "GENE_OR_GENE_PRODUCT", 70, 75], ["CIITA", "PROTEIN", 0, 5], ["transcription factor", "PROTEIN", 11, 31], ["MHCII", "PROTEIN", 70, 75], ["a transcription factor", "PROBLEM", 9, 31]]], ["Expression of Ciita mRNA transcripts is significantly reduced in microglia isolated from GF or antibiotic-treated mice compared to SPF mice, further corroborating a reduction in the antigen presentation machinery in the absence of microbes (Figure 3H,I) (Butovsky et al., 2014).", [["microglia", "ANATOMY", 65, 74], ["Ciita", "GENE_OR_GENE_PRODUCT", 14, 19], ["microglia", "CELL", 65, 74], ["antibiotic", "SIMPLE_CHEMICAL", 95, 105], ["mice", "ORGANISM", 114, 118], ["SPF mice", "ORGANISM", 131, 139], ["Ciita mRNA transcripts", "RNA", 14, 36], ["microglia", "CELL_TYPE", 65, 74], ["mice", "SPECIES", 114, 118], ["mice", "SPECIES", 135, 139], ["mice", "SPECIES", 114, 118], ["SPF", "SPECIES", 131, 134], ["mice", "SPECIES", 135, 139], ["Ciita mRNA transcripts", "PROBLEM", 14, 36], ["microglia", "PROBLEM", 65, 74], ["antibiotic", "TREATMENT", 95, 105], ["a reduction", "TREATMENT", 163, 174], ["Ciita mRNA", "OBSERVATION", 14, 24], ["significantly", "OBSERVATION_MODIFIER", 40, 53], ["reduced", "OBSERVATION_MODIFIER", 54, 61], ["reduction", "OBSERVATION_MODIFIER", 165, 174]]], ["Three days post-infection, antigen presentation markers were also reduced in antibiotic-treated mice (Figure 3\u2014figure supplement 1D-G), suggesting a weakened ability to activate T lymphocytes.", [["T lymphocytes", "ANATOMY", 178, 191], ["antibiotic", "SIMPLE_CHEMICAL", 77, 87], ["mice", "ORGANISM", 96, 100], ["1D-G", "SIMPLE_CHEMICAL", 129, 133], ["T lymphocytes", "CELL", 178, 191], ["antigen presentation markers", "PROTEIN", 27, 55], ["T lymphocytes", "CELL_TYPE", 178, 191], ["mice", "SPECIES", 96, 100], ["mice", "SPECIES", 96, 100], ["antigen presentation markers", "TEST", 27, 55], ["antibiotic", "TREATMENT", 77, 87], ["Figure 3\u2014figure supplement", "TREATMENT", 102, 128], ["a weakened ability", "PROBLEM", 147, 165]]], ["To functionally validate these findings, we measured CD8+ T cell proliferation during coculture with microglia from either SPF or antibiotic-treated mice.", [["CD8+ T cell", "ANATOMY", 53, 64], ["microglia", "ANATOMY", 101, 110], ["CD8", "GENE_OR_GENE_PRODUCT", 53, 56], ["microglia", "CELL", 101, 110], ["antibiotic", "SIMPLE_CHEMICAL", 130, 140], ["mice", "ORGANISM", 149, 153], ["CD8", "PROTEIN", 53, 56], ["microglia", "CELL_TYPE", 101, 110], ["mice", "SPECIES", 149, 153], ["mice", "SPECIES", 149, 153], ["CD8", "TEST", 53, 56], ["T cell proliferation", "PROBLEM", 58, 78], ["microglia", "PROBLEM", 101, 110], ["antibiotic", "TREATMENT", 130, 140], ["cell proliferation", "OBSERVATION", 60, 78]]], ["Corroborating the reduced antigen presentation markers on microglia from antibiotic-treated mice, the ability of these microglia to induce T cell proliferation was reduced when presenting the immunodominant JHMV peptide S510\u2013518 (Figure 3J).Microglia depletion worsens neurologic damage ::: ResultsMicroglia are considered to be the first line of defense during a CNS infection.", [["microglia", "ANATOMY", 58, 67], ["microglia", "ANATOMY", 119, 128], ["T cell", "ANATOMY", 139, 145], ["neurologic", "ANATOMY", 269, 279], ["CNS", "ANATOMY", 364, 367], ["S510\u2013518", "CHEMICAL", 220, 228], ["neurologic damage", "DISEASE", 269, 286], ["CNS infection", "DISEASE", 364, 377], ["microglia", "CELL", 58, 67], ["antibiotic", "SIMPLE_CHEMICAL", 73, 83], ["mice", "ORGANISM", 92, 96], ["microglia", "CELL", 119, 128], ["T cell", "CELL", 139, 145], ["Microglia", "CELL", 241, 250], ["CNS", "ANATOMICAL_SYSTEM", 364, 367], ["antigen presentation markers", "PROTEIN", 26, 54], ["microglia", "CELL_TYPE", 58, 67], ["microglia", "CELL_TYPE", 119, 128], ["mice", "SPECIES", 92, 96], ["mice", "SPECIES", 92, 96], ["antibiotic", "TREATMENT", 73, 83], ["these microglia", "PROBLEM", 113, 128], ["T cell proliferation", "PROBLEM", 139, 159], ["Microglia depletion", "PROBLEM", 241, 260], ["neurologic damage", "PROBLEM", 269, 286], ["a CNS infection", "PROBLEM", 362, 377], ["reduced", "OBSERVATION_MODIFIER", 18, 25], ["cell proliferation", "OBSERVATION", 141, 159], ["CNS", "ANATOMY", 364, 367], ["infection", "OBSERVATION", 368, 377]]], ["Indeed, recent studies have demonstrated that a reduction in microglia leads to a defect in control of JHMV replication within the CNS (Wheeler et al., 2018).", [["microglia", "ANATOMY", 61, 70], ["JHMV", "ANATOMY", 103, 107], ["CNS", "ANATOMY", 131, 134], ["microglia", "CELL", 61, 70], ["JHMV", "GENE_OR_GENE_PRODUCT", 103, 107], ["CNS", "ANATOMICAL_SYSTEM", 131, 134], ["microglia", "CELL_TYPE", 61, 70], ["JHMV", "SPECIES", 103, 107], ["recent studies", "TEST", 8, 22], ["a reduction in microglia", "PROBLEM", 46, 70], ["a defect", "PROBLEM", 80, 88], ["JHMV replication", "TREATMENT", 103, 119], ["reduction", "OBSERVATION_MODIFIER", 48, 57], ["microglia leads", "OBSERVATION", 61, 76], ["defect", "OBSERVATION", 82, 88], ["CNS", "ANATOMY", 131, 134]]], ["However, the effect of microglia depletion on neurologic damage and demyelination remains unclear.", [["microglia", "ANATOMY", 23, 32], ["neurologic", "ANATOMY", 46, 56], ["neurologic damage", "DISEASE", 46, 63], ["demyelination", "DISEASE", 68, 81], ["microglia", "CELL", 23, 32], ["microglia", "CELL_TYPE", 23, 32], ["microglia depletion", "PROBLEM", 23, 42], ["neurologic damage", "PROBLEM", 46, 63], ["demyelination", "PROBLEM", 68, 81], ["microglia depletion", "OBSERVATION", 23, 42], ["demyelination", "OBSERVATION", 68, 81]]], ["To address this, we reduced the number of microglia using a colony-stimulating factor one receptor (CSFR1) inhibitor drug, PLX-3397 (Elmore et al., 2014).", [["microglia", "ANATOMY", 42, 51], ["PLX-3397", "CHEMICAL", 123, 131], ["PLX-3397", "CHEMICAL", 123, 131], ["microglia", "CELL", 42, 51], ["a colony-stimulating factor one receptor", "GENE_OR_GENE_PRODUCT", 58, 98], ["CSFR1", "GENE_OR_GENE_PRODUCT", 100, 105], ["PLX-3397", "SIMPLE_CHEMICAL", 123, 131], ["microglia", "CELL_TYPE", 42, 51], ["colony-stimulating factor one receptor", "PROTEIN", 60, 98], ["CSFR1", "PROTEIN", 100, 105], ["a colony-stimulating factor", "TREATMENT", 58, 85]]], ["Administration of PLX-3397 1 week prior to JHMV infection of SPF mice resulted in a marked reduction in microglia (CD45lo, CD11b+, F4/80+ cells as determined by flow cytometric staining) in both number and percentage at days 7 and 14 p.i.", [["microglia", "ANATOMY", 104, 113], ["CD45lo", "ANATOMY", 115, 121], ["CD11b+, F4/80+ cells", "ANATOMY", 123, 143], ["PLX-3397", "CHEMICAL", 18, 26], ["infection", "DISEASE", 48, 57], ["PLX-3397", "CHEMICAL", 18, 26], ["PLX-3397", "GENE_OR_GENE_PRODUCT", 18, 26], ["JHMV", "ORGANISM", 43, 47], ["SPF mice", "ORGANISM", 61, 69], ["microglia", "CELL", 104, 113], ["CD45lo", "GENE_OR_GENE_PRODUCT", 115, 121], ["CD11b", "GENE_OR_GENE_PRODUCT", 123, 128], ["microglia", "CELL_TYPE", 104, 113], ["mice", "SPECIES", 65, 69], ["JHMV", "SPECIES", 43, 47], ["SPF", "SPECIES", 61, 64], ["mice", "SPECIES", 65, 69], ["PLX", "TREATMENT", 18, 21], ["JHMV infection of SPF mice", "PROBLEM", 43, 69], ["a marked reduction in microglia", "PROBLEM", 82, 113], ["CD45lo", "TEST", 115, 121], ["CD11", "TEST", 123, 127], ["cells", "PROBLEM", 138, 143], ["flow cytometric staining", "TEST", 161, 185], ["infection", "OBSERVATION", 48, 57], ["marked", "OBSERVATION_MODIFIER", 84, 90], ["reduction", "OBSERVATION_MODIFIER", 91, 100], ["microglia", "ANATOMY", 104, 113]]], ["Recent studies have demonstrated that treatment of West Nile Virus-infected mice with a CSF1R inhibitor results in limited viral control associated with impaired activation of antigen presenting cells (APCs) in both blood and draining lymph nodes arguing that in addition to targeting microglia other immune cells are also depleted leading to a potentially immunosuppressed state (Funk and Klein, 2019).", [["antigen presenting cells", "ANATOMY", 176, 200], ["APCs", "ANATOMY", 202, 206], ["blood", "ANATOMY", 216, 221], ["lymph nodes", "ANATOMY", 235, 246], ["microglia", "ANATOMY", 285, 294], ["immune cells", "ANATOMY", 301, 313], ["West Nile Virus", "ORGANISM", 51, 66], ["mice", "ORGANISM", 76, 80], ["CSF1R", "GENE_OR_GENE_PRODUCT", 88, 93], ["antigen presenting cells", "CELL", 176, 200], ["APCs", "CELL", 202, 206], ["blood", "ORGANISM_SUBSTANCE", 216, 221], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 235, 246], ["microglia", "CELL", 285, 294], ["immune cells", "CELL", 301, 313], ["antigen presenting cells", "CELL_TYPE", 176, 200], ["APCs", "CELL_TYPE", 202, 206], ["microglia", "CELL_TYPE", 285, 294], ["immune cells", "CELL_TYPE", 301, 313], ["Nile Virus", "SPECIES", 56, 66], ["mice", "SPECIES", 76, 80], ["West Nile Virus", "SPECIES", 51, 66], ["mice", "SPECIES", 76, 80], ["Recent studies", "TEST", 0, 14], ["West Nile Virus", "PROBLEM", 51, 66], ["a CSF1R inhibitor", "TREATMENT", 86, 103], ["limited viral control", "TREATMENT", 115, 136], ["impaired activation of antigen presenting cells", "PROBLEM", 153, 200], ["APCs", "TEST", 202, 206], ["draining lymph nodes", "PROBLEM", 226, 246], ["targeting microglia other immune cells", "PROBLEM", 275, 313], ["both", "ANATOMY_MODIFIER", 211, 215], ["blood", "ANATOMY", 216, 221], ["draining", "OBSERVATION_MODIFIER", 226, 234], ["lymph nodes", "OBSERVATION", 235, 246], ["immune cells", "OBSERVATION", 301, 313]]], ["Similar to this study, we did not observe a reduction in either splenic (CD45+, CD11b+) or CNS-infiltrating macrophage (CD45hi, CD11b+) populations (Figure 4\u2014figure supplement 1A; Figure 4\u2014figure supplement 1B; Figure 4\u2014figure supplement 1C).", [["splenic", "ANATOMY", 64, 71], ["CD45+, CD11b+", "ANATOMY", 73, 86], ["CNS-infiltrating macrophage", "ANATOMY", 91, 118], ["CD45hi", "ANATOMY", 120, 126], ["CD11b+) populations", "ANATOMY", 128, 147], ["CD45", "GENE_OR_GENE_PRODUCT", 73, 77], ["CD11b", "GENE_OR_GENE_PRODUCT", 80, 85], ["macrophage", "CELL", 108, 118], ["CD45hi", "CELL", 120, 126], ["CD45", "PROTEIN", 73, 77], ["CD11b", "PROTEIN", 80, 85], ["infiltrating macrophage", "CELL_TYPE", 95, 118], ["this study", "TEST", 11, 21], ["a reduction", "PROBLEM", 42, 53], ["CD45", "TEST", 73, 77], ["CD11", "TEST", 80, 84], ["CNS", "TEST", 91, 94], ["infiltrating macrophage", "PROBLEM", 95, 118], ["CD45hi", "TEST", 120, 126], ["Figure 4\u2014figure supplement 1A", "TREATMENT", 149, 178], ["Figure 4\u2014figure supplement 1B", "TREATMENT", 180, 209], ["Figure 4\u2014figure supplement", "TREATMENT", 211, 237], ["splenic", "ANATOMY", 64, 71], ["CNS", "ANATOMY", 91, 94], ["infiltrating macrophage", "OBSERVATION", 95, 118]]], ["We observed enhanced mortality in JHMV-infected mice following microglia reduction that correlated with an impaired ability to control viral replication within the CNS (Figure 4C,D).", [["microglia", "ANATOMY", 63, 72], ["CNS", "ANATOMY", 164, 167], ["JHMV-infected", "DISEASE", 34, 47], ["JHMV", "ORGANISM", 34, 38], ["mice", "ORGANISM", 48, 52], ["microglia", "CELL", 63, 72], ["CNS", "ANATOMICAL_SYSTEM", 164, 167], ["mice", "SPECIES", 48, 52], ["JHMV", "SPECIES", 34, 38], ["mice", "SPECIES", 48, 52], ["enhanced mortality in JHMV", "PROBLEM", 12, 38], ["microglia reduction", "TREATMENT", 63, 82], ["an impaired ability", "PROBLEM", 104, 123], ["enhanced", "OBSERVATION_MODIFIER", 12, 20], ["mortality", "OBSERVATION_MODIFIER", 21, 30], ["infected", "OBSERVATION", 39, 47], ["impaired", "OBSERVATION", 107, 115]]], ["Most importantly, microglia depletion leads to increased demyelination compared to control mice (Figure 4E,F).", [["microglia", "ANATOMY", 18, 27], ["demyelination", "DISEASE", 57, 70], ["microglia", "CELL", 18, 27], ["mice", "ORGANISM", 91, 95], ["mice", "SPECIES", 91, 95], ["mice", "SPECIES", 91, 95], ["microglia depletion", "PROBLEM", 18, 37], ["increased demyelination", "PROBLEM", 47, 70], ["microglia depletion", "OBSERVATION", 18, 37], ["increased", "OBSERVATION_MODIFIER", 47, 56], ["demyelination", "OBSERVATION", 57, 70]]], ["Similar to what we observe in GF mice, both CD4+ and CD8+ T cell responses are deficient in the absence of microglia and IFN-\u03b3 production from these cells is impaired (Figure 4G\u2013l and Figure 4\u2014figure supplement 1D; Figure 4\u2014figure supplement 1E; Figure 4\u2014figure supplement 1F; Figure 4\u2014figure supplement 1G; Figure 4\u2014figure supplement 1H).", [["CD4+ and CD8+", "ANATOMY", 44, 57], ["T cell", "ANATOMY", 58, 64], ["microglia", "ANATOMY", 107, 116], ["cells", "ANATOMY", 149, 154], ["1H", "CHEMICAL", 335, 337], ["GF mice", "ORGANISM", 30, 37], ["CD4", "GENE_OR_GENE_PRODUCT", 44, 47], ["CD8", "GENE_OR_GENE_PRODUCT", 53, 56], ["T cell", "CELL", 58, 64], ["microglia", "CELL", 107, 116], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 121, 126], ["cells", "CELL", 149, 154], ["CD4", "PROTEIN", 44, 47], ["CD8", "PROTEIN", 53, 56], ["microglia", "CELL_TYPE", 107, 116], ["IFN", "PROTEIN", 121, 124], ["mice", "SPECIES", 33, 37], ["mice", "SPECIES", 33, 37], ["CD4", "TEST", 44, 47], ["microglia", "PROBLEM", 107, 116], ["IFN", "TEST", 121, 124], ["these cells", "PROBLEM", 143, 154], ["Figure 4\u2014figure supplement", "TREATMENT", 184, 210], ["Figure 4\u2014figure supplement", "TREATMENT", 215, 241], ["Figure 4\u2014figure supplement", "TREATMENT", 246, 272], ["Figure 4\u2014figure supplement", "TREATMENT", 277, 303], ["Figure", "TREATMENT", 308, 314]]], ["Collectively, these data support a role for microglia for limiting neurologic damage.Oral administration of TLR ligands is sufficient to enhance microglia activation and protect from neurologic disease ::: ResultsPrevious reports have identified that short chain fatty acids (SCFAs) are able to influence the morphology and transcriptome of microglia (Erny et al., 2015); however, the microbiota is also a rich source of microbial ligands that can bind to Toll-like receptors (TLRs) that are known to influence systemic immune responses (Kubinak and Round, 2012).", [["microglia", "ANATOMY", 44, 53], ["neurologic", "ANATOMY", 67, 77], ["Oral", "ANATOMY", 85, 89], ["microglia", "ANATOMY", 145, 154], ["neurologic", "ANATOMY", 183, 193], ["microglia", "ANATOMY", 341, 350], ["neurologic damage", "DISEASE", 67, 84], ["neurologic disease", "DISEASE", 183, 201], ["fatty acids", "CHEMICAL", 263, 274], ["SCFAs", "CHEMICAL", 276, 281], ["fatty acids", "CHEMICAL", 263, 274], ["SCFAs", "CHEMICAL", 276, 281], ["microglia", "CELL", 44, 53], ["Oral", "ORGANISM_SUBDIVISION", 85, 89], ["TLR", "GENE_OR_GENE_PRODUCT", 108, 111], ["microglia", "CELL", 145, 154], ["short chain fatty acids", "SIMPLE_CHEMICAL", 251, 274], ["SCFAs", "SIMPLE_CHEMICAL", 276, 281], ["microglia", "CELL", 341, 350], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 456, 475], ["TLRs", "GENE_OR_GENE_PRODUCT", 477, 481], ["microglia", "CELL_TYPE", 44, 53], ["TLR", "PROTEIN", 108, 111], ["microglia", "CELL_TYPE", 145, 154], ["microglia", "CELL_TYPE", 341, 350], ["Toll-like receptors", "PROTEIN", 456, 475], ["TLRs", "PROTEIN", 477, 481], ["microglia", "PROBLEM", 44, 53], ["limiting neurologic damage", "PROBLEM", 58, 84], ["Oral administration of TLR ligands", "TREATMENT", 85, 119], ["short chain fatty acids (SCFAs)", "PROBLEM", 251, 282], ["microbial ligands", "PROBLEM", 421, 438]]], ["Furthermore, the microbiota is also known to induce several cytokines that have the potential to influence microglial function (Pinteaux et al., 2002).", [["microglial", "ANATOMY", 107, 117], ["microglial", "CELL", 107, 117], ["cytokines", "PROTEIN", 60, 69]]], ["To identify relevant microbial products that might directly activate microglia, we screened various SCFAs, TLR ligands and innate cytokines on BV2 cells to evaluate induction of MHC expression.", [["microglia", "ANATOMY", 69, 78], ["BV2 cells", "ANATOMY", 143, 152], ["SCFAs", "CHEMICAL", 100, 105], ["SCFAs", "CHEMICAL", 100, 105], ["microglia", "CELL", 69, 78], ["SCFAs", "SIMPLE_CHEMICAL", 100, 105], ["TLR", "GENE_OR_GENE_PRODUCT", 107, 110], ["BV2 cells", "CELL", 143, 152], ["MHC", "GENE_OR_GENE_PRODUCT", 178, 181], ["microglia", "CELL_TYPE", 69, 78], ["TLR ligands", "PROTEIN", 107, 118], ["innate cytokines", "PROTEIN", 123, 139], ["BV2 cells", "CELL_LINE", 143, 152], ["MHC", "PROTEIN", 178, 181], ["TLR ligands", "TREATMENT", 107, 118], ["innate cytokines on BV2 cells", "TREATMENT", 123, 152], ["microbial products", "OBSERVATION", 21, 39], ["microglia", "OBSERVATION", 69, 78]]], ["The BV2 cell line was originally developed by infecting primary microglial cell cultures with a -raf/v-myc oncogene carrying retrovirus (J2) (Blasi et al., 1990) and has been used by numerous investigators as an effective alternative model system for primary microglia cultures to study various cell biology aspects (Henn et al., 2009).", [["BV2 cell line", "ANATOMY", 4, 17], ["microglial cell cultures", "ANATOMY", 64, 88], ["primary microglia cultures", "ANATOMY", 251, 277], ["cell", "ANATOMY", 295, 299], ["BV2 cell line", "CELL", 4, 17], ["microglial cell cultures", "CELL", 64, 88], ["v-myc", "GENE_OR_GENE_PRODUCT", 101, 106], ["retrovirus", "ORGANISM", 125, 135], ["microglia cultures", "CELL", 259, 277], ["cell", "CELL", 295, 299], ["BV2 cell line", "CELL_LINE", 4, 17], ["primary microglial cell cultures", "CELL_LINE", 56, 88], ["raf/v-myc oncogene", "DNA", 97, 115], ["primary microglia cultures", "CELL_LINE", 251, 277], ["The BV2 cell line", "TREATMENT", 0, 17], ["infecting primary microglial cell cultures", "PROBLEM", 46, 88], ["primary microglia cultures", "TEST", 251, 277], ["BV2 cell line", "OBSERVATION", 4, 17], ["infecting", "OBSERVATION_MODIFIER", 46, 55], ["primary microglial cell cultures", "OBSERVATION", 56, 88]]], ["While SCFAs were able to induce MHCII expression at very high concentrations, lower levels of most SCFAs and cytokines associated with the innate immune response, for example IL-1, IL-18 and IL-33, did not stimulate MHCI and II expression in BV2 cells (Figure 5A,B and Figure 5\u2014figure supplement 1A\u2013C).", [["BV2 cells", "ANATOMY", 242, 251], ["SCFAs", "CHEMICAL", 6, 11], ["SCFAs", "CHEMICAL", 99, 104], ["SCFAs", "CHEMICAL", 6, 11], ["SCFAs", "CHEMICAL", 99, 104], ["SCFAs", "SIMPLE_CHEMICAL", 6, 11], ["MHCII", "GENE_OR_GENE_PRODUCT", 32, 37], ["SCFAs", "SIMPLE_CHEMICAL", 99, 104], ["IL-1", "GENE_OR_GENE_PRODUCT", 175, 179], ["IL-18", "GENE_OR_GENE_PRODUCT", 181, 186], ["IL-33", "GENE_OR_GENE_PRODUCT", 191, 196], ["MHCI", "GENE_OR_GENE_PRODUCT", 216, 220], ["II", "GENE_OR_GENE_PRODUCT", 225, 227], ["BV2 cells", "CELL", 242, 251], ["B", "CELL", 263, 264], ["MHCII", "PROTEIN", 32, 37], ["cytokines", "PROTEIN", 109, 118], ["MHCI", "PROTEIN", 216, 220], ["BV2 cells", "CELL_LINE", 242, 251], ["very high concentrations", "PROBLEM", 52, 76], ["IL", "TEST", 175, 177], ["IL", "TEST", 181, 183], ["IL", "TEST", 191, 193], ["Figure 5A", "TEST", 253, 262], ["Figure", "TEST", 269, 275], ["BV2 cells", "OBSERVATION", 242, 251]]], ["Butyrate was able to stimulate a small, but significant, increase in MHC expression; however, the highest levels of MHCI and II upregulation were achieved by bacterial-associated TLR ligands (Figure 5A,B and Figure 5\u2014figure supplement 1C).", [["Butyrate", "CHEMICAL", 0, 8], ["Butyrate", "CHEMICAL", 0, 8], ["Butyrate", "SIMPLE_CHEMICAL", 0, 8], ["MHC", "GENE_OR_GENE_PRODUCT", 69, 72], ["MHCI", "GENE_OR_GENE_PRODUCT", 116, 120], ["II", "GENE_OR_GENE_PRODUCT", 125, 127], ["TLR", "GENE_OR_GENE_PRODUCT", 179, 182], ["MHC", "PROTEIN", 69, 72], ["MHCI", "PROTEIN", 116, 120], ["TLR ligands", "PROTEIN", 179, 190], ["Butyrate", "TREATMENT", 0, 8], ["Figure 5A", "TEST", 192, 201], ["B and Figure 5\u2014figure supplement", "TREATMENT", 202, 234], ["small", "OBSERVATION_MODIFIER", 33, 38], ["significant", "OBSERVATION_MODIFIER", 44, 55], ["increase", "OBSERVATION_MODIFIER", 57, 65], ["MHC expression", "OBSERVATION", 69, 83]]], ["LPS (and to a lesser extent, the TLR1/2 heterodimer ligand Pam3CysK4) significantly upregulated both the frequency of MHCII expressing cells and the total amount of MHCI per cell (Figure 5A,B and Figure 5\u2014figure supplement 1C).", [["cells", "ANATOMY", 135, 140], ["cell", "ANATOMY", 174, 178], ["LPS", "CHEMICAL", 0, 3], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["TLR1", "GENE_OR_GENE_PRODUCT", 33, 37], ["2", "GENE_OR_GENE_PRODUCT", 38, 39], ["Pam3CysK4", "GENE_OR_GENE_PRODUCT", 59, 68], ["MHCII", "GENE_OR_GENE_PRODUCT", 118, 123], ["cells", "CELL", 135, 140], ["MHCI", "GENE_OR_GENE_PRODUCT", 165, 169], ["cell", "CELL", 174, 178], ["B", "CELL", 190, 191], ["TLR1", "PROTEIN", 33, 37], ["Pam3CysK4", "PROTEIN", 59, 68], ["MHCII expressing cells", "CELL_TYPE", 118, 140], ["MHCI", "PROTEIN", 165, 169], ["LPS", "TEST", 0, 3], ["B and Figure 5\u2014figure supplement", "TREATMENT", 190, 222], ["MHCII expressing cells", "OBSERVATION", 118, 140], ["total", "OBSERVATION_MODIFIER", 149, 154], ["amount", "OBSERVATION_MODIFIER", 155, 161]]], ["These data suggest that TLR ligands from the microbiota are able to prime microglia for antigen presentation.Oral administration of TLR ligands is sufficient to enhance microglia activation and protect from neurologic disease ::: ResultsTo test if microbial ligands could increase antigen presentation machinery on microglia in vivo, GF mice were orally fed either the TLR4 ligand LPS or LPS in combination with the TLR1/2 ligand Pam3CysK4 to replicate the natural route of exposure to microbiota-produced ligands.", [["microglia", "ANATOMY", 74, 83], ["Oral", "ANATOMY", 109, 113], ["microglia", "ANATOMY", 169, 178], ["neurologic", "ANATOMY", 207, 217], ["microglia", "ANATOMY", 315, 324], ["neurologic disease", "DISEASE", 207, 225], ["LPS", "CHEMICAL", 381, 384], ["LPS", "CHEMICAL", 388, 391], ["TLR ligands", "GENE_OR_GENE_PRODUCT", 24, 35], ["microglia", "CELL", 74, 83], ["Oral", "ORGANISM_SUBDIVISION", 109, 113], ["TLR", "GENE_OR_GENE_PRODUCT", 132, 135], ["microglia", "CELL", 169, 178], ["microglia", "CELL", 315, 324], ["GF mice", "ORGANISM", 334, 341], ["TLR4", "GENE_OR_GENE_PRODUCT", 369, 373], ["LPS", "SIMPLE_CHEMICAL", 381, 384], ["LPS", "SIMPLE_CHEMICAL", 388, 391], ["TLR1", "GENE_OR_GENE_PRODUCT", 416, 420], ["2", "GENE_OR_GENE_PRODUCT", 421, 422], ["Pam3CysK4", "GENE_OR_GENE_PRODUCT", 430, 439], ["TLR", "PROTEIN", 24, 27], ["microglia", "CELL_TYPE", 74, 83], ["TLR", "PROTEIN", 132, 135], ["microglia", "CELL_TYPE", 169, 178], ["microglia", "CELL_TYPE", 315, 324], ["TLR4", "PROTEIN", 369, 373], ["TLR1/2 ligand", "PROTEIN", 416, 429], ["Pam3CysK4", "PROTEIN", 430, 439], ["mice", "SPECIES", 337, 341], ["mice", "SPECIES", 337, 341], ["These data", "TEST", 0, 10], ["TLR ligands", "PROBLEM", 24, 35], ["Oral administration of TLR ligands", "TREATMENT", 109, 143], ["microbial ligands", "PROBLEM", 248, 265], ["the TLR4 ligand LPS", "TREATMENT", 365, 384], ["LPS", "TREATMENT", 388, 391], ["the TLR1/2 ligand Pam3CysK4", "TREATMENT", 412, 439]]], ["Animals were fed TLR ligands for 2 weeks, and subsequently infected with JHMV.", [["Animals", "ORGANISM", 0, 7], ["TLR", "PROTEIN", 17, 20], ["JHMV", "SPECIES", 73, 77], ["JHMV", "TREATMENT", 73, 77], ["infected", "OBSERVATION", 59, 67]]], ["The level of TLR ligands fed in these experiments does not lead to excessive levels of TLRs in the serum and does not exceed those found in SPF animals (Figure 5\u2014figure supplement 2A,B).", [["serum", "ANATOMY", 99, 104], ["TLR", "GENE_OR_GENE_PRODUCT", 13, 16], ["TLRs", "GENE_OR_GENE_PRODUCT", 87, 91], ["serum", "ORGANISM_SUBSTANCE", 99, 104], ["TLR ligands", "PROTEIN", 13, 24], ["TLRs", "PROTEIN", 87, 91], ["TLR ligands", "TREATMENT", 13, 24], ["excessive levels of TLRs in the serum", "PROBLEM", 67, 104]]], ["Feeding GF mice bacterial cell wall components resulted in reduced paralysis and lower viral titers at day 9 p.i.", [["cell wall", "ANATOMY", 26, 35], ["paralysis", "DISEASE", 67, 76], ["mice", "ORGANISM", 11, 15], ["cell wall", "MULTI-TISSUE_STRUCTURE", 26, 35], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 11, 15], ["Feeding GF mice bacterial cell wall components", "TREATMENT", 0, 46], ["reduced paralysis", "PROBLEM", 59, 76], ["lower viral titers", "PROBLEM", 81, 99], ["bacterial cell", "OBSERVATION", 16, 30], ["wall", "ANATOMY_MODIFIER", 31, 35], ["reduced", "OBSERVATION_MODIFIER", 59, 66], ["paralysis", "OBSERVATION", 67, 76], ["lower", "OBSERVATION_MODIFIER", 81, 86], ["viral titers", "OBSERVATION", 87, 99]]], ["Consistent with this, increases in cell number, CD4 and CD8 T cells in the CNS of TLR ligand fed animals was also observed (Figure 5\u2014figure supplement 2C\u2013H).", [["cell", "ANATOMY", 35, 39], ["CD4", "ANATOMY", 48, 51], ["CD8 T cells", "ANATOMY", 56, 67], ["CNS", "ANATOMY", 75, 78], ["cell", "CELL", 35, 39], ["CD4", "GENE_OR_GENE_PRODUCT", 48, 51], ["CD8 T", "GENE_OR_GENE_PRODUCT", 56, 61], ["CNS", "ANATOMICAL_SYSTEM", 75, 78], ["TLR ligand", "GENE_OR_GENE_PRODUCT", 82, 92], ["CD4 and CD8 T cells", "CELL_TYPE", 48, 67], ["CD4", "TEST", 48, 51], ["increases", "OBSERVATION_MODIFIER", 22, 31], ["cell number", "OBSERVATION", 35, 46], ["CNS", "ANATOMY", 75, 78]]], ["Feeding GF animals LPS alone, led to similar increases in cell number in the CNS of infected mice (Figure 5E), more MHCII expressing microglia and increased CD4 T cell trafficking to the CNS during infection (Figure 5F,G).", [["cell", "ANATOMY", 58, 62], ["CNS", "ANATOMY", 77, 80], ["microglia", "ANATOMY", 133, 142], ["CD4 T cell", "ANATOMY", 157, 167], ["CNS", "ANATOMY", 187, 190], ["LPS", "CHEMICAL", 19, 22], ["increases in cell number", "DISEASE", 45, 69], ["infection", "DISEASE", 198, 207], ["LPS", "SIMPLE_CHEMICAL", 19, 22], ["cell", "CELL", 58, 62], ["CNS", "ANATOMICAL_SYSTEM", 77, 80], ["mice", "ORGANISM", 93, 97], ["MHCII", "GENE_OR_GENE_PRODUCT", 116, 121], ["microglia", "CELL", 133, 142], ["CD4 T cell", "GENE_OR_GENE_PRODUCT", 157, 167], ["CNS", "ANATOMICAL_SYSTEM", 187, 190], ["MHCII expressing microglia", "CELL_TYPE", 116, 142], ["CD4", "PROTEIN", 157, 160], ["mice", "SPECIES", 93, 97], ["mice", "SPECIES", 93, 97], ["similar increases in cell number", "PROBLEM", 37, 69], ["microglia", "PROBLEM", 133, 142], ["increased CD4 T cell trafficking", "PROBLEM", 147, 179], ["the CNS during infection", "PROBLEM", 183, 207], ["increases", "OBSERVATION_MODIFIER", 45, 54], ["cell number", "OBSERVATION", 58, 69], ["increased", "OBSERVATION_MODIFIER", 147, 156], ["CD4 T cell", "OBSERVATION", 157, 167], ["CNS", "ANATOMY", 187, 190], ["infection", "OBSERVATION", 198, 207]]], ["Interestingly, feeding mice both ligands increased numbers and frequency of CD4 and number of CD8 T cells in the CNS (Figure 5\u2014figure supplement 2D\u2013H), while LPS only increased total numbers of CD4 T cells (Figure 5G and data not shown).", [["CD8 T cells", "ANATOMY", 94, 105], ["CNS", "ANATOMY", 113, 116], ["CD4 T cells", "ANATOMY", 194, 205], ["LPS", "CHEMICAL", 158, 161], ["mice", "ORGANISM", 23, 27], ["CD4", "GENE_OR_GENE_PRODUCT", 76, 79], ["CD8 T cells", "CELL", 94, 105], ["CNS", "ANATOMICAL_SYSTEM", 113, 116], ["LPS", "SIMPLE_CHEMICAL", 158, 161], ["CD4 T cells", "CELL", 194, 205], ["CD4", "PROTEIN", 76, 79], ["CD8 T cells", "CELL_TYPE", 94, 105], ["CD4 T cells", "CELL_TYPE", 194, 205], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 23, 27], ["CD4", "TEST", 76, 79], ["LPS", "TEST", 158, 161], ["CD4 T cells", "PROBLEM", 194, 205], ["Figure 5G and data", "TEST", 207, 225], ["CNS", "ANATOMY", 113, 116], ["increased", "OBSERVATION_MODIFIER", 167, 176]]], ["Feeding mice LPS alone, however, increased MHCII expression on microglia during disease (Figure 5F), but this was not observed when feeding both LPS and Pam3Cysk4 (data not shown).", [["microglia", "ANATOMY", 63, 72], ["LPS", "CHEMICAL", 13, 16], ["LPS", "CHEMICAL", 145, 148], ["mice", "ORGANISM", 8, 12], ["LPS", "SIMPLE_CHEMICAL", 13, 16], ["MHCII", "GENE_OR_GENE_PRODUCT", 43, 48], ["microglia", "CELL", 63, 72], ["LPS", "SIMPLE_CHEMICAL", 145, 148], ["Pam3Cysk4", "SIMPLE_CHEMICAL", 153, 162], ["MHCII", "PROTEIN", 43, 48], ["microglia", "CELL_TYPE", 63, 72], ["mice", "SPECIES", 8, 12], ["mice", "SPECIES", 8, 12], ["Feeding mice LPS", "TREATMENT", 0, 16], ["increased", "OBSERVATION_MODIFIER", 33, 42], ["MHCII expression", "OBSERVATION", 43, 59]]], ["These results demonstrate that TLR ligands derived from the gut microbiota are sufficient to influence microglial activation and protection in response to viral-induced neurologic disease.Tlr4, but not Tlr2, is required for protection from viral-induced neurologic damage ::: ResultsOur results demonstrate that gut microbiota products influence priming of resident cells of the CNS through TLR-dependent signals.", [["gut microbiota", "ANATOMY", 60, 74], ["microglial", "ANATOMY", 103, 113], ["neurologic", "ANATOMY", 169, 179], ["neurologic", "ANATOMY", 254, 264], ["gut microbiota", "ANATOMY", 312, 326], ["cells", "ANATOMY", 366, 371], ["CNS", "ANATOMY", 379, 382], ["neurologic disease", "DISEASE", 169, 187], ["neurologic damage", "DISEASE", 254, 271], ["TLR", "GENE_OR_GENE_PRODUCT", 31, 34], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 60, 74], ["microglial", "CELL", 103, 113], ["Tlr4", "GENE_OR_GENE_PRODUCT", 188, 192], ["Tlr2", "GENE_OR_GENE_PRODUCT", 202, 206], ["cells", "CELL", 366, 371], ["CNS", "ANATOMICAL_SYSTEM", 379, 382], ["TLR", "GENE_OR_GENE_PRODUCT", 391, 394], ["TLR", "PROTEIN", 31, 34], ["Tlr4", "PROTEIN", 188, 192], ["Tlr2", "PROTEIN", 202, 206], ["resident cells", "CELL_TYPE", 357, 371], ["TLR", "PROTEIN", 391, 394], ["TLR ligands", "PROBLEM", 31, 42], ["microglial activation", "TREATMENT", 103, 124], ["viral-induced neurologic disease", "PROBLEM", 155, 187], ["Tlr4", "TREATMENT", 188, 192], ["Tlr2", "TREATMENT", 202, 206], ["protection", "TREATMENT", 224, 234], ["microglial activation", "OBSERVATION", 103, 124], ["neurologic disease", "OBSERVATION", 169, 187], ["CNS", "ANATOMY", 379, 382], ["dependent signals", "OBSERVATION", 395, 412]]], ["Feeding TLR ligands to GF mice suggests that these microbial products are sufficient to decrease neurologic disease, and our results show that TLR4 exposure may play a more prominent role than TLR2 signaling in this process.", [["neurologic", "ANATOMY", 97, 107], ["neurologic disease", "DISEASE", 97, 115], ["TLR", "GENE_OR_GENE_PRODUCT", 8, 11], ["GF mice", "ORGANISM", 23, 30], ["TLR4", "GENE_OR_GENE_PRODUCT", 143, 147], ["TLR2", "GENE_OR_GENE_PRODUCT", 193, 197], ["TLR", "PROTEIN", 8, 11], ["TLR4", "PROTEIN", 143, 147], ["TLR2", "PROTEIN", 193, 197], ["mice", "SPECIES", 26, 30], ["these microbial products", "TREATMENT", 45, 69], ["neurologic disease", "PROBLEM", 97, 115], ["TLR4 exposure", "PROBLEM", 143, 156], ["more prominent", "OBSERVATION_MODIFIER", 168, 182]]], ["A previous report demonstrated that there is no difference in the morphology of microglia from TLR deficient mice (Erny et al., 2015), but antigen presentation in these mice was not evaluated in these studies.", [["microglia", "ANATOMY", 80, 89], ["microglia", "CELL", 80, 89], ["TLR", "GENE_OR_GENE_PRODUCT", 95, 98], ["mice", "ORGANISM", 109, 113], ["mice", "ORGANISM", 169, 173], ["microglia", "CELL_TYPE", 80, 89], ["TLR", "PROTEIN", 95, 98], ["mice", "SPECIES", 109, 113], ["mice", "SPECIES", 169, 173], ["mice", "SPECIES", 109, 113], ["mice", "SPECIES", 169, 173], ["these studies", "TEST", 195, 208], ["no", "UNCERTAINTY", 45, 47], ["difference", "OBSERVATION_MODIFIER", 48, 58]]], ["Therefore, we infected TLR2-/- and TLR4-/- animals with JHMV and assayed for neurologic damage.", [["neurologic", "ANATOMY", 77, 87], ["neurologic damage", "DISEASE", 77, 94], ["TLR2", "GENE_OR_GENE_PRODUCT", 23, 27], ["/-", "GENE_OR_GENE_PRODUCT", 28, 30], ["TLR4", "GENE_OR_GENE_PRODUCT", 35, 39], ["JHMV", "CANCER", 56, 60], ["TLR2", "PROTEIN", 23, 27], ["TLR4", "PROTEIN", 35, 39], ["JHMV", "SPECIES", 56, 60], ["JHMV", "TREATMENT", 56, 60], ["neurologic damage", "PROBLEM", 77, 94]]], ["Compared to WT mice, TLR2-/- animals had no difference in mortality (not shown) or clinical presentation of disease (Figure 6\u2014figure supplement 1A).", [["WT mice", "ORGANISM", 12, 19], ["TLR2", "GENE_OR_GENE_PRODUCT", 21, 25], ["TLR2", "PROTEIN", 21, 25], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 15, 19], ["TLR2", "TEST", 21, 25], ["disease", "PROBLEM", 108, 115]]], ["TLR4-/- mice had significantly worsened disease symptoms that were similar to GF mice (Figure 6A).", [["TLR4", "GENE_OR_GENE_PRODUCT", 0, 4], ["mice", "ORGANISM", 8, 12], ["GF mice", "ORGANISM", 78, 85], ["TLR4", "PROTEIN", 0, 4], ["mice", "SPECIES", 8, 12], ["mice", "SPECIES", 81, 85], ["mice", "SPECIES", 8, 12], ["mice", "SPECIES", 81, 85], ["significantly worsened disease symptoms", "PROBLEM", 17, 56], ["worsened", "OBSERVATION_MODIFIER", 31, 39], ["disease", "OBSERVATION", 40, 47]]], ["Importantly, TLR4-/- animals had significantly increased demyelination, indicating that TLR4 signals are important for protection from neurologic damage (Figure 6B,C).", [["neurologic", "ANATOMY", 135, 145], ["demyelination", "DISEASE", 57, 70], ["neurologic damage", "DISEASE", 135, 152], ["TLR4", "GENE_OR_GENE_PRODUCT", 13, 17], ["TLR4", "GENE_OR_GENE_PRODUCT", 88, 92], ["TLR4", "PROTEIN", 13, 17], ["TLR4", "PROTEIN", 88, 92], ["TLR4", "TEST", 13, 17], ["significantly increased demyelination", "PROBLEM", 33, 70], ["TLR4 signals", "PROBLEM", 88, 100], ["neurologic damage", "PROBLEM", 135, 152], ["increased", "OBSERVATION_MODIFIER", 47, 56], ["demyelination", "OBSERVATION", 57, 70]]], ["Consistent with this, microglia, but not macrophages, from TLR4-/- animals express lower levels of MHCII under homeostatic conditions, prior to infection (Figure 6D,E and Figure 6\u2014figure supplement 1B) and lower total numbers of MHCII expressing microglia (and total microglia) during JHMV infection when compared to WT mice (Figure 6F and G).", [["microglia", "ANATOMY", 22, 31], ["macrophages", "ANATOMY", 41, 52], ["microglia", "ANATOMY", 246, 255], ["microglia", "ANATOMY", 267, 276], ["infection", "DISEASE", 144, 153], ["infection", "DISEASE", 290, 299], ["microglia", "CELL", 22, 31], ["macrophages", "CELL", 41, 52], ["TLR4", "GENE_OR_GENE_PRODUCT", 59, 63], ["MHCII", "GENE_OR_GENE_PRODUCT", 99, 104], ["MHCII", "GENE_OR_GENE_PRODUCT", 229, 234], ["microglia", "CELL", 246, 255], ["microglia", "CELL", 267, 276], ["JHMV", "GENE_OR_GENE_PRODUCT", 285, 289], ["mice", "ORGANISM", 320, 324], ["microglia", "CELL_TYPE", 22, 31], ["macrophages", "CELL_TYPE", 41, 52], ["TLR4", "PROTEIN", 59, 63], ["MHCII", "PROTEIN", 99, 104], ["MHCII", "PROTEIN", 229, 234], ["microglia", "CELL_TYPE", 246, 255], ["microglia", "CELL_TYPE", 267, 276], ["mice", "SPECIES", 320, 324], ["JHMV", "SPECIES", 285, 289], ["mice", "SPECIES", 320, 324], ["macrophages", "PROBLEM", 41, 52], ["TLR4", "TEST", 59, 63], ["infection", "PROBLEM", 144, 153], ["E and Figure 6\u2014figure supplement", "TREATMENT", 165, 197], ["JHMV infection", "PROBLEM", 285, 299], ["not", "UNCERTAINTY", 37, 40], ["macrophages", "OBSERVATION", 41, 52], ["infection", "OBSERVATION", 290, 299]]], ["JHMV is unable to directly activate TLR4 (Figure 6\u2014figure supplement 1C), further arguing that microbiota-based signals function to prime microglia against CNS infection.", [["microglia", "ANATOMY", 138, 147], ["CNS", "ANATOMY", 156, 159], ["infection", "DISEASE", 160, 169], ["JHMV", "SIMPLE_CHEMICAL", 0, 4], ["TLR4", "GENE_OR_GENE_PRODUCT", 36, 40], ["microglia", "CELL", 138, 147], ["CNS", "ANATOMICAL_SYSTEM", 156, 159], ["JHMV", "PROTEIN", 0, 4], ["TLR4", "PROTEIN", 36, 40], ["Figure 6", "PROTEIN", 42, 50], ["microglia", "CELL_TYPE", 138, 147], ["JHMV", "SPECIES", 0, 4], ["Figure 6\u2014figure supplement 1C", "TREATMENT", 42, 71], ["CNS infection", "PROBLEM", 156, 169], ["infection", "OBSERVATION", 160, 169]]], ["Collectively, these results argue that brain resident immune cells are specifically influenced by TLR4 signals to protect from viral-induced CNS damage.Microglia-intrinsic TLR4 signaling is required for protection from viral-induced paralysis ::: ResultsCollectively, these data argue that gut microbial products are important for priming microglia within the CNS.", [["brain", "ANATOMY", 39, 44], ["immune cells", "ANATOMY", 54, 66], ["CNS", "ANATOMY", 141, 144], ["microglia", "ANATOMY", 339, 348], ["CNS", "ANATOMY", 360, 363], ["CNS damage", "DISEASE", 141, 151], ["paralysis", "DISEASE", 233, 242], ["brain resident immune cells", "CELL", 39, 66], ["TLR4", "GENE_OR_GENE_PRODUCT", 98, 102], ["CNS", "ANATOMICAL_SYSTEM", 141, 144], ["Microglia", "CELL", 152, 161], ["TLR4", "GENE_OR_GENE_PRODUCT", 172, 176], ["microglia", "CELL", 339, 348], ["CNS", "ANATOMICAL_SYSTEM", 360, 363], ["brain resident immune cells", "CELL_TYPE", 39, 66], ["TLR4", "PROTEIN", 98, 102], ["TLR4", "PROTEIN", 172, 176], ["microglia", "CELL_TYPE", 339, 348], ["viral-induced CNS damage", "PROBLEM", 127, 151], ["Microglia-intrinsic TLR4 signaling", "TREATMENT", 152, 186], ["paralysis", "PROBLEM", 233, 242], ["these data", "TEST", 268, 278], ["priming microglia", "PROBLEM", 331, 348], ["viral", "OBSERVATION", 127, 132], ["CNS", "ANATOMY", 141, 144], ["damage", "OBSERVATION", 145, 151], ["paralysis", "OBSERVATION", 233, 242], ["CNS", "ANATOMY", 360, 363]]], ["However, these experiments cannot differentiate between TLR4 signals exerting activity within the gut or by directly priming microglia themselves.", [["gut", "ANATOMY", 98, 101], ["microglia", "ANATOMY", 125, 134], ["TLR4", "GENE_OR_GENE_PRODUCT", 56, 60], ["gut", "ORGANISM_SUBDIVISION", 98, 101], ["microglia", "CELL", 125, 134], ["TLR4", "PROTEIN", 56, 60], ["microglia", "CELL_TYPE", 125, 134], ["activity", "OBSERVATION_MODIFIER", 78, 86]]], ["Indeed, we and others have detected TLR4 agonists within the blood of mice and humans, suggesting that microbial products could be circulating within the blood and thus be available to prime cells at sites distant from mucosal tissue (Clarke et al., 2010; Soto et al., 2017).", [["blood", "ANATOMY", 61, 66], ["blood", "ANATOMY", 154, 159], ["cells", "ANATOMY", 191, 196], ["sites", "ANATOMY", 200, 205], ["mucosal tissue", "ANATOMY", 219, 233], ["TLR4", "GENE_OR_GENE_PRODUCT", 36, 40], ["blood", "ORGANISM_SUBSTANCE", 61, 66], ["mice", "ORGANISM", 70, 74], ["humans", "ORGANISM", 79, 85], ["blood", "ORGANISM_SUBSTANCE", 154, 159], ["cells", "CELL", 191, 196], ["mucosal tissue", "TISSUE", 219, 233], ["TLR4", "PROTEIN", 36, 40], ["prime cells", "CELL_TYPE", 185, 196], ["mice", "SPECIES", 70, 74], ["humans", "SPECIES", 79, 85], ["mice", "SPECIES", 70, 74], ["humans", "SPECIES", 79, 85], ["TLR4 agonists", "TREATMENT", 36, 49], ["microbial products", "TREATMENT", 103, 121], ["mucosal tissue", "ANATOMY", 219, 233]]], ["One study, however, has suggested that LPS is unable to cross the blood-brain barrier; therefore, it is unclear how TLR4 signals derived from the gut microbiota could influence microglia within the CNS (Banks and Robinson, 2010).", [["blood-brain barrier", "ANATOMY", 66, 85], ["gut microbiota", "ANATOMY", 146, 160], ["microglia", "ANATOMY", 177, 186], ["CNS", "ANATOMY", 198, 201], ["LPS", "CHEMICAL", 39, 42], ["LPS", "SIMPLE_CHEMICAL", 39, 42], ["blood-", "MULTI-TISSUE_STRUCTURE", 66, 72], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 72, 85], ["TLR4", "GENE_OR_GENE_PRODUCT", 116, 120], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 146, 160], ["microglia", "CELL", 177, 186], ["CNS", "ANATOMICAL_SYSTEM", 198, 201], ["TLR4", "PROTEIN", 116, 120], ["microglia", "CELL_TYPE", 177, 186], ["One study", "TEST", 0, 9], ["LPS", "TEST", 39, 42], ["brain", "ANATOMY", 72, 77]]], ["To initially address this, we performed a bone marrow chimera experiment.", [["bone marrow", "ANATOMY", 42, 53], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 42, 53], ["a bone marrow chimera experiment", "TREATMENT", 40, 72], ["bone", "ANATOMY", 42, 46]]], ["Radiation of animals followed by a bone marrow transplant readily replaces cells of the hematopoietic system in most compartments; however, microglia are known to be radio-resistant and therefore, during these experiments the majority of microglia are still from the recipient animal.", [["bone marrow", "ANATOMY", 35, 46], ["cells", "ANATOMY", 75, 80], ["hematopoietic system", "ANATOMY", 88, 108], ["compartments", "ANATOMY", 117, 129], ["microglia", "ANATOMY", 140, 149], ["microglia", "ANATOMY", 238, 247], ["animals", "ORGANISM", 13, 20], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 35, 46], ["cells", "CELL", 75, 80], ["hematopoietic system", "ANATOMICAL_SYSTEM", 88, 108], ["microglia", "CELL", 140, 149], ["microglia", "CELL", 238, 247], ["microglia", "CELL_TYPE", 140, 149], ["microglia", "CELL_TYPE", 238, 247], ["Radiation of animals", "TREATMENT", 0, 20], ["a bone marrow transplant", "TREATMENT", 33, 57], ["microglia", "PROBLEM", 140, 149], ["bone", "ANATOMY", 35, 39], ["marrow", "ANATOMY", 40, 46], ["transplant", "OBSERVATION", 47, 57], ["hematopoietic system", "ANATOMY", 88, 108], ["most compartments", "OBSERVATION_MODIFIER", 112, 129], ["microglia", "OBSERVATION", 140, 149], ["microglia", "OBSERVATION", 238, 247]]], ["Based on this, we performed bone marrow chimeras where we transplanted either WT or TLR4-/- bone marrow into WT recipients.", [["bone marrow", "ANATOMY", 28, 39], ["TLR4-/- bone marrow", "ANATOMY", 84, 103], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 28, 39], ["TLR4", "GENE_OR_GENE_PRODUCT", 84, 88], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 92, 103], ["TLR4", "PROTEIN", 84, 88], ["bone marrow chimeras", "PROBLEM", 28, 48], ["WT", "TEST", 78, 80], ["TLR4", "TEST", 84, 88], ["bone", "ANATOMY", 28, 32], ["bone marrow", "ANATOMY", 92, 103]]], ["Similarly to our previous results, we find that TLR4-/- animals develop significantly worsened clinical disease compared to WT animals (Figure 7A).", [["TLR4", "GENE_OR_GENE_PRODUCT", 48, 52], ["TLR4", "PROTEIN", 48, 52], ["TLR4", "TEST", 48, 52], ["significantly worsened clinical disease", "PROBLEM", 72, 111], ["worsened", "OBSERVATION_MODIFIER", 86, 94]]], ["Moreover, animals receiving either WT or TLR4-/- bone marrow, where most of the systemic hematopoietic system is replaced by TLR4 deficient cells, still develop disease similar to WT animals (Figure 7A).", [["bone marrow", "ANATOMY", 49, 60], ["hematopoietic system", "ANATOMY", 89, 109], ["cells", "ANATOMY", 140, 145], ["TLR4", "GENE_OR_GENE_PRODUCT", 41, 45], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 49, 60], ["TLR4", "GENE_OR_GENE_PRODUCT", 125, 129], ["cells", "CELL", 140, 145], ["TLR4", "PROTEIN", 41, 45], ["TLR4", "PROTEIN", 125, 129], ["the systemic hematopoietic system", "PROBLEM", 76, 109], ["TLR4 deficient cells", "PROBLEM", 125, 145], ["disease", "PROBLEM", 161, 168], ["bone marrow", "ANATOMY", 49, 60], ["systemic hematopoietic", "ANATOMY", 80, 102]]], ["To address this using a genetic approach, we crossed TLR4-floxed animals to either a nestin-Cre (CNS\u0394TLR4) driver or an inducible CX3CR1CreER driver (CX3CR1\u0394TLR4).", [["TLR4", "GENE_OR_GENE_PRODUCT", 53, 57], ["nestin", "GENE_OR_GENE_PRODUCT", 85, 91], ["Cre", "GENE_OR_GENE_PRODUCT", 92, 95], ["CNS\u0394TLR4", "GENE_OR_GENE_PRODUCT", 97, 105], ["CX3CR1", "GENE_OR_GENE_PRODUCT", 130, 136], ["CX3CR1\u0394TLR4", "GENE_OR_GENE_PRODUCT", 150, 161], ["TLR4", "PROTEIN", 53, 57], ["nestin-Cre (CNS\u0394TLR4) driver", "DNA", 85, 113], ["CX3CR1CreER driver", "DNA", 130, 148], ["CX3CR1\u0394TLR4", "DNA", 150, 161], ["a genetic approach", "TREATMENT", 22, 40], ["a nestin-Cre (CNS\u0394TLR4)", "TREATMENT", 83, 106]]], ["Nestin is expressed in neural progenitor cells that give rise to neurons, oligodendrocytes and astrocytes of the CNS; however, its expression in microglia has been contentious.", [["neural progenitor cells", "ANATOMY", 23, 46], ["neurons", "ANATOMY", 65, 72], ["oligodendrocytes", "ANATOMY", 74, 90], ["astrocytes", "ANATOMY", 95, 105], ["CNS", "ANATOMY", 113, 116], ["microglia", "ANATOMY", 145, 154], ["Nestin", "GENE_OR_GENE_PRODUCT", 0, 6], ["neural progenitor cells", "CELL", 23, 46], ["neurons", "CELL", 65, 72], ["oligodendrocytes", "CELL", 74, 90], ["astrocytes", "CELL", 95, 105], ["CNS", "ANATOMICAL_SYSTEM", 113, 116], ["microglia", "CELL", 145, 154], ["Nestin", "PROTEIN", 0, 6], ["neural progenitor cells", "CELL_TYPE", 23, 46], ["oligodendrocytes", "CELL_TYPE", 74, 90], ["astrocytes", "CELL_TYPE", 95, 105], ["microglia", "CELL_TYPE", 145, 154], ["neural progenitor cells", "TREATMENT", 23, 46], ["oligodendrocytes and astrocytes of the CNS", "PROBLEM", 74, 116], ["neural progenitor cells", "OBSERVATION", 23, 46], ["CNS", "ANATOMY", 113, 116]]], ["To verify that Nestin is not expressed in microglia, we crossed the nestin-Cre driver to a Rosa-lox-stop-lox-eYFP animal, allowing us to fate map nestin (and thus YFP) expressing cells.", [["microglia", "ANATOMY", 42, 51], ["cells", "ANATOMY", 179, 184], ["Nestin", "GENE_OR_GENE_PRODUCT", 15, 21], ["microglia", "CELL", 42, 51], ["nestin", "GENE_OR_GENE_PRODUCT", 68, 74], ["Cre", "GENE_OR_GENE_PRODUCT", 75, 78], ["lox", "GENE_OR_GENE_PRODUCT", 96, 99], ["nestin", "GENE_OR_GENE_PRODUCT", 146, 152], ["YFP", "GENE_OR_GENE_PRODUCT", 163, 166], ["cells", "CELL", 179, 184], ["Nestin", "PROTEIN", 15, 21], ["microglia", "CELL_TYPE", 42, 51], ["nestin", "PROTEIN", 68, 74], ["Rosa-lox-stop-lox", "DNA", 91, 108], ["nestin", "PROTEIN", 146, 152], ["YFP", "PROTEIN", 163, 166], ["expressing cells", "CELL_TYPE", 168, 184], ["Rosa", "ANATOMY", 91, 95]]], ["While we could readily detect YFP expression within the CNS, we were unable to detect YFP+ cells in the microglia fraction (Figure 7\u2014figure supplement 1A), further corroborating that nestin-Cre will not drive recombination in microglia.", [["CNS", "ANATOMY", 56, 59], ["YFP+ cells", "ANATOMY", 86, 96], ["microglia", "ANATOMY", 104, 113], ["microglia", "ANATOMY", 226, 235], ["YFP", "GENE_OR_GENE_PRODUCT", 30, 33], ["CNS", "ANATOMICAL_SYSTEM", 56, 59], ["YFP", "GENE_OR_GENE_PRODUCT", 86, 89], ["microglia", "CELL", 104, 113], ["nestin", "GENE_OR_GENE_PRODUCT", 183, 189], ["Cre", "GENE_OR_GENE_PRODUCT", 190, 193], ["microglia", "CELL", 226, 235], ["YFP", "PROTEIN", 30, 33], ["YFP", "PROTEIN", 86, 89], ["microglia fraction", "CELL_TYPE", 104, 122], ["nestin", "PROTEIN", 183, 189], ["Cre", "PROTEIN", 190, 193], ["microglia", "CELL_TYPE", 226, 235], ["YFP", "TEST", 86, 89], ["microglia fraction", "OBSERVATION", 104, 122], ["microglia", "ANATOMY", 226, 235]]], ["CX3CR1 is expressed in microglia, but also in other immune cells such as dendritic cells in the gut; however, since microglia are long-lived, the use of an inducible system allows for depletion of a gene within microglia, while other immune cells that might be affected by the tamoxifen treatment will rapidly turn over and revert back to a WT status (Goldmann et al., 2013).", [["microglia", "ANATOMY", 23, 32], ["immune cells", "ANATOMY", 52, 64], ["dendritic cells", "ANATOMY", 73, 88], ["gut", "ANATOMY", 96, 99], ["microglia", "ANATOMY", 116, 125], ["microglia", "ANATOMY", 211, 220], ["immune cells", "ANATOMY", 234, 246], ["tamoxifen", "CHEMICAL", 277, 286], ["tamoxifen", "CHEMICAL", 277, 286], ["CX3CR1", "GENE_OR_GENE_PRODUCT", 0, 6], ["microglia", "CELL", 23, 32], ["immune cells", "CELL", 52, 64], ["dendritic cells", "CELL", 73, 88], ["gut", "ORGANISM_SUBDIVISION", 96, 99], ["microglia", "CELL", 116, 125], ["microglia", "CELL", 211, 220], ["immune cells", "CELL", 234, 246], ["tamoxifen", "SIMPLE_CHEMICAL", 277, 286], ["CX3CR1", "PROTEIN", 0, 6], ["microglia", "CELL_TYPE", 23, 32], ["immune cells", "CELL_TYPE", 52, 64], ["dendritic cells", "CELL_TYPE", 73, 88], ["microglia", "CELL_TYPE", 116, 125], ["microglia", "CELL_TYPE", 211, 220], ["immune cells", "CELL_TYPE", 234, 246], ["CX3CR1", "TEST", 0, 6], ["microglia", "PROBLEM", 23, 32], ["other immune cells", "PROBLEM", 46, 64], ["dendritic cells in the gut", "PROBLEM", 73, 99], ["an inducible system", "PROBLEM", 153, 172], ["a gene within microglia", "PROBLEM", 197, 220], ["other immune cells", "PROBLEM", 228, 246], ["the tamoxifen treatment", "TREATMENT", 273, 296], ["microglia", "OBSERVATION", 23, 32], ["immune cells", "OBSERVATION", 52, 64], ["dendritic cells", "OBSERVATION", 73, 88], ["gut", "ANATOMY", 96, 99]]], ["This is currently the most widely used method to knock genes out within microglia.", [["microglia", "ANATOMY", 72, 81], ["microglia", "CELL", 72, 81], ["knock genes", "DNA", 49, 60], ["microglia", "CELL_TYPE", 72, 81], ["most widely", "OBSERVATION_MODIFIER", 22, 33]]], ["We verified that this treatment lead to disruption of TLR4 within microglia (Figure 7\u2014figure supplement 1B).", [["microglia", "ANATOMY", 66, 75], ["TLR4", "GENE_OR_GENE_PRODUCT", 54, 58], ["microglia", "CELL", 66, 75], ["TLR4", "PROTEIN", 54, 58], ["microglia", "CELL_TYPE", 66, 75], ["this treatment", "TREATMENT", 17, 31], ["TLR4 within microglia (Figure 7\u2014figure supplement", "TREATMENT", 54, 103]]], ["Based on this, CX3CR1\u0394TLR4 animals were tamoxifen treated and subsequently infected 1 month post-tamoxifen treatment.", [["tamoxifen", "CHEMICAL", 40, 49], ["tamoxifen", "CHEMICAL", 97, 106], ["tamoxifen", "CHEMICAL", 40, 49], ["tamoxifen", "CHEMICAL", 97, 106], ["CX3CR1\u0394TLR4 animals", "ORGANISM", 15, 34], ["tamoxifen", "SIMPLE_CHEMICAL", 40, 49], ["tamoxifen", "SIMPLE_CHEMICAL", 97, 106], ["this, CX3CR1\u0394TLR4 animals", "TREATMENT", 9, 34], ["tamoxifen", "TREATMENT", 40, 49], ["tamoxifen treatment", "TREATMENT", 97, 116]]], ["While infection of CNS\u0394TLR4 animals did not demonstrate a difference in clinical disease compared to WT animals (Figure 7B), disruption of TLR4 specifically within microglia, lead to worsened paralysis (Figure 7C).", [["microglia", "ANATOMY", 164, 173], ["infection", "DISEASE", 6, 15], ["paralysis", "DISEASE", 192, 201], ["CNS\u0394TLR4", "GENE_OR_GENE_PRODUCT", 19, 27], ["TLR4", "GENE_OR_GENE_PRODUCT", 139, 143], ["microglia", "CELL", 164, 173], ["TLR4", "PROTEIN", 139, 143], ["microglia", "CELL_TYPE", 164, 173], ["infection of CNS\u0394TLR4 animals", "PROBLEM", 6, 35], ["clinical disease", "PROBLEM", 72, 88], ["disruption of TLR4", "PROBLEM", 125, 143], ["worsened paralysis", "PROBLEM", 183, 201], ["TLR4", "ANATOMY_MODIFIER", 139, 143], ["worsened", "OBSERVATION_MODIFIER", 183, 191], ["paralysis", "OBSERVATION", 192, 201]]], ["Collectively, these data demonstrate that gut microbial signals can directly influence microglia function to prevent viral-induced neurologic diseases.DiscussionConsistent with the known contribution of the microbiota to immune system development, studies performed almost 50 years ago suggested that resident commensals aid in protection from influenza virus (Dolowy and Muldoon, 1964).", [["gut", "ANATOMY", 42, 45], ["microglia", "ANATOMY", 87, 96], ["neurologic", "ANATOMY", 131, 141], ["immune system", "ANATOMY", 221, 234], ["neurologic diseases", "DISEASE", 131, 150], ["influenza", "DISEASE", 344, 353], ["microglia", "CELL", 87, 96], ["influenza virus", "ORGANISM", 344, 359], ["microglia", "CELL_TYPE", 87, 96], ["influenza virus", "SPECIES", 344, 359], ["these data", "TEST", 14, 24], ["gut microbial signals", "PROBLEM", 42, 63], ["viral-induced neurologic diseases", "PROBLEM", 117, 150], ["influenza virus", "PROBLEM", 344, 359], ["neurologic diseases", "OBSERVATION", 131, 150]]], ["However, more recent studies have uncovered that other viruses take advantage of the microbiota to enhance infectivity (Robinson and Pfeiffer, 2014).", [["recent studies", "TEST", 14, 28], ["other viruses", "PROBLEM", 49, 62]]], ["Many human neurotropic viral pathogens are associated with the development of neurologic dysfunction (Koyuncu et al., 2013), yet little is known about the functional contribution of bacterial symbionts in host defense and disease following infection of the CNS.", [["neurologic", "ANATOMY", 78, 88], ["CNS", "ANATOMY", 257, 260], ["neurotropic viral pathogens", "DISEASE", 11, 38], ["neurologic dysfunction", "DISEASE", 78, 100], ["infection of the CNS", "DISEASE", 240, 260], ["human", "ORGANISM", 5, 10], ["CNS", "ANATOMICAL_SYSTEM", 257, 260], ["human", "SPECIES", 5, 10], ["human", "SPECIES", 5, 10], ["Many human neurotropic viral pathogens", "PROBLEM", 0, 38], ["neurologic dysfunction", "PROBLEM", 78, 100], ["bacterial symbionts", "PROBLEM", 182, 201], ["disease", "PROBLEM", 222, 229], ["infection of the CNS", "PROBLEM", 240, 260], ["neurotropic viral pathogens", "OBSERVATION", 11, 38], ["neurologic dysfunction", "OBSERVATION", 78, 100], ["bacterial symbionts", "OBSERVATION", 182, 201], ["host defense", "OBSERVATION", 205, 217], ["infection", "OBSERVATION", 240, 249], ["CNS", "ANATOMY", 257, 260]]], ["We demonstrate that products from the microbiota are sufficient to prime microglia within the CNS that aid in control of viral replication through microglia-intrinsic TLR4 signaling.", [["microglia", "ANATOMY", 73, 82], ["CNS", "ANATOMY", 94, 97], ["microglia", "CELL", 73, 82], ["CNS", "ANATOMICAL_SYSTEM", 94, 97], ["microglia", "CELL", 147, 156], ["TLR4", "GENE_OR_GENE_PRODUCT", 167, 171], ["microglia", "CELL_TYPE", 73, 82], ["microglia", "CELL_TYPE", 147, 156], ["TLR4", "PROTEIN", 167, 171], ["viral replication", "TREATMENT", 121, 138], ["viral replication", "OBSERVATION", 121, 138], ["TLR4 signaling", "OBSERVATION", 167, 181]]], ["Reductions in microbial stimulation through increased antibiotic use and sanitation, has been suggested to contribute to the significant increase in obesity, autoimmunity and even some neurologic disorders in the western world (Blaser, 2016; Strachan, 2000).", [["neurologic", "ANATOMY", 185, 195], ["obesity", "DISEASE", 149, 156], ["autoimmunity", "DISEASE", 158, 170], ["neurologic disorders", "DISEASE", 185, 205], ["microbial stimulation", "TREATMENT", 14, 35], ["increased antibiotic use", "TREATMENT", 44, 68], ["sanitation", "TREATMENT", 73, 83], ["obesity", "PROBLEM", 149, 156], ["autoimmunity", "PROBLEM", 158, 170], ["some neurologic disorders", "PROBLEM", 180, 205], ["microbial stimulation", "OBSERVATION", 14, 35], ["significant", "OBSERVATION_MODIFIER", 125, 136], ["increase", "OBSERVATION_MODIFIER", 137, 145], ["obesity", "OBSERVATION", 149, 156]]], ["Supporting this hypothesis, our findings demonstrate that loss of immune stimulation by the gut microbiota leads to failure to control viral replication within the CNS leading to enhanced neuropathy.", [["gut microbiota", "ANATOMY", 92, 106], ["CNS", "ANATOMY", 164, 167], ["neuropathy", "DISEASE", 188, 198], ["gut", "ORGANISM_SUBDIVISION", 92, 95], ["CNS", "ANATOMICAL_SYSTEM", 164, 167], ["immune stimulation", "TREATMENT", 66, 84], ["failure to control viral replication", "PROBLEM", 116, 152], ["enhanced neuropathy", "PROBLEM", 179, 198], ["immune stimulation", "OBSERVATION", 66, 84], ["viral replication", "OBSERVATION", 135, 152], ["CNS", "ANATOMY", 164, 167], ["enhanced", "OBSERVATION_MODIFIER", 179, 187], ["neuropathy", "OBSERVATION", 188, 198]]], ["Thus, loss of protective resident microbes can lead to CNS dysfunction.DiscussionThere is an emerging interest in how gut commensals can influence diverse processes within the nervous system (Fung et al., 2017).", [["CNS", "ANATOMY", 55, 58], ["gut", "ANATOMY", 118, 121], ["nervous system", "ANATOMY", 176, 190], ["CNS dysfunction", "DISEASE", 55, 70], ["CNS", "ANATOMICAL_SYSTEM", 55, 58], ["gut", "ORGANISM_SUBDIVISION", 118, 121], ["nervous system", "ANATOMICAL_SYSTEM", 176, 190], ["CNS dysfunction", "PROBLEM", 55, 70], ["CNS", "ANATOMY", 55, 58], ["dysfunction", "OBSERVATION", 59, 70], ["nervous system", "ANATOMY", 176, 190]]], ["The microbiota influences serotonin production, microglia gene expression patterns, and disease pathology in a mouse model of Parkinson\u2019s disease (Erny et al., 2015; Reigstad et al., 2015; Sampson et al., 2016; Yano et al., 2015), yet little is known about the mechanisms by which the microbiota govern these processes.", [["serotonin", "CHEMICAL", 26, 35], ["Parkinson\u2019s disease", "DISEASE", 126, 145], ["serotonin", "CHEMICAL", 26, 35], ["serotonin", "SIMPLE_CHEMICAL", 26, 35], ["microglia", "CELL", 48, 57], ["mouse", "ORGANISM", 111, 116], ["mouse", "SPECIES", 111, 116], ["mouse", "SPECIES", 111, 116], ["The microbiota influences serotonin production", "PROBLEM", 0, 46], ["microglia gene expression patterns", "PROBLEM", 48, 82], ["disease pathology", "PROBLEM", 88, 105], ["Parkinson\u2019s disease", "PROBLEM", 126, 145], ["serotonin production", "OBSERVATION", 26, 46]]], ["Recent studies have demonstrated that SCFAs are able to influence the gene expression pattern and activation state of microglia (Erny et al., 2015); however, it is likely that other molecules exist that could influence the maturation of the CNS.", [["microglia", "ANATOMY", 118, 127], ["CNS", "ANATOMY", 241, 244], ["SCFAs", "CHEMICAL", 38, 43], ["SCFAs", "CHEMICAL", 38, 43], ["SCFAs", "SIMPLE_CHEMICAL", 38, 43], ["microglia", "CELL", 118, 127], ["CNS", "ANATOMICAL_SYSTEM", 241, 244], ["microglia", "CELL_TYPE", 118, 127], ["Recent studies", "TEST", 0, 14], ["other molecules", "PROBLEM", 176, 191]]], ["We identify that bacterial cell wall products, such as LPS, are sufficient to prime microglia for antigen presentation to effectively clear virus.", [["cell wall", "ANATOMY", 27, 36], ["microglia", "ANATOMY", 84, 93], ["LPS", "CHEMICAL", 55, 58], ["LPS", "SIMPLE_CHEMICAL", 55, 58], ["microglia", "CELL", 84, 93], ["microglia", "CELL_TYPE", 84, 93], ["bacterial cell wall products", "PROBLEM", 17, 45], ["LPS", "PROBLEM", 55, 58], ["clear virus", "PROBLEM", 134, 145], ["bacterial cell wall products", "OBSERVATION", 17, 45]]], ["While microglia have long been known to express TLRs, this family of receptors has been primarily thought to function only during infection.", [["microglia", "ANATOMY", 6, 15], ["infection", "DISEASE", 130, 139], ["microglia", "CELL", 6, 15], ["TLRs", "GENE_OR_GENE_PRODUCT", 48, 52], ["microglia", "CELL_TYPE", 6, 15], ["TLRs", "PROTEIN", 48, 52], ["infection", "PROBLEM", 130, 139], ["infection", "OBSERVATION", 130, 139]]], ["Here, we show that the microbiota regulates microglia function through TLR4, priming these cells to respond to infection.", [["microglia", "ANATOMY", 44, 53], ["cells", "ANATOMY", 91, 96], ["infection", "DISEASE", 111, 120], ["microglia", "CELL", 44, 53], ["TLR4", "GENE_OR_GENE_PRODUCT", 71, 75], ["cells", "CELL", 91, 96], ["microglia", "CELL_TYPE", 44, 53], ["TLR4", "PROTEIN", 71, 75], ["infection", "PROBLEM", 111, 120], ["infection", "OBSERVATION", 111, 120]]], ["Microglia develop early in embryogenesis from yolk sac progenitors; however, in contrast to macrophages, microglia are long-lived without any significant input from circulating blood cells (Prinz et al., 2014).", [["Microglia", "ANATOMY", 0, 9], ["yolk sac progenitors", "ANATOMY", 46, 66], ["macrophages", "ANATOMY", 92, 103], ["microglia", "ANATOMY", 105, 114], ["blood cells", "ANATOMY", 177, 188], ["Microglia", "CELL", 0, 9], ["yolk sac progenitors", "CELL", 46, 66], ["macrophages", "CELL", 92, 103], ["microglia", "CELL", 105, 114], ["blood cells", "CELL", 177, 188], ["Microglia", "CELL_TYPE", 0, 9], ["yolk sac progenitors", "CELL_TYPE", 46, 66], ["macrophages", "CELL_TYPE", 92, 103], ["microglia", "CELL_TYPE", 105, 114], ["circulating blood cells", "CELL_TYPE", 165, 188], ["Microglia", "PROBLEM", 0, 9], ["yolk sac progenitors", "PROBLEM", 46, 66], ["circulating blood cells", "TEST", 165, 188], ["yolk sac progenitors", "OBSERVATION", 46, 66], ["macrophages", "ANATOMY", 92, 103]]], ["How TLR ligands signal to cells within the CNS is unclear, however, there is evidence that gut microbial products are found circulating within the blood and could reach the CNS through this route (Clarke et al., 2010).", [["cells", "ANATOMY", 26, 31], ["CNS", "ANATOMY", 43, 46], ["blood", "ANATOMY", 147, 152], ["CNS", "ANATOMY", 173, 176], ["TLR", "GENE_OR_GENE_PRODUCT", 4, 7], ["cells", "CELL", 26, 31], ["CNS", "ANATOMICAL_SYSTEM", 43, 46], ["blood", "ORGANISM_SUBSTANCE", 147, 152], ["CNS", "ANATOMICAL_SYSTEM", 173, 176], ["TLR ligands", "PROTEIN", 4, 15], ["gut microbial products", "PROBLEM", 91, 113], ["CNS", "ANATOMY", 43, 46], ["CNS", "ANATOMY", 173, 176]]], ["This requires further investigation as some reports have shown that LPS is not able to penetrate the blood\u2013brain barrier.", [["blood\u2013brain barrier", "ANATOMY", 101, 120], ["LPS", "CHEMICAL", 68, 71], ["LPS", "SIMPLE_CHEMICAL", 68, 71], ["blood\u2013brain barrier", "TISSUE", 101, 120], ["further investigation", "TEST", 14, 35], ["LPS", "PROBLEM", 68, 71]]], ["While our data demonstrate that TLR4 signaling by microglia is, in part, responsible for orchestrating microglia activation, the possibility exists that gut microbiota signals can be transmitted to the CNS from the enteric nervous system.", [["microglia", "ANATOMY", 50, 59], ["microglia", "ANATOMY", 103, 112], ["gut microbiota", "ANATOMY", 153, 167], ["CNS", "ANATOMY", 202, 205], ["enteric nervous system", "ANATOMY", 215, 237], ["TLR4", "GENE_OR_GENE_PRODUCT", 32, 36], ["microglia", "CELL", 50, 59], ["microglia", "CELL", 103, 112], ["CNS", "ANATOMICAL_SYSTEM", 202, 205], ["enteric nervous system", "ANATOMICAL_SYSTEM", 215, 237], ["TLR4", "PROTEIN", 32, 36], ["microglia", "CELL_TYPE", 50, 59], ["microglia", "CELL_TYPE", 103, 112], ["orchestrating microglia activation", "PROBLEM", 89, 123], ["microglia", "OBSERVATION", 50, 59], ["responsible for", "UNCERTAINTY", 73, 88], ["microglia activation", "OBSERVATION", 103, 123], ["enteric nervous", "ANATOMY", 215, 230]]], ["Indeed, enteroendocrine cells have been reported to contain neuropods that are directly linked to neuronal cells and are able to transmit signals to the CNS (Boh\u00f3rquez et al., 2015).", [["enteroendocrine cells", "ANATOMY", 8, 29], ["neuropods", "ANATOMY", 60, 69], ["neuronal cells", "ANATOMY", 98, 112], ["CNS", "ANATOMY", 153, 156], ["enteroendocrine cells", "CELL", 8, 29], ["neuropods", "GENE_OR_GENE_PRODUCT", 60, 69], ["neuronal cells", "CELL", 98, 112], ["CNS", "ANATOMICAL_SYSTEM", 153, 156], ["enteroendocrine cells", "CELL_TYPE", 8, 29], ["neuronal cells", "CELL_TYPE", 98, 112], ["enteroendocrine cells", "OBSERVATION", 8, 29], ["CNS", "ANATOMY", 153, 156]]], ["It should also be noted that many of our experiments do not differentiate effects of the gastrointestinal microbiota from commensals occupying other niches.", [["gastrointestinal", "ANATOMY", 89, 105], ["gastrointestinal microbiota", "PATHOLOGICAL_FORMATION", 89, 116], ["gastrointestinal", "ANATOMY", 89, 105]]], ["Our data from orally administered LPS likely limits effects to gastrointestinal exposure, but oronasalpharyngeal and pneumonic exposure may be occurring as well.", [["gastrointestinal", "ANATOMY", 63, 79], ["LPS", "CHEMICAL", 34, 37], ["pneumonic", "DISEASE", 117, 126], ["LPS", "SIMPLE_CHEMICAL", 34, 37], ["gastrointestinal", "ORGAN", 63, 79], ["Our data", "TEST", 0, 8], ["LPS", "TREATMENT", 34, 37], ["gastrointestinal exposure", "PROBLEM", 63, 88], ["oronasalpharyngeal", "PROBLEM", 94, 112], ["pneumonic exposure", "PROBLEM", 117, 135], ["gastrointestinal", "ANATOMY", 63, 79], ["pneumonic", "OBSERVATION", 117, 126]]], ["Relatedly, differences observed between feeding mice LPS alone, and in combination with Pam3CysK4 suggest that more research could be performed investigating the interaction between multiple TLR ligands on microglia function and response to infection.", [["microglia", "ANATOMY", 206, 215], ["LPS", "CHEMICAL", 53, 56], ["infection", "DISEASE", 241, 250], ["mice", "ORGANISM", 48, 52], ["LPS", "SIMPLE_CHEMICAL", 53, 56], ["Pam3CysK4", "GENE_OR_GENE_PRODUCT", 88, 97], ["TLR", "GENE_OR_GENE_PRODUCT", 191, 194], ["microglia", "CELL", 206, 215], ["Pam3CysK4", "PROTEIN", 88, 97], ["TLR ligands", "PROTEIN", 191, 202], ["mice", "SPECIES", 48, 52], ["mice", "SPECIES", 48, 52], ["feeding mice LPS", "TREATMENT", 40, 56], ["Pam3CysK4", "TREATMENT", 88, 97], ["microglia function", "TEST", 206, 224], ["infection", "PROBLEM", 241, 250], ["infection", "OBSERVATION", 241, 250]]], ["Moreover, we cannot completely rule out a contribution from gut-resident CX3CR1 cells to this phenotype or other migrating DC populations.", [["gut-resident CX3CR1 cells", "ANATOMY", 60, 85], ["DC", "ANATOMY", 123, 125], ["gut-resident CX3CR1 cells", "CELL", 60, 85], ["DC populations", "CELL", 123, 137], ["gut-resident CX3CR1 cells", "CELL_TYPE", 60, 85], ["migrating DC populations", "CELL_TYPE", 113, 137], ["this phenotype", "PROBLEM", 89, 103], ["gut", "ANATOMY", 60, 63]]], ["Recent studies have demonstrated that cells from the gut can migrate to the brain and there exist a population of long-lived CX3CR1 cells within the gut (Shaw et al., 2018).", [["cells", "ANATOMY", 38, 43], ["gut", "ANATOMY", 53, 56], ["brain", "ANATOMY", 76, 81], ["CX3CR1 cells", "ANATOMY", 125, 137], ["gut", "ANATOMY", 149, 152], ["cells", "CELL", 38, 43], ["gut", "ORGANISM_SUBDIVISION", 53, 56], ["brain", "ORGAN", 76, 81], ["CX3CR1 cells", "CELL", 125, 137], ["gut", "ORGAN", 149, 152], ["CX3CR1 cells", "CELL_TYPE", 125, 137], ["Recent studies", "TEST", 0, 14], ["brain", "ANATOMY", 76, 81], ["population", "OBSERVATION_MODIFIER", 100, 110], ["long", "OBSERVATION_MODIFIER", 114, 118], ["CX3CR1 cells", "OBSERVATION", 125, 137], ["gut", "ANATOMY", 149, 152]]], ["As these gut cells are still radio-sensitive (microglia are not), our bone marrow chimera studies argue, that these cells likely only play a minor role, if any.", [["gut cells", "ANATOMY", 9, 18], ["microglia", "ANATOMY", 46, 55], ["bone marrow", "ANATOMY", 70, 81], ["cells", "ANATOMY", 116, 121], ["gut cells", "CELL", 9, 18], ["microglia", "CELL", 46, 55], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 70, 81], ["cells", "CELL", 116, 121], ["gut cells", "CELL_TYPE", 9, 18], ["microglia", "CELL_TYPE", 46, 55], ["these gut cells", "TEST", 3, 18], ["our bone marrow chimera studies", "TEST", 66, 97], ["gut cells", "ANATOMY", 9, 18], ["bone", "ANATOMY", 70, 74]]], ["Future investigations using animal models that allow tracking of specific populations from the gut will aid in parsing out these details.", [["gut", "ANATOMY", 95, 98], ["gut", "ORGANISM_SUBDIVISION", 95, 98], ["Future investigations", "TEST", 0, 21], ["animal models", "TREATMENT", 28, 41]]], ["Therefore, additional work remains to be performed to identify how gut microbes influence distal CNS processes.DiscussionThe clinical implications of this work further support that maintenance of a complex microbial community is important to protect from diseases that plague the western world.", [["gut microbes", "ANATOMY", 67, 79], ["distal CNS", "ANATOMY", 90, 100], ["gut", "ORGANISM_SUBDIVISION", 67, 70], ["CNS", "ANATOMICAL_SYSTEM", 97, 100], ["distal", "ANATOMY_MODIFIER", 90, 96], ["CNS", "ANATOMY", 97, 100]]], ["Indeed, there are several examples of cell wall molecules from the microbiota that are sufficient to treat disease in various animal models (An et al., 2014; Mazmanian et al., 2008; Vatanen et al., 2016; Wang et al., 2014).", [["cell wall", "ANATOMY", 38, 47], ["cell", "CELL", 38, 42], ["cell wall molecules", "PROBLEM", 38, 57], ["disease", "PROBLEM", 107, 114], ["cell wall molecules", "OBSERVATION", 38, 57]]], ["Our findings support that immunostimulatory LPS is one of these microbial cell wall products.", [["cell wall", "ANATOMY", 74, 83], ["LPS", "CHEMICAL", 44, 47], ["LPS", "SIMPLE_CHEMICAL", 44, 47], ["cell wall products", "CELL", 74, 92], ["immunostimulatory LPS", "TREATMENT", 26, 47], ["these microbial cell wall products", "TREATMENT", 58, 92], ["immunostimulatory LPS", "OBSERVATION", 26, 47], ["microbial cell", "OBSERVATION", 64, 78], ["wall products", "OBSERVATION", 79, 92]]], ["There are several different types of LPS that are derived from the microbiota, indeed LPS from Bacteriodes is less stimulatory than LPS derived from E. coli (Vatanen et al., 2016); therefore, the composition of the microbiota and the type of immune stimulatory products being delivered by the microbiota likely dictate maturation of microglia within the CNS.", [["microglia", "ANATOMY", 333, 342], ["CNS", "ANATOMY", 354, 357], ["LPS", "CHEMICAL", 37, 40], ["LPS", "CHEMICAL", 86, 89], ["Bacteriodes", "CHEMICAL", 95, 106], ["LPS", "CHEMICAL", 132, 135], ["LPS", "SIMPLE_CHEMICAL", 37, 40], ["LPS", "SIMPLE_CHEMICAL", 86, 89], ["Bacteriodes", "SIMPLE_CHEMICAL", 95, 106], ["LPS", "SIMPLE_CHEMICAL", 132, 135], ["E. coli", "ORGANISM", 149, 156], ["microglia", "CELL", 333, 342], ["CNS", "ANATOMICAL_SYSTEM", 354, 357], ["microglia", "CELL_TYPE", 333, 342], ["E. coli", "SPECIES", 149, 156], ["E. coli", "SPECIES", 149, 156], ["LPS", "PROBLEM", 37, 40], ["E. coli", "PROBLEM", 149, 156], ["immune stimulatory products", "TREATMENT", 242, 269], ["several", "OBSERVATION_MODIFIER", 10, 17], ["different", "OBSERVATION_MODIFIER", 18, 27], ["types", "OBSERVATION_MODIFIER", 28, 33], ["LPS", "OBSERVATION", 37, 40], ["less stimulatory", "OBSERVATION_MODIFIER", 110, 126], ["microglia", "OBSERVATION", 333, 342], ["CNS", "ANATOMY", 354, 357]]], ["Additionally, fatty acids that can be produced by the microbiota are also capable of binding TLR4, and might constitute other relevant agonists (Wong et al., 2009).", [["fatty acids", "CHEMICAL", 14, 25], ["fatty acids", "CHEMICAL", 14, 25], ["fatty acids", "SIMPLE_CHEMICAL", 14, 25], ["TLR4", "GENE_OR_GENE_PRODUCT", 93, 97], ["TLR4", "PROTEIN", 93, 97], ["fatty acids", "PROBLEM", 14, 25], ["fatty acids", "OBSERVATION", 14, 25]]], ["As microglia are also known to influence the function of neurons, these results suggest that microbial control of microglia could influence neuronal activity and function (Parkhurst et al., 2013).", [["microglia", "ANATOMY", 3, 12], ["neurons", "ANATOMY", 57, 64], ["microglia", "ANATOMY", 114, 123], ["neuronal", "ANATOMY", 140, 148], ["microglia", "CELL", 3, 12], ["neurons", "CELL", 57, 64], ["microglia", "CELL", 114, 123], ["neuronal", "CELL", 140, 148], ["microglia", "CELL_TYPE", 3, 12], ["microglia", "CELL_TYPE", 114, 123], ["microbial control of microglia", "PROBLEM", 93, 123]]], ["Much remains to be explored regarding the mechanisms by which gut microbes influence the brain; however, our findings highlight that appropriate microbial stimulation is critical to steady state development of the CNS and optimum neurologic health.Mice ::: Materials and methodsSPF C57BL/6J, birth antibiotic C57BL/6J, Rag1-/-, nestin-Cre, Il1r-/-, Il18-/-, Tlr4-/-, TLR4-floxed, Cx3xrCreER, and Tlr2-/- mice were originally purchased from Jackson Labs and reared in the SPF facility at the University of Utah.", [["gut microbes", "ANATOMY", 62, 74], ["brain", "ANATOMY", 89, 94], ["CNS", "ANATOMY", 214, 217], ["neurologic", "ANATOMY", 230, 240], ["gut", "ORGANISM_SUBDIVISION", 62, 65], ["brain", "ORGAN", 89, 94], ["CNS", "ANATOMICAL_SYSTEM", 214, 217], ["Mice", "ORGANISM", 248, 252], ["SPF C57BL/6J", "ORGANISM", 278, 290], ["C57BL/6J", "ORGANISM", 309, 317], ["Rag1", "GENE_OR_GENE_PRODUCT", 319, 323], ["nestin", "GENE_OR_GENE_PRODUCT", 328, 334], ["Cre", "GENE_OR_GENE_PRODUCT", 335, 338], ["Il1r", "GENE_OR_GENE_PRODUCT", 340, 344], ["Il18", "GENE_OR_GENE_PRODUCT", 349, 353], ["Tlr4", "GENE_OR_GENE_PRODUCT", 358, 362], ["TLR4", "GENE_OR_GENE_PRODUCT", 367, 371], ["floxed", "GENE_OR_GENE_PRODUCT", 372, 378], ["Cx3xrCreER", "GENE_OR_GENE_PRODUCT", 380, 390], ["Tlr2", "GENE_OR_GENE_PRODUCT", 396, 400], ["mice", "ORGANISM", 404, 408], ["Jackson Labs", "ORGANISM", 440, 452], ["nestin", "PROTEIN", 328, 334], ["Il1r", "PROTEIN", 340, 344], ["Tlr4", "DNA", 358, 362], ["TLR4", "PROTEIN", 367, 371], ["Cx3xrCreER", "DNA", 380, 390], ["Tlr2", "DNA", 396, 400], ["Mice", "SPECIES", 248, 252], ["mice", "SPECIES", 404, 408], ["mice", "SPECIES", 404, 408], ["the CNS and optimum neurologic health", "PROBLEM", 210, 247], ["Materials", "TEST", 257, 266], ["methods", "TEST", 271, 278], ["birth antibiotic", "TREATMENT", 292, 308], ["Rag1", "TEST", 319, 323], ["nestin", "TEST", 328, 334], ["Cre", "TEST", 335, 338], ["Il1r", "TEST", 340, 344], ["Il18", "TEST", 349, 353], ["Tlr4", "TEST", 358, 362], ["Cx3xrCreER", "TEST", 380, 390], ["Jackson Labs", "TEST", 440, 452], ["brain", "ANATOMY", 89, 94], ["CNS", "ANATOMY", 214, 217]]], ["Germfree C57BL/6J mice were reared in gnotobiotic chambers in the germfree facility at the University of Utah.", [["Germfree C57BL/6J mice", "ORGANISM", 0, 22], ["mice", "SPECIES", 18, 22], ["mice", "SPECIES", 18, 22], ["Germfree C57BL/6J mice", "TREATMENT", 0, 22], ["gnotobiotic chambers", "OBSERVATION", 38, 58]]], ["Microbial sterility is determined every 3 weeks by plating and PCR.", [["Microbial sterility", "PROBLEM", 0, 19], ["PCR", "TEST", 63, 66], ["sterility", "OBSERVATION", 10, 19]]], ["Mice used in this study were 6\u201310 weeks old at time of infection.", [["infection", "DISEASE", 55, 64], ["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4], ["this study", "TEST", 13, 23], ["infection", "PROBLEM", 55, 64], ["infection", "OBSERVATION", 55, 64]]], ["For microglia depletion, PLX-3397 (formulated in an AIN-76A) was prepared by Research Diets and provided by Plexxikon Inc SPF mice were provided PLX-3397 in their chow beginning 7 days prior to viral infection.", [["microglia", "ANATOMY", 4, 13], ["PLX-3397", "CHEMICAL", 25, 33], ["AIN-76A", "CHEMICAL", 52, 59], ["PLX-3397", "CHEMICAL", 145, 153], ["viral infection", "DISEASE", 194, 209], ["PLX-3397", "CHEMICAL", 25, 33], ["PLX-3397", "CHEMICAL", 145, 153], ["microglia", "CELL", 4, 13], ["PLX-3397", "SIMPLE_CHEMICAL", 25, 33], ["Plexxikon Inc SPF mice", "ORGANISM", 108, 130], ["PLX-3397", "CELL", 145, 153], ["microglia", "CELL_TYPE", 4, 13], ["mice", "SPECIES", 126, 130], ["mice", "SPECIES", 126, 130], ["microglia depletion", "PROBLEM", 4, 23], ["PLX", "TEST", 25, 28], ["viral infection", "PROBLEM", 194, 209], ["microglia depletion", "OBSERVATION", 4, 23], ["infection", "OBSERVATION", 200, 209]]], ["Mice were chosen at random to receive either PLX-3397 or control chow.", [["PLX-3397", "CHEMICAL", 45, 53], ["PLX-3397", "CHEMICAL", 45, 53], ["Mice", "ORGANISM", 0, 4], ["PLX-3397", "SIMPLE_CHEMICAL", 45, 53], ["Mice", "SPECIES", 0, 4], ["PLX", "TREATMENT", 45, 48]]], ["All experiments were performed in accordance to federal regulations as well as the guidelines for animal use set forth by the University of Utah Institutional Animal Care and Use Committee.Viral infection ::: Materials and methodsMice were intra-cranially infected with 150\u2013600 plaque forming units (PFU) of the neurotropic JHMV strain J2.2v-1 suspended in 30 \u03bcL of PBS and clinical disease monitored using an established scoring sysem previously described (Blanc et al., 2014; Carbajal et al., 2010; Chen et al., 2014; Greenberg et al., 2014; Marro et al., 2016; Schrauf et al., 2008; Stiles et al., 2006).", [["Viral infection", "DISEASE", 189, 204], ["Mice", "ORGANISM", 230, 234], ["Mice", "SPECIES", 230, 234], ["Viral infection", "PROBLEM", 189, 204], ["the neurotropic JHMV strain", "TEST", 308, 335], ["PBS", "PROBLEM", 366, 369], ["clinical disease", "PROBLEM", 374, 390], ["infection", "OBSERVATION", 195, 204]]], ["Germ-free mice were maintained on antibiotics (see below) during JHMV infection.", [["infection", "DISEASE", 70, 79], ["mice", "ORGANISM", 10, 14], ["JHMV", "ORGANISM", 65, 69], ["mice", "SPECIES", 10, 14], ["mice", "SPECIES", 10, 14], ["JHMV", "SPECIES", 65, 69], ["antibiotics", "TREATMENT", 34, 45], ["JHMV infection", "PROBLEM", 65, 79], ["free", "OBSERVATION_MODIFIER", 5, 9], ["infection", "OBSERVATION", 70, 79]]], ["For transfer of virus-specific T cells, mice were intraperitoneally (i.p.) infected with 2.5 \u00d7 105 PFU the DM strain of MHV (Stiles et al., 2006; Bergmann et al., 2004; Glass and Lane, 2003; Dickey et al., 2016; Glass et al., 2004; Glass and Lane, 2003; Plaisted et al., 2014).", [["T cells", "ANATOMY", 31, 38], ["intraperitoneally", "ANATOMY", 50, 67], ["T cells", "CELL", 31, 38], ["mice", "ORGANISM", 40, 44], ["MHV", "ORGANISM", 120, 123], ["T cells", "CELL_TYPE", 31, 38], ["mice", "SPECIES", 40, 44], ["mice", "SPECIES", 40, 44], ["MHV", "SPECIES", 120, 123], ["virus", "PROBLEM", 16, 21], ["infected", "PROBLEM", 75, 83], ["MHV", "ANATOMY", 120, 123]]], ["At day 7 post-infection (p.i.), spleens were collected and CD4 +or CD8+ T cells were enriched using magnetic based separation columns (MACS Miltenyi Biotec).", [["spleens", "ANATOMY", 32, 39], ["CD4 +", "ANATOMY", 59, 64], ["CD8+ T cells", "ANATOMY", 67, 79], ["spleens", "ORGAN", 32, 39], ["CD4", "GENE_OR_GENE_PRODUCT", 59, 62], ["CD8", "GENE_OR_GENE_PRODUCT", 67, 70], ["CD4", "PROTEIN", 59, 62], ["CD8+ T cells", "CELL_TYPE", 67, 79], ["MACS Miltenyi Biotec", "PROTEIN", 135, 155], ["infection", "PROBLEM", 14, 23], ["spleens", "TEST", 32, 39], ["CD4", "TEST", 59, 62], ["CD8+ T cells", "PROBLEM", 67, 79], ["magnetic based separation columns", "TREATMENT", 100, 133], ["infection", "OBSERVATION", 14, 23], ["spleens", "ANATOMY", 32, 39]]], ["The frequencies of virus-specific T cells were determined using CD4+ and CD8+ immunodominant tetramers (PE-conjugated tetramers I-Ab/M133\u2013147 and Db/S510\u2013518, respectively) at 8 \u03bcg/ml (NIH Tetramer Core Facility) (Stiles et al., 2006), JI; Chen et al. (2014), Stem Cell Reports); 2.5 \u00d7 105 virus-specific cells were transferred via retro-orbital injection into SPF Rag1-/- recipient animals 3 days p.i. and brains from recipient mice were collected 7 days post-transfer to determine brain viral titers (Dickey et al., 2016; Stiles et al., 2006).", [["T cells", "ANATOMY", 34, 41], ["Cell", "ANATOMY", 265, 269], ["cells", "ANATOMY", 305, 310], ["retro-orbital", "ANATOMY", 332, 345], ["brains", "ANATOMY", 407, 413], ["brain", "ANATOMY", 483, 488], ["T cells", "CELL", 34, 41], ["CD4", "GENE_OR_GENE_PRODUCT", 64, 67], ["CD8", "GENE_OR_GENE_PRODUCT", 73, 76], ["PE", "SIMPLE_CHEMICAL", 104, 106], ["Stem Cell", "CELL", 260, 269], ["cells", "CELL", 305, 310], ["retro-orbital", "ORGANISM_SUBDIVISION", 332, 345], ["SPF", "ORGANISM", 361, 364], ["Rag1", "GENE_OR_GENE_PRODUCT", 365, 369], ["brains", "ORGAN", 407, 413], ["mice", "ORGANISM", 429, 433], ["brain", "ORGAN", 483, 488], ["T cells", "CELL_TYPE", 34, 41], ["CD4", "PROTEIN", 64, 67], ["CD8", "PROTEIN", 73, 76], ["PE", "PROTEIN", 104, 106], ["I", "PROTEIN", 128, 129], ["Ab", "PROTEIN", 130, 132], ["M133", "PROTEIN", 133, 137], ["Db", "PROTEIN", 146, 148], ["Rag1", "PROTEIN", 365, 369], ["mice", "SPECIES", 429, 433], ["mice", "SPECIES", 429, 433], ["virus", "PROBLEM", 19, 24], ["CD4", "TEST", 64, 67], ["CD8", "TEST", 73, 76], ["immunodominant tetramers", "TEST", 78, 102], ["PE", "TEST", 104, 106], ["Db", "TEST", 146, 148], ["Stem Cell Reports", "TEST", 260, 277], ["specific cells", "TREATMENT", 296, 310], ["SPF Rag1", "TEST", 361, 369], ["immunodominant tetramers", "OBSERVATION", 78, 102], ["retro-orbital", "ANATOMY", 332, 345]]], ["Rag1-/- mice were randomly chosen to receive either SPF or GF T cells.", [["GF T cells", "ANATOMY", 59, 69], ["Rag1", "GENE_OR_GENE_PRODUCT", 0, 4], ["mice", "ORGANISM", 8, 12], ["GF T cells", "CELL", 59, 69], ["Rag1", "PROTEIN", 0, 4], ["SPF or GF T cells", "CELL_LINE", 52, 69], ["mice", "SPECIES", 8, 12], ["mice", "SPECIES", 8, 12]]], ["Viral titers within the brains were determined on the DBT astrocytoma line using previously defined protocols.CNS cell isolation and flow cytometry\u00a0 ::: Materials and methodsAfter animal sacrifice and perfusion with ice cold PBS, half of the brain of mice was collected and homogenized at defined times p.i. and leukocytes enriched on a Percoll gradient as previously described (Blanc et al., 2014).", [["brains", "ANATOMY", 24, 30], ["DBT astrocytoma line", "ANATOMY", 54, 74], ["CNS cell", "ANATOMY", 110, 118], ["brain", "ANATOMY", 242, 247], ["leukocytes", "ANATOMY", 312, 322], ["astrocytoma", "DISEASE", 58, 69], ["Viral", "ORGANISM", 0, 5], ["brains", "ORGAN", 24, 30], ["DBT astrocytoma line", "CELL", 54, 74], ["CNS cell", "CELL", 110, 118], ["brain", "ORGAN", 242, 247], ["mice", "ORGANISM", 251, 255], ["leukocytes", "CELL", 312, 322], ["DBT astrocytoma line", "CELL_LINE", 54, 74], ["leukocytes", "CELL_TYPE", 312, 322], ["mice", "SPECIES", 251, 255], ["mice", "SPECIES", 251, 255], ["Viral titers within the brains", "PROBLEM", 0, 30], ["the DBT astrocytoma line", "TREATMENT", 50, 74], ["previously defined protocols", "TREATMENT", 81, 109], ["ice cold PBS", "TREATMENT", 216, 228], ["leukocytes", "TEST", 312, 322], ["a Percoll gradient", "TREATMENT", 335, 353], ["titers", "OBSERVATION", 6, 12], ["brains", "ANATOMY", 24, 30], ["astrocytoma line", "OBSERVATION", 58, 74], ["cell isolation", "OBSERVATION", 114, 128], ["flow cytometry", "OBSERVATION", 133, 147], ["brain", "ANATOMY", 242, 247], ["leukocytes enriched", "OBSERVATION", 312, 331], ["Percoll gradient", "OBSERVATION", 337, 353]]], ["Cells were stained using the following antibodies: CD4 (GK1.5, Biolegend), CD3 (145\u20132 C11, Biolegend), IFN-\u03b3 (XMG1.2, Biolegend), FoxP3 (FJK-16s, eBioscience), IL-10 (JES5-16E3, Biolegend), CD8 (53-6.7, Biolegend), CD45 (30-F11, Biolegend), F4/80 (BM8, Biolegend), CD11b (M1/70, Biolegend), CD40 (HM40-3, Biolegend), CD86 (GL-1, Biolegend), MHCI (M1/42, Biolegend), and MHCII (M5/114.15.2, Biolegend).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["CD4", "GENE_OR_GENE_PRODUCT", 51, 54], ["GK1.5", "GENE_OR_GENE_PRODUCT", 56, 61], ["Biolegend", "GENE_OR_GENE_PRODUCT", 63, 72], ["CD3", "GENE_OR_GENE_PRODUCT", 75, 78], ["Biolegend", "GENE_OR_GENE_PRODUCT", 91, 100], ["IFN-\u03b3", "SIMPLE_CHEMICAL", 103, 108], ["XMG1.2", "SIMPLE_CHEMICAL", 110, 116], ["Biolegend", "GENE_OR_GENE_PRODUCT", 118, 127], ["FoxP3", "GENE_OR_GENE_PRODUCT", 130, 135], ["FJK-16s", "GENE_OR_GENE_PRODUCT", 137, 144], ["eBioscience", "GENE_OR_GENE_PRODUCT", 146, 157], ["IL-10", "GENE_OR_GENE_PRODUCT", 160, 165], ["JES5-16E3", "GENE_OR_GENE_PRODUCT", 167, 176], ["Biolegend", "GENE_OR_GENE_PRODUCT", 178, 187], ["CD8", "GENE_OR_GENE_PRODUCT", 190, 193], ["Biolegend", "GENE_OR_GENE_PRODUCT", 203, 212], ["CD45", "GENE_OR_GENE_PRODUCT", 215, 219], ["Biolegend", "GENE_OR_GENE_PRODUCT", 229, 238], ["BM8", "ORGANISM", 248, 251], ["Biolegend", "GENE_OR_GENE_PRODUCT", 253, 262], ["CD11b", "GENE_OR_GENE_PRODUCT", 265, 270], ["Biolegend", "GENE_OR_GENE_PRODUCT", 279, 288], ["CD40", "GENE_OR_GENE_PRODUCT", 291, 295], ["HM40-3", "GENE_OR_GENE_PRODUCT", 297, 303], ["Biolegend", "GENE_OR_GENE_PRODUCT", 305, 314], ["CD86", "GENE_OR_GENE_PRODUCT", 317, 321], ["GL-1", "GENE_OR_GENE_PRODUCT", 323, 327], ["Biolegend", "GENE_OR_GENE_PRODUCT", 329, 338], ["MHCI", "GENE_OR_GENE_PRODUCT", 341, 345], ["Biolegend", "GENE_OR_GENE_PRODUCT", 354, 363], ["MHCII", "GENE_OR_GENE_PRODUCT", 370, 375], ["Biolegend", "GENE_OR_GENE_PRODUCT", 390, 399], ["antibodies", "PROTEIN", 39, 49], ["CD4", "PROTEIN", 51, 54], ["GK1.5", "PROTEIN", 56, 61], ["Biolegend", "PROTEIN", 63, 72], ["CD3", "PROTEIN", 75, 78], ["145\u20132 C11", "PROTEIN", 80, 89], ["Biolegend", "PROTEIN", 91, 100], ["IFN", "PROTEIN", 103, 106], ["\u03b3", "PROTEIN", 107, 108], ["XMG1.2", "PROTEIN", 110, 116], ["Biolegend", "PROTEIN", 118, 127], ["FoxP3", "PROTEIN", 130, 135], ["FJK", "PROTEIN", 137, 140], ["eBioscience", "PROTEIN", 146, 157], ["IL", "PROTEIN", 160, 162], ["JES5", "PROTEIN", 167, 171], ["16E3", "PROTEIN", 172, 176], ["Biolegend", "PROTEIN", 178, 187], ["CD8", "PROTEIN", 190, 193], ["Biolegend", "PROTEIN", 203, 212], ["CD45", "PROTEIN", 215, 219], ["F11", "PROTEIN", 224, 227], ["Biolegend", "PROTEIN", 229, 238], ["F4", "PROTEIN", 241, 243], ["80", "PROTEIN", 244, 246], ["BM8", "PROTEIN", 248, 251], ["Biolegend", "PROTEIN", 253, 262], ["CD11b", "PROTEIN", 265, 270], ["M1", "PROTEIN", 272, 274], ["70", "PROTEIN", 275, 277], ["Biolegend", "PROTEIN", 279, 288], ["CD40", "PROTEIN", 291, 295], ["HM40", "PROTEIN", 297, 301], ["Biolegend", "PROTEIN", 305, 314], ["CD86", "PROTEIN", 317, 321], ["GL", "PROTEIN", 323, 325], ["Biolegend", "PROTEIN", 329, 338], ["MHCI", "PROTEIN", 341, 345], ["M1", "PROTEIN", 347, 349], ["/42", "PROTEIN", 349, 352], ["Biolegend", "PROTEIN", 354, 363], ["MHCII", "PROTEIN", 370, 375], ["M5", "PROTEIN", 377, 379], ["114.15.2", "PROTEIN", 380, 388], ["Biolegend", "PROTEIN", 390, 399], ["CD4", "TEST", 51, 54], ["Biolegend", "TEST", 63, 72], ["CD3", "TEST", 75, 78], ["C11", "TEST", 86, 89], ["Biolegend", "TEST", 91, 100], ["IFN", "TEST", 103, 106], ["Biolegend", "TEST", 118, 127], ["FoxP3", "TEST", 130, 135], ["FJK", "TEST", 137, 140], ["eBioscience", "TEST", 146, 157], ["IL", "TEST", 160, 162], ["JES5", "TEST", 167, 171], ["CD8", "TEST", 190, 193], ["Biolegend", "TEST", 203, 212], ["CD45", "TEST", 215, 219], ["Biolegend", "TEST", 229, 238], ["Biolegend", "TEST", 253, 262], ["CD11b", "TEST", 265, 270], ["M1", "TEST", 272, 274], ["Biolegend", "TEST", 279, 288], ["CD40", "TEST", 291, 295], ["HM40", "TEST", 297, 301], ["Biolegend", "TEST", 305, 314], ["CD86", "TEST", 317, 321], ["GL", "TEST", 323, 325], ["Biolegend", "TEST", 329, 338], ["MHCI", "TEST", 341, 345], ["Biolegend", "TEST", 354, 363], ["MHCII", "TEST", 370, 375], ["CD11b", "ANATOMY", 265, 270], ["CD40", "ANATOMY", 291, 295]]], ["Virus-specific T cells were determined via flow cytometric analysis through either intracellular staining for IFN-\u03b3 or defined tetramers specific for immunodominant CD4 +and CD8+T cell-specific viral epitopes (Chen et al., 2014; Stiles et al., 2006).", [["T cells", "ANATOMY", 15, 22], ["intracellular", "ANATOMY", 83, 96], ["CD4 +and CD8+T cell", "ANATOMY", 165, 184], ["Virus", "ORGANISM", 0, 5], ["T cells", "CELL", 15, 22], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 83, 96], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 110, 115], ["CD4", "GENE_OR_GENE_PRODUCT", 165, 168], ["CD8", "GENE_OR_GENE_PRODUCT", 174, 177], ["Virus-specific T cells", "CELL_TYPE", 0, 22], ["IFN", "PROTEIN", 110, 113], ["\u03b3", "PROTEIN", 114, 115], ["CD4", "PROTEIN", 165, 168], ["CD8", "PROTEIN", 174, 177], ["viral epitopes", "PROTEIN", 194, 208], ["Virus", "PROBLEM", 0, 5], ["specific T cells", "PROBLEM", 6, 22], ["flow cytometric analysis", "TEST", 43, 67], ["intracellular staining", "TEST", 83, 105], ["IFN", "TEST", 110, 113], ["immunodominant CD4", "TEST", 150, 168], ["CD8", "TEST", 174, 177], ["T cell", "PROBLEM", 178, 184]]], ["Samples were analyzed using BD LSRFortessa and FACSDiva software and data was measured using FlowJo.qPCR analysis ::: Materials and methodsRNA was collected from cells using a Ribozol (Amresco) extraction method.", [["Samples", "ANATOMY", 0, 7], ["cells", "ANATOMY", 162, 167], ["Ribozol", "CHEMICAL", 176, 183], ["Ribozol", "CHEMICAL", 176, 183], ["cells", "CELL", 162, 167], ["Ribozol", "SIMPLE_CHEMICAL", 176, 183], ["Amresco", "SIMPLE_CHEMICAL", 185, 192], ["Samples", "TEST", 0, 7], ["BD LSRFortessa", "TEST", 28, 42], ["FACSDiva software", "TEST", 47, 64], ["methodsRNA", "TEST", 132, 142], ["a Ribozol (Amresco) extraction method", "TREATMENT", 174, 211]]], ["RNA was treated with DNaseI (Sigma-Aldrich) per supplier protocol. cDNA was synthesized using qScript cDNA SuperMix (Quantigene).", [["DNaseI", "SIMPLE_CHEMICAL", 21, 27], ["RNA", "RNA", 0, 3], ["DNaseI", "PROTEIN", 21, 27], ["cDNA", "DNA", 67, 71], ["qScript cDNA SuperMix", "DNA", 94, 115], ["Quantigene", "DNA", 117, 127], ["DNaseI (Sigma-Aldrich)", "TREATMENT", 21, 43], ["qScript cDNA SuperMix (Quantigene)", "TREATMENT", 94, 128]]], ["Amplification of cDNA was measured using Lightcycler 480 SYBR Green I Master (Roche) with the CT method and normalized to L32.", [["cDNA", "DNA", 17, 21], ["L32", "PROTEIN", 122, 125], ["Lightcycler", "TEST", 41, 52], ["the CT method", "TEST", 90, 103]]], ["Primers used were L32F 5-AAGCGAAACTGGCGGAAAC-3, L32R 5-TAACCGATGTTGGGCATCAG-3, CIITAF 5-ACACCTGGACCTGGACTCAC-3, CIITAR 5-GCTCTTGGCTCCTTTGTCAC-3, TGF-BF 5-CTGCTGAGGCTCAAGTTAAAAGTG-3, TGF-BR 5-CAGCCGGTTGCTGAGGTA-3.", [["TGF-BF", "GENE_OR_GENE_PRODUCT", 145, 151], ["TGF-BR 5-CAGCCGGTTGCTGAGGTA-3", "GENE_OR_GENE_PRODUCT", 182, 211], ["TGF-BF 5-CTGCTGAGGCTCAAGTTAAAAGTG-3", "DNA", 145, 180], ["TGF-BR 5-CAGCCGGTTGCTGAGGTA-3", "DNA", 182, 211], ["Primers", "TEST", 0, 7], ["L32F", "TEST", 18, 22], ["AAGCGAAACTGGCGGAAAC", "TEST", 25, 44], ["L32R", "TEST", 48, 52], ["TAACCGATGTTGGGCATCAG", "TEST", 55, 75], ["CIITAF", "TEST", 79, 85], ["ACACCTGGACCTGGACTCAC", "TEST", 88, 108], ["CIITAR", "TEST", 112, 118], ["TGF", "TEST", 145, 148], ["CTGCTGAGGCTCAAGTTAAAAGTG", "TEST", 154, 178]]], ["JHMV-F 5-CGAGCCGTAGCATGTTTATCTA-3, JHMVR 5-CGCATACACGCAATTGAACATA-3.", [["JHMVR 5-CGCATACACGCAATTGAACATA-3", "GENE_OR_GENE_PRODUCT", 35, 67], ["JHMVR 5-CGCATACACGCAATTGAACATA-3", "DNA", 35, 67], ["JHMV", "TEST", 0, 4], ["5-CGAGCCGTAGCATGTTTATCTA", "TEST", 7, 31]]], ["TLR4F 5-TGGGTCAAGGAACAGAAGCAGT-3 TLR4R 5-AATCCAACACTAAGGAGGTATTCA-3.CD11b\u00a0+\u00a0cell enrichment ::: Materials and methodsEnrichment of CD11b + cells was performed by subjecting single-cell suspension of brain homogenates (as performed in CNS Cell Isolation and Flow Cytometry) to CD11b+ (microglia) Microbead MACS purification (Miltenyi Biotec) according to manufacture instruction.Microglia isolation and analysis ::: Materials and methodsAfter animal sacrifice at defined times p.i. and leukocytes enriched on a Percoll gradient as previously described (Blanc et al., 2014).", [["cell", "ANATOMY", 76, 80], ["CD11b + cells", "ANATOMY", 131, 144], ["cell", "ANATOMY", 180, 184], ["brain homogenates", "ANATOMY", 199, 216], ["Cell", "ANATOMY", 238, 242], ["CD11b+ (microglia", "ANATOMY", 276, 293], ["leukocytes", "ANATOMY", 485, 495], ["CD11b", "CELL", 131, 136], ["brain homogenates", "TISSUE", 199, 216], ["CNS Cell", "CELL", 234, 242], ["microglia", "CELL", 284, 293], ["Microglia", "CELL", 378, 387], ["leukocytes", "CELL", 485, 495], ["CD11b + cells", "CELL_LINE", 131, 144], ["CD11b", "PROTEIN", 276, 281], ["microglia", "CELL_TYPE", 284, 293], ["Miltenyi Biotec", "PROTEIN", 324, 339], ["leukocytes", "CELL_TYPE", 485, 495], ["TGGGTCAAGGAACAGAAGCAGT", "TEST", 8, 30], ["AATCCAACACTAAGGAGGTATTCA", "TEST", 41, 65], ["methodsEnrichment of CD11b + cells", "TEST", 110, 144], ["brain homogenates", "PROBLEM", 199, 216], ["CNS Cell Isolation", "TEST", 234, 252], ["Flow Cytometry", "TEST", 257, 271], ["CD11", "TEST", 276, 280], ["Microbead MACS purification", "TREATMENT", 295, 322], ["Miltenyi Biotec)", "TREATMENT", 324, 340], ["Microglia isolation", "TEST", 378, 397], ["animal sacrifice", "TREATMENT", 442, 458], ["leukocytes", "PROBLEM", 485, 495], ["a Percoll gradient", "TREATMENT", 508, 526], ["brain", "ANATOMY", 199, 204], ["leukocytes", "ANATOMY", 485, 495], ["Percoll gradient", "OBSERVATION", 510, 526]]], ["Cell were sorted at the University of Utah Flow Cytometry Core based using the following markers, CD45lo, CD11b+, F4/80+.", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4], ["CD45lo", "GENE_OR_GENE_PRODUCT", 98, 104], ["CD11", "GENE_OR_GENE_PRODUCT", 106, 110], ["CD45lo", "PROTEIN", 98, 104], ["CD11b", "PROTEIN", 106, 111], ["F4", "PROTEIN", 114, 116], ["the following markers", "TEST", 75, 96], ["CD45lo", "TEST", 98, 104], ["CD11", "TEST", 106, 110]]], ["Microglia were then plated in a 96-well flat bottom plate coated with Poly-D-Lysine (Sigma Aldrich) and incubated with the S510 peptide overnight.", [["Microglia", "ANATOMY", 0, 9], ["Poly-D-Lysine", "CHEMICAL", 70, 83], ["Poly-D-Lysine", "CHEMICAL", 70, 83], ["Microglia", "CELL", 0, 9], ["Poly-D-Lysine", "SIMPLE_CHEMICAL", 70, 83], ["Sigma Aldrich", "SIMPLE_CHEMICAL", 85, 98], ["Microglia", "CELL_TYPE", 0, 9], ["Microglia", "TEST", 0, 9], ["Poly-D-Lysine (Sigma Aldrich)", "TREATMENT", 70, 99], ["the S510 peptide", "TREATMENT", 119, 135]]], ["Spleens were collected from MHV-DM infected SPF mice 7 D.P.I., viral-specific CD8 +T cells were sorted at the University of Utah flow cytometry core.", [["Spleens", "ANATOMY", 0, 7], ["CD8 +T cells", "ANATOMY", 78, 90], ["Spleens", "ORGAN", 0, 7], ["MHV-DM", "ORGANISM", 28, 34], ["mice", "ORGANISM", 48, 52], ["CD8 +T cells", "CELL", 78, 90], ["CD8 +T cells", "CELL_TYPE", 78, 90], ["mice", "SPECIES", 48, 52], ["MHV", "SPECIES", 28, 31], ["mice", "SPECIES", 48, 52], ["DM", "PROBLEM", 32, 34], ["viral", "TEST", 63, 68], ["MHV", "OBSERVATION_MODIFIER", 28, 31], ["DM", "OBSERVATION_MODIFIER", 32, 34], ["infected", "OBSERVATION_MODIFIER", 35, 43]]], ["T cells were stained using Far Red Cell Trace or CFSE (Thermo Fisher), CD8 +T cells were then co-cultured with microglia for 72 hr, samples were analyzed using BD LSRFortessa and FACSDiva software and data was measured using FlowJo.Histology ::: Materials and methodsExperimental mice were sacrificed at defined times points and the length of spinal cord extending from thoracic vertebrate 6\u201310 was cryoprotected in 30% sucrose, cut into 1 mm transverse blocks and processed so as to preserve the craniocaudal sequence/orientation and subsequently embedded in O.C.T. (VWR, Radnor, PA).", [["T cells", "ANATOMY", 0, 7], ["Cell", "ANATOMY", 35, 39], ["CD8 +T cells", "ANATOMY", 71, 83], ["microglia", "ANATOMY", 111, 120], ["samples", "ANATOMY", 132, 139], ["spinal cord", "ANATOMY", 343, 354], ["thoracic", "ANATOMY", 370, 378], ["sucrose", "CHEMICAL", 420, 427], ["CFSE", "CHEMICAL", 49, 53], ["sucrose", "CHEMICAL", 420, 427], ["T cells", "CELL", 0, 7], ["CFSE", "SIMPLE_CHEMICAL", 49, 53], ["CD8", "GENE_OR_GENE_PRODUCT", 71, 74], ["microglia", "CELL", 111, 120], ["mice", "ORGANISM", 280, 284], ["spinal cord", "ORGAN", 343, 354], ["sucrose", "SIMPLE_CHEMICAL", 420, 427], ["T cells", "CELL_TYPE", 0, 7], ["CD8 +T cells", "CELL_LINE", 71, 83], ["microglia", "CELL_TYPE", 111, 120], ["mice", "SPECIES", 280, 284], ["mice", "SPECIES", 280, 284], ["T cells", "PROBLEM", 0, 7], ["Red Cell Trace", "TEST", 31, 45], ["CD8 +T cells", "TEST", 71, 83], ["microglia", "TEST", 111, 120], ["samples", "TEST", 132, 139], ["BD LSRFortessa", "TEST", 160, 174], ["FACSDiva software", "TEST", 179, 196], ["Histology", "TEST", 232, 241], ["Materials", "TREATMENT", 246, 255], ["1 mm transverse blocks", "TREATMENT", 438, 460], ["the craniocaudal sequence", "TEST", 493, 518], ["spinal cord", "ANATOMY", 343, 354], ["thoracic vertebrate", "ANATOMY", 370, 389]]], ["Eight-\u03bc M-thick coronal sections were cut and sections were stained with hematoxylin/eosin (H &E) in combination with luxol fast blue (LFB) and between 4 and 8 sections/mouse analyzed.", [["coronal sections", "ANATOMY", 16, 32], ["sections", "ANATOMY", 46, 54], ["sections", "ANATOMY", 160, 168], ["H &E", "CHEMICAL", 92, 96], ["hematoxylin", "CHEMICAL", 73, 84], ["eosin", "CHEMICAL", 85, 90], ["coronal sections", "MULTI-TISSUE_STRUCTURE", 16, 32], ["hematoxylin/eosin", "SIMPLE_CHEMICAL", 73, 90], ["H &E", "SIMPLE_CHEMICAL", 92, 96], ["mouse", "ORGANISM", 169, 174], ["mouse", "SPECIES", 169, 174], ["mouse", "SPECIES", 169, 174], ["hematoxylin", "TEST", 73, 84]]], ["Areas of total white matter and demyelinated white matter were determined with Image J Software and demyelination was scored as a percentage of total demyelination from spinal cord sections analyzed as previously described (Blanc et al., 2015; Blanc et al., 2014; Dickey et al., 2016).Antibiotic treatment and TLR ligands\u00a0 ::: Materials and methodsBreeder pairs of Adult SPF mice were treated with an antibiotic cocktail of Ampicillin, Erythromycin, Neomycin, and Gentamycin (0.5 g/L) supplemented with Equal (4 g/L), progeny of these breeder pairs were also kept on the same antibiotic cocktail after weaning.", [["white matter", "ANATOMY", 15, 27], ["demyelinated white matter", "ANATOMY", 32, 57], ["spinal cord sections", "ANATOMY", 169, 189], ["demyelination", "DISEASE", 100, 113], ["demyelination", "DISEASE", 150, 163], ["Ampicillin", "CHEMICAL", 424, 434], ["Erythromycin", "CHEMICAL", 436, 448], ["Neomycin", "CHEMICAL", 450, 458], ["Gentamycin", "CHEMICAL", 464, 474], ["Ampicillin", "CHEMICAL", 424, 434], ["Erythromycin", "CHEMICAL", 436, 448], ["Neomycin", "CHEMICAL", 450, 458], ["Gentamycin", "CHEMICAL", 464, 474], ["spinal cord sections", "MULTI-TISSUE_STRUCTURE", 169, 189], ["SPF", "ORGANISM", 371, 374], ["mice", "ORGANISM", 375, 379], ["Ampicillin", "SIMPLE_CHEMICAL", 424, 434], ["Erythromycin", "SIMPLE_CHEMICAL", 436, 448], ["Neomycin", "SIMPLE_CHEMICAL", 450, 458], ["Gentamycin", "SIMPLE_CHEMICAL", 464, 474], ["TLR", "PROTEIN", 310, 313], ["mice", "SPECIES", 375, 379], ["mice", "SPECIES", 375, 379], ["total white matter and demyelinated white matter", "PROBLEM", 9, 57], ["Image J Software", "TEST", 79, 95], ["demyelination", "PROBLEM", 100, 113], ["total demyelination from spinal cord sections", "PROBLEM", 144, 189], ["Antibiotic treatment", "TREATMENT", 285, 305], ["Materials", "TREATMENT", 327, 336], ["Adult SPF mice", "TREATMENT", 365, 379], ["an antibiotic cocktail", "TREATMENT", 398, 420], ["Ampicillin", "TREATMENT", 424, 434], ["Erythromycin", "TREATMENT", 436, 448], ["Neomycin", "TREATMENT", 450, 458], ["Gentamycin", "TREATMENT", 464, 474], ["the same antibiotic cocktail", "TREATMENT", 567, 595], ["total", "OBSERVATION_MODIFIER", 9, 14], ["white matter", "OBSERVATION_MODIFIER", 15, 27], ["demyelinated", "OBSERVATION_MODIFIER", 32, 44], ["white matter", "OBSERVATION_MODIFIER", 45, 57], ["demyelination", "OBSERVATION", 100, 113], ["total", "OBSERVATION_MODIFIER", 144, 149], ["demyelination", "OBSERVATION", 150, 163], ["spinal cord", "ANATOMY", 169, 180]]], ["For TLR ligand experiments, Pam3CSK4 (10 \u03bcg/mL) (Invivogen) and LPS (10 \u03bcg/mL) (Sigma-Aldrich) were added to the drinking water of germfree mice for 2 weeks prior to infection.", [["Pam3CSK4", "CHEMICAL", 28, 36], ["LPS", "CHEMICAL", 64, 67], ["infection", "DISEASE", 166, 175], ["TLR ligand", "GENE_OR_GENE_PRODUCT", 4, 14], ["Pam3CSK4", "SIMPLE_CHEMICAL", 28, 36], ["Invivogen", "SIMPLE_CHEMICAL", 49, 58], ["LPS", "SIMPLE_CHEMICAL", 64, 67], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 80, 93], ["germfree", "ORGANISM", 131, 139], ["mice", "ORGANISM", 140, 144], ["TLR", "PROTEIN", 4, 7], ["mice", "SPECIES", 140, 144], ["mice", "SPECIES", 140, 144], ["TLR ligand experiments", "TREATMENT", 4, 26], ["Pam3CSK4", "TREATMENT", 28, 36], ["LPS", "TREATMENT", 64, 67], ["Sigma-Aldrich)", "TREATMENT", 80, 94], ["germfree mice", "TREATMENT", 131, 144], ["infection", "PROBLEM", 166, 175], ["infection", "OBSERVATION", 166, 175]]], ["Germfree mice were chosen at random to receive TLR ligands or to serve as controls.BV-2 cells ::: Materials and methodsThe murine BV-2 cell line was acquired from the ATCC and was mycoplasma-free grown in RPMI and supplemented with SCFAs [Acetate, Butyrate, Propionate (0.1 \u03bcg/mL), Sigma Aldrich] TLR ligands [LPS, Pam3CysK4, FSL-1 and Poly I:C (0.1 \u03bcg/mL), Invivogen] and recombinant mouse cytokines [IL-1 IL-18, and IL-33 (0.25 \u03bcg/mL), Biolegend] for 24 hr.Tamoxifen treatment\u00a0 ::: Materials and methodsAt age of weaning (3 weeks), mice were orally gavaged with 0.2 mg tamoxifen per g body weight once daily for 5 days as previously described (Fonseca et al Journal of Neuroinflammation 201714:48).", [["BV-2 cells", "ANATOMY", 83, 93], ["BV-2 cell line", "ANATOMY", 130, 144], ["ATCC", "ANATOMY", 167, 171], ["body", "ANATOMY", 587, 591], ["SCFAs", "CHEMICAL", 232, 237], ["Acetate", "CHEMICAL", 239, 246], ["Butyrate", "CHEMICAL", 248, 256], ["Propionate", "CHEMICAL", 258, 268], ["LPS", "CHEMICAL", 310, 313], ["Tamoxifen", "CHEMICAL", 459, 468], ["tamoxifen", "CHEMICAL", 571, 580], ["SCFAs", "CHEMICAL", 232, 237], ["Acetate", "CHEMICAL", 239, 246], ["Butyrate", "CHEMICAL", 248, 256], ["Propionate", "CHEMICAL", 258, 268], ["Tamoxifen", "CHEMICAL", 459, 468], ["tamoxifen", "CHEMICAL", 571, 580], ["mice", "ORGANISM", 9, 13], ["BV-2 cells", "CELL", 83, 93], ["murine", "ORGANISM", 123, 129], ["BV-2 cell line", "CELL", 130, 144], ["ATCC", "CELL", 167, 171], ["SCFAs", "SIMPLE_CHEMICAL", 232, 237], ["Acetate", "SIMPLE_CHEMICAL", 239, 246], ["Butyrate", "SIMPLE_CHEMICAL", 248, 256], ["Propionate", "SIMPLE_CHEMICAL", 258, 268], ["Sigma Aldrich] TLR ligands", "SIMPLE_CHEMICAL", 282, 308], ["LPS", "SIMPLE_CHEMICAL", 310, 313], ["Pam3CysK4", "SIMPLE_CHEMICAL", 315, 324], ["FSL-1", "SIMPLE_CHEMICAL", 326, 331], ["Poly I:C", "SIMPLE_CHEMICAL", 336, 344], ["Invivogen", "SIMPLE_CHEMICAL", 358, 367], ["mouse", "ORGANISM", 385, 390], ["IL-1 IL-18", "GENE_OR_GENE_PRODUCT", 402, 412], ["IL-33", "SIMPLE_CHEMICAL", 418, 423], ["Tamoxifen", "SIMPLE_CHEMICAL", 459, 468], ["mice", "ORGANISM", 534, 538], ["tamoxifen", "SIMPLE_CHEMICAL", 571, 580], ["body", "ORGANISM_SUBDIVISION", 587, 591], ["TLR", "PROTEIN", 47, 50], ["murine BV-2 cell line", "CELL_LINE", 123, 144], ["TLR", "PROTEIN", 297, 300], ["Invivogen", "PROTEIN", 358, 367], ["recombinant mouse cytokines", "PROTEIN", 373, 400], ["IL-1 IL-18", "PROTEIN", 402, 412], ["IL", "PROTEIN", 418, 420], ["Biolegend", "PROTEIN", 438, 447], ["mice", "SPECIES", 9, 13], ["murine", "SPECIES", 123, 129], ["mouse", "SPECIES", 385, 390], ["mice", "SPECIES", 534, 538], ["mice", "SPECIES", 9, 13], ["ATCC", "SPECIES", 167, 171], ["mouse", "SPECIES", 385, 390], ["mice", "SPECIES", 534, 538], ["Germfree mice", "TREATMENT", 0, 13], ["TLR ligands", "TREATMENT", 47, 58], ["BV", "TEST", 83, 85], ["The murine BV", "TEST", 119, 132], ["the ATCC", "TEST", 163, 171], ["mycoplasma", "PROBLEM", 180, 190], ["SCFAs [Acetate", "TREATMENT", 232, 246], ["Butyrate", "TREATMENT", 248, 256], ["Propionate", "TREATMENT", 258, 268], ["Sigma Aldrich] TLR ligands", "TREATMENT", 282, 308], ["LPS", "TEST", 310, 313], ["Pam3CysK4", "TREATMENT", 315, 324], ["FSL", "TEST", 326, 329], ["Poly I:C", "TREATMENT", 336, 344], ["Invivogen] and recombinant mouse cytokines [IL", "TREATMENT", 358, 404], ["IL", "TREATMENT", 418, 420], ["Tamoxifen treatment", "TREATMENT", 459, 478], ["0.2 mg tamoxifen", "TREATMENT", 564, 580], ["cell line", "OBSERVATION", 135, 144]]], ["Mice were given 1 month after tamoxifen administration to allow for myeloid cell turnover before infection with JHMV.TLR2 and 4 detection ::: Materials and methodsHEK-Blue mTLR2 or mTLR4 cells (InvivoGen) were used according to manufacturer\u2019s instruction to determine serum concentrations of TLR2 and TLR4 and if JHMV signals through TLR4.", [["myeloid cell", "ANATOMY", 68, 80], ["mTLR4 cells", "ANATOMY", 181, 192], ["serum", "ANATOMY", 268, 273], ["tamoxifen", "CHEMICAL", 30, 39], ["infection", "DISEASE", 97, 106], ["tamoxifen", "CHEMICAL", 30, 39], ["Mice", "ORGANISM", 0, 4], ["tamoxifen", "SIMPLE_CHEMICAL", 30, 39], ["myeloid cell", "CELL", 68, 80], ["TLR2", "GENE_OR_GENE_PRODUCT", 117, 121], ["methodsHEK-Blue mTLR2", "GENE_OR_GENE_PRODUCT", 156, 177], ["mTLR4 cells", "CELL", 181, 192], ["serum", "ORGANISM_SUBSTANCE", 268, 273], ["TLR2", "GENE_OR_GENE_PRODUCT", 292, 296], ["TLR4", "GENE_OR_GENE_PRODUCT", 301, 305], ["JHMV", "GENE_OR_GENE_PRODUCT", 313, 317], ["TLR4", "GENE_OR_GENE_PRODUCT", 334, 338], ["TLR2", "PROTEIN", 117, 121], ["methodsHEK-Blue mTLR2", "CELL_LINE", 156, 177], ["mTLR4 cells", "CELL_LINE", 181, 192], ["InvivoGen", "CELL_LINE", 194, 203], ["TLR2", "PROTEIN", 292, 296], ["TLR4", "PROTEIN", 301, 305], ["JHMV", "PROTEIN", 313, 317], ["TLR4", "PROTEIN", 334, 338], ["Mice", "SPECIES", 0, 4], ["JHMV", "SPECIES", 112, 116], ["tamoxifen administration", "TREATMENT", 30, 54], ["myeloid cell turnover", "PROBLEM", 68, 89], ["infection", "PROBLEM", 97, 106], ["JHMV", "TREATMENT", 112, 116], ["Materials", "TEST", 142, 151], ["methodsHEK-Blue mTLR2", "TREATMENT", 156, 177], ["mTLR4 cells (InvivoGen)", "TREATMENT", 181, 204], ["serum concentrations", "TEST", 268, 288], ["TLR2 and TLR4", "TREATMENT", 292, 305], ["JHMV signals", "TEST", 313, 325], ["myeloid cell", "OBSERVATION", 68, 80]]], ["After passaging according to manufacturer instruction, a flat-bottom 96-well plate was loaded with 25,000 cells per well.", [["cells", "ANATOMY", 106, 111], ["cells", "CELL", 106, 111], ["25,000 cells", "CELL_LINE", 99, 111], ["a flat-bottom", "TEST", 55, 68]]], ["Then, 20 \u03bcL of PBS, mouse serum, varying dilutions of JHMV or serial dilutions of 0.1 \u03bcg/ml LPS added to each well.", [["serum", "ANATOMY", 26, 31], ["JHMV", "CHEMICAL", 54, 58], ["LPS", "CHEMICAL", 92, 95], ["mouse", "ORGANISM", 20, 25], ["serum", "ORGANISM_SUBSTANCE", 26, 31], ["JHMV", "SIMPLE_CHEMICAL", 54, 58], ["LPS", "SIMPLE_CHEMICAL", 92, 95], ["mouse", "SPECIES", 20, 25], ["mouse", "SPECIES", 20, 25], ["JHMV", "SPECIES", 54, 58], ["PBS", "TREATMENT", 15, 18], ["mouse serum", "TEST", 20, 31], ["JHMV", "TREATMENT", 54, 58], ["serial dilutions", "TEST", 62, 78]]], ["Cells were incubated for 6 hr, spun down and supernatant isolated.", [["Cells", "ANATOMY", 0, 5], ["supernatant", "ANATOMY", 45, 56], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5], ["spun", "TEST", 31, 35]]], ["20 \u03bcL of supernatant was then incubated with 180 \u03bcL of QUANTI-Blue solution (InvivoGen) for 15 min.", [["supernatant", "ANATOMY", 9, 20], ["QUANTI-Blue", "CHEMICAL", 55, 66], ["InvivoGen", "CHEMICAL", 77, 86], ["QUANTI-Blue", "CHEMICAL", 55, 66], ["QUANTI-Blue solution", "SIMPLE_CHEMICAL", 55, 75], ["InvivoGen", "SIMPLE_CHEMICAL", 77, 86], ["QUANTI-Blue solution", "TREATMENT", 55, 75]]], ["Optical density at 620 nm was then measured using a Biotek Synergy H1M plate reader.Sample size estimation ::: Materials and methodsNo a priori power analyses were used to determine sample size.", [["a Biotek Synergy H1M plate reader", "TREATMENT", 50, 83], ["Sample size estimation", "TEST", 84, 106], ["a priori power analyses", "TEST", 135, 158], ["density", "OBSERVATION", 8, 15], ["620 nm", "OBSERVATION_MODIFIER", 19, 25], ["size", "OBSERVATION_MODIFIER", 91, 95], ["size", "OBSERVATION_MODIFIER", 189, 193]]], ["Sample size was determined by availability of germ-free mice and age/sex matched controls (when applicable).", [["germ", "ANATOMY", 46, 50], ["mice", "ORGANISM", 56, 60], ["mice", "SPECIES", 56, 60], ["Sample size", "TEST", 0, 11], ["size", "OBSERVATION_MODIFIER", 7, 11]]], ["The sample sizes reported here are similar to those in previous literature utilizing the JHMV model (Ireland et al., 2008).", [["The sample sizes", "TEST", 0, 16], ["the JHMV model", "TREATMENT", 85, 99], ["sizes", "OBSERVATION_MODIFIER", 11, 16]]], ["Sample sizes are provided within the legend of each figure.Statistics ::: Materials and methodsPair-wise comparison of experimental groups were performed with an unpaired two-tailed Student\u2019 t-test or one-way ANOVA or Mann-Whitney test for viral titers.", [["Sample sizes", "TEST", 0, 12], ["Whitney test", "TEST", 223, 235], ["viral titers", "PROBLEM", 240, 252], ["sizes", "OBSERVATION_MODIFIER", 7, 12]]], ["JHMV disease curves were analyzed using two-way ANOVA or area under the curve analysis.", [["JHMV", "SPECIES", 0, 4], ["JHMV disease curves", "PROBLEM", 0, 19], ["the curve analysis", "TEST", 68, 86]]], ["Outlier testing was performed using Grubb\u2019s test for outliers.", [["Outlier testing", "TEST", 0, 15], ["Grubb\u2019s test", "TEST", 36, 48]]], ["If an outlier was detected (p<0.05), that data point was omitted from any analysis.", [["any analysis", "TEST", 70, 82]]]], "9d7bc4630d924f613e13e76d71281f6a405afb00": [["IntroductionDespite the great advances in medicine, particularly in new therapeutic drugs, diagnostic tools, and even ways to prevent diseases, the human species still faces serious health problems.", [["human", "ORGANISM", 148, 153], ["human", "SPECIES", 148, 153], ["human", "SPECIES", 148, 153], ["medicine", "TREATMENT", 42, 50], ["diagnostic tools", "TEST", 91, 107], ["diseases", "PROBLEM", 134, 142], ["the human species", "PROBLEM", 144, 161]]], ["Among these problems, those that draw the most attention are infectious diseases, especially in poor regions.", [["infectious diseases", "DISEASE", 61, 80], ["infectious diseases", "PROBLEM", 61, 80], ["infectious", "OBSERVATION", 61, 71]]], ["An important feature of infectious disease is its potential to arise globally, as exemplified by known devastating past and present pandemics such as the bubonic-pneumonic plague, Spanish flu (1918 influenza pandemic), and the present pandemic of human immunodeficiency virus (HIV), in which an estimated 33.3 million persons were living with the HIV infection worldwide at the end of 2009 [1] [2] [3] .", [["infectious disease", "DISEASE", 24, 42], ["bubonic-pneumonic plague", "DISEASE", 154, 178], ["Spanish flu", "DISEASE", 180, 191], ["influenza pandemic", "DISEASE", 198, 216], ["human immunodeficiency virus (HIV)", "DISEASE", 247, 281], ["HIV infection", "DISEASE", 347, 360], ["human immunodeficiency virus", "ORGANISM", 247, 275], ["persons", "ORGANISM", 318, 325], ["human", "SPECIES", 247, 252], ["immunodeficiency virus", "SPECIES", 253, 275], ["persons", "SPECIES", 318, 325], ["HIV", "SPECIES", 347, 350], ["Spanish flu (1918 influenza pandemic", "SPECIES", 180, 216], ["human immunodeficiency virus", "SPECIES", 247, 275], ["HIV", "SPECIES", 277, 280], ["HIV", "SPECIES", 347, 350], ["infectious disease", "PROBLEM", 24, 42], ["the bubonic-pneumonic plague", "PROBLEM", 150, 178], ["human immunodeficiency virus", "PROBLEM", 247, 275], ["the HIV infection", "PROBLEM", 343, 360], ["important feature of", "UNCERTAINTY", 3, 23], ["infectious", "OBSERVATION", 24, 34], ["devastating", "OBSERVATION_MODIFIER", 103, 114], ["bubonic", "OBSERVATION_MODIFIER", 154, 161], ["pneumonic", "OBSERVATION_MODIFIER", 162, 171], ["plague", "OBSERVATION", 172, 178]]], ["In addition, other non-viral diseases are significant public health problems, as exemplified by tuberculosis (TB).", [["non-viral diseases", "DISEASE", 19, 37], ["tuberculosis", "DISEASE", 96, 108], ["TB", "DISEASE", 110, 112], ["other non-viral diseases", "PROBLEM", 13, 37], ["significant public health problems", "PROBLEM", 42, 76], ["tuberculosis", "PROBLEM", 96, 108], ["non-viral diseases", "OBSERVATION", 19, 37], ["significant", "OBSERVATION_MODIFIER", 42, 53], ["tuberculosis", "OBSERVATION", 96, 108]]], ["This infectious disease accounts for one third of the world's bacterial infections (TB infected), and in 2010 a total of 8.8 million people worldwide became sick with TB [1, 4] .IntroductionIn recent years, new forms of infectious diseases have become significantly important to medical and scientific communities; these forms are now widely known as emergent and re-emergent infectious diseases.", [["infectious disease", "DISEASE", 5, 23], ["bacterial infections", "DISEASE", 62, 82], ["TB infected", "DISEASE", 84, 95], ["TB", "DISEASE", 167, 169], ["infectious diseases", "DISEASE", 220, 239], ["infectious diseases", "DISEASE", 376, 395], ["people", "ORGANISM", 133, 139], ["people", "SPECIES", 133, 139], ["This infectious disease", "PROBLEM", 0, 23], ["the world's bacterial infections", "PROBLEM", 50, 82], ["TB", "PROBLEM", 167, 169], ["infectious diseases", "PROBLEM", 220, 239], ["re-emergent infectious diseases", "PROBLEM", 364, 395], ["infectious", "OBSERVATION", 5, 15], ["infections", "OBSERVATION", 72, 82], ["infectious", "OBSERVATION", 220, 230], ["infectious", "OBSERVATION", 376, 386]]], ["With the appearance of new transmissible diseases, such as SARS, West Nile and H5N1/H1N1 Influenza viruses, in addition to reemerging diseases like dengue fever, the concerns about a global epidemic are not unfounded [5] .", [["transmissible diseases", "DISEASE", 27, 49], ["SARS", "DISEASE", 59, 63], ["Influenza viruses", "DISEASE", 89, 106], ["dengue fever", "DISEASE", 148, 160], ["West Nile", "ORGANISM", 65, 74], ["H5N1/H1N1 Influenza viruses", "ORGANISM", 79, 106], ["H5N1/H1N1 Influenza", "SPECIES", 79, 98], ["West Nile and H5N1/H1N1 Influenza viruses", "SPECIES", 65, 106], ["new transmissible diseases", "PROBLEM", 23, 49], ["SARS", "PROBLEM", 59, 63], ["H5N1", "PROBLEM", 79, 83], ["H1N1 Influenza viruses", "PROBLEM", 84, 106], ["reemerging diseases", "PROBLEM", 123, 142], ["dengue fever", "PROBLEM", 148, 160], ["a global epidemic", "PROBLEM", 181, 198], ["new", "OBSERVATION_MODIFIER", 23, 26], ["transmissible", "OBSERVATION_MODIFIER", 27, 40], ["diseases", "OBSERVATION", 41, 49]]], ["Moreover, in the tropical and subtropical regions of the world, parasitic infections are a common cause of death.", [["parasitic infections", "DISEASE", 64, 84], ["death", "DISEASE", 107, 112], ["parasitic infections", "PROBLEM", 64, 84], ["death", "PROBLEM", 107, 112], ["tropical", "ANATOMY_MODIFIER", 17, 25], ["subtropical", "ANATOMY_MODIFIER", 30, 41], ["parasitic", "OBSERVATION_MODIFIER", 64, 73], ["infections", "OBSERVATION", 74, 84]]], ["Since one of the major characteristics of infectious diseases is its inter-individual transmission, advances in personal protection, effective public policy, and immunological procedures are efficient means of controlling the spread of these diseases.", [["infectious diseases", "DISEASE", 42, 61], ["infectious diseases", "PROBLEM", 42, 61], ["personal protection", "TREATMENT", 112, 131], ["immunological procedures", "TREATMENT", 162, 186], ["these diseases", "PROBLEM", 236, 250], ["infectious", "OBSERVATION", 42, 52]]], ["Thus, improvement of pre-existing technologies commonly used to monitor, prevent, and treat infectious diseases is of crucial importance not only to the medical community, but also to humankind.IntroductionHere, we describe recent strategies used to fight infectious diseases, with a special focus on recent advances in the fields of molecular biology, examining the development of different methods for their control.", [["infectious diseases", "DISEASE", 92, 111], ["infectious diseases", "DISEASE", 256, 275], ["pre-existing technologies", "PROBLEM", 21, 46], ["infectious diseases", "PROBLEM", 92, 111], ["infectious diseases", "PROBLEM", 256, 275], ["different methods", "TREATMENT", 382, 399], ["improvement", "OBSERVATION_MODIFIER", 6, 17]]], ["We emphasize that regardless of the great advances in science, in new drugs, and in methods used to diagnose infectious diseases, the number of available vaccines is still limited.PreventionDengue fever is a significant disease that has spread around the tropical and subtropical regions of the globe.", [["infectious diseases", "DISEASE", 109, 128], ["Dengue fever", "DISEASE", 190, 202], ["globe", "ORGAN", 295, 300], ["infectious diseases", "PROBLEM", 109, 128], ["available vaccines", "TREATMENT", 144, 162], ["Dengue fever", "PROBLEM", 190, 202], ["a significant disease", "PROBLEM", 206, 227], ["fever", "OBSERVATION", 197, 202], ["significant", "OBSERVATION_MODIFIER", 208, 219], ["disease", "OBSERVATION", 220, 227], ["spread", "OBSERVATION_MODIFIER", 237, 243], ["tropical", "ANATOMY_MODIFIER", 255, 263], ["subtropical", "ANATOMY_MODIFIER", 268, 279], ["regions", "ANATOMY_MODIFIER", 280, 287], ["globe", "ANATOMY", 295, 300]]], ["The virus is transmitted by infected mosquitoes, mainly Aedes aegypti, and it is estimated that annually the number of infections exceeds more than 50 million cases in more than 100 countries [6] .", [["infected mosquitoes", "DISEASE", 28, 47], ["infections", "DISEASE", 119, 129], ["Aedes aegypti", "ORGANISM", 56, 69], ["Aedes aegypti", "SPECIES", 56, 69], ["Aedes aegypti", "SPECIES", 56, 69], ["The virus", "PROBLEM", 0, 9], ["infected mosquitoes", "PROBLEM", 28, 47], ["infections", "PROBLEM", 119, 129], ["virus", "OBSERVATION", 4, 9], ["infected", "OBSERVATION_MODIFIER", 28, 36], ["mosquitoes", "OBSERVATION", 37, 47], ["number", "OBSERVATION_MODIFIER", 109, 115], ["infections", "OBSERVATION", 119, 129]]], ["Initial attempts at vector control were based on the eradication of mosquitoes, by programs with extensive use of insecticides; thus, as a consequence many Aedes aegypti field populations are presenting increased resistance to such compounds (pyrethroids and organophosphates).", [["pyrethroids", "CHEMICAL", 243, 254], ["organophosphates", "CHEMICAL", 259, 275], ["pyrethroids", "CHEMICAL", 243, 254], ["organophosphates", "CHEMICAL", 259, 275], ["Aedes aegypti", "ORGANISM", 156, 169], ["pyrethroids", "SIMPLE_CHEMICAL", 243, 254], ["organophosphates", "SIMPLE_CHEMICAL", 259, 275], ["Aedes aegypti", "SPECIES", 156, 169], ["Aedes aegypti", "SPECIES", 156, 169], ["vector control", "TREATMENT", 20, 34], ["insecticides", "TREATMENT", 114, 126], ["Aedes aegypti field populations", "PROBLEM", 156, 187], ["increased resistance", "PROBLEM", 203, 223], ["pyrethroids and organophosphates", "TREATMENT", 243, 275], ["increased resistance", "OBSERVATION", 203, 223]]], ["A recent intervention, that aims to reduce the survival rate or life span of adult mosquitoes, limiting the potential of dengue infection by affecting the period of vector pathogen transmission, is now being tested in areas where dengue is endemic.", [["dengue infection", "DISEASE", 121, 137], ["dengue", "DISEASE", 230, 236], ["dengue", "SPECIES", 121, 127], ["dengue", "SPECIES", 230, 236], ["A recent intervention", "TREATMENT", 0, 21], ["the survival rate", "PROBLEM", 43, 60], ["adult mosquitoes", "PROBLEM", 77, 93], ["dengue infection", "PROBLEM", 121, 137], ["dengue", "OBSERVATION_MODIFIER", 121, 127], ["infection", "OBSERVATION", 128, 137]]], ["This methodology employs a genetically modified strain of Wolbachia pipientis (an obligate intracellular bacterium).", [["intracellular", "ANATOMY", 91, 104], ["Wolbachia pipientis", "ORGANISM", 58, 77], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 91, 104], ["Wolbachia pipientis", "SPECIES", 58, 77], ["Wolbachia pipientis", "SPECIES", 58, 77], ["Wolbachia pipientis", "PROBLEM", 58, 77], ["an obligate intracellular bacterium", "PROBLEM", 79, 114], ["Wolbachia pipientis", "OBSERVATION", 58, 77]]], ["This bacterium was adapted to infect Aedes aegypti mosquitoes by continuous serial passage in mosquito cell culture for approximately 3 years.", [["cell", "ANATOMY", 103, 107], ["Aedes aegypti", "ORGANISM", 37, 50], ["mosquitoes", "ORGANISM", 51, 61], ["mosquito cell culture", "CELL", 94, 115], ["mosquito cell culture", "CELL_LINE", 94, 115], ["Aedes aegypti", "SPECIES", 37, 50], ["Aedes aegypti", "SPECIES", 37, 50], ["This bacterium", "PROBLEM", 0, 14], ["continuous serial passage in mosquito cell culture", "PROBLEM", 65, 115], ["mosquito cell", "OBSERVATION", 94, 107]]], ["More importantly, the mosquitoes remained infected for a period of 30 generations, allowing its use in field populations [7] .", [["mosquitoes", "ORGANISM", 22, 32], ["infected", "OBSERVATION", 42, 50]]], ["Initial field tests showed that Wolbachia (strain wMelPop-CLA) successfully invaded two natural A. aegypti populations in Australia with almost 100 % fixation rate 5 months after release [8] .", [["A. aegypti", "ORGANISM", 96, 106], ["A. aegypti", "SPECIES", 96, 106], ["A. aegypti", "SPECIES", 96, 106], ["Initial field tests", "TEST", 0, 19], ["Wolbachia (strain", "PROBLEM", 32, 49], ["MelPop-CLA", "TREATMENT", 51, 61], ["almost 100 % fixation rate", "TREATMENT", 137, 163], ["Wolbachia", "OBSERVATION", 32, 41], ["aegypti populations", "OBSERVATION", 99, 118]]], ["Thus, with low implementation costs, Wolbachia-based strategies can represent a practical approach to dengue fever suppression in endemic areas.PreventionIn women, HIV infection is a prevalent risk, mainly in sub-Saharan Africa.", [["fever", "DISEASE", 109, 114], ["HIV infection", "DISEASE", 164, 177], ["women", "ORGANISM", 157, 162], ["HIV", "ORGANISM", 164, 167], ["women", "SPECIES", 157, 162], ["HIV", "SPECIES", 164, 167], ["dengue", "SPECIES", 102, 108], ["HIV", "SPECIES", 164, 167], ["Wolbachia-based strategies", "TREATMENT", 37, 63], ["a practical approach", "TREATMENT", 78, 98], ["dengue fever suppression in endemic areas", "PROBLEM", 102, 143], ["HIV infection", "PROBLEM", 164, 177], ["infection", "OBSERVATION", 168, 177]]], ["In this region women are unable or reluctant to negotiate condom use.", [["women", "ORGANISM", 15, 20], ["women", "SPECIES", 15, 20]]], ["An alternative strategy is the use of microbicide vaginal gels.", [["microbicide vaginal gels", "TREATMENT", 38, 62]]], ["Over the last few years, several formulations of microbicide gels were tested with variable efficacy, leading to disappointing results.", [["microbicide gels", "TREATMENT", 49, 65]]], ["As exemplified by a recent phase III clinical trial of PRO2000, a synthetic naphthalene sulfonate polymer of around 5 kDa in molecular weight with antiviral activity against HIV-1.", [["PRO2000", "CHEMICAL", 55, 62], ["naphthalene sulfonate", "CHEMICAL", 76, 97], ["PRO2000", "CHEMICAL", 55, 62], ["naphthalene sulfonate", "CHEMICAL", 76, 97], ["PRO2000", "SIMPLE_CHEMICAL", 55, 62], ["naphthalene sulfonate polymer", "SIMPLE_CHEMICAL", 76, 105], ["HIV-1", "ORGANISM", 174, 179], ["HIV-1", "SPECIES", 174, 179], ["HIV-1", "SPECIES", 174, 179], ["PRO2000", "TREATMENT", 55, 62], ["a synthetic naphthalene sulfonate polymer", "TREATMENT", 64, 105], ["antiviral activity", "TREATMENT", 147, 165], ["HIV", "PROBLEM", 174, 177]]], ["In this trial a randomized, double-blind, parallel group showed that 0.5 % PRO2000 and 2 % PRO2000 formulations are not efficacious against vaginal HIV-1 transmission [9] .", [["vaginal", "ANATOMY", 140, 147], ["PRO2000", "CHEMICAL", 75, 82], ["PRO2000", "CHEMICAL", 91, 98], ["vaginal HIV-1 transmission", "DISEASE", 140, 166], ["PRO2000", "CHEMICAL", 75, 82], ["PRO2000", "CHEMICAL", 91, 98], ["PRO2000", "SIMPLE_CHEMICAL", 75, 82], ["PRO2000", "SIMPLE_CHEMICAL", 91, 98], ["vaginal HIV-1", "ORGANISM", 140, 153], ["HIV-1", "SPECIES", 148, 153], ["HIV-1", "SPECIES", 148, 153], ["2 % PRO2000 formulations", "TREATMENT", 87, 111]]], ["However, positive results were also reported; in 2010, a clinical trial demonstrated the effectiveness of tenofovir 1 % (a nucleotide reverse transcriptase inhibitor) intravaginal gel for the prevention of HIV acquisition in women.", [["tenofovir", "CHEMICAL", 106, 115], ["nucleotide", "CHEMICAL", 123, 133], ["HIV acquisition", "DISEASE", 206, 221], ["tenofovir", "CHEMICAL", 106, 115], ["nucleotide", "CHEMICAL", 123, 133], ["tenofovir", "SIMPLE_CHEMICAL", 106, 115], ["HIV", "ORGANISM", 206, 209], ["women", "ORGANISM", 225, 230], ["HIV", "SPECIES", 206, 209], ["women", "SPECIES", 225, 230], ["HIV", "SPECIES", 206, 209], ["a clinical trial", "TEST", 55, 71], ["tenofovir", "TREATMENT", 106, 115], ["a nucleotide reverse transcriptase inhibitor", "TREATMENT", 121, 165], ["intravaginal gel", "TREATMENT", 167, 183], ["HIV acquisition", "TREATMENT", 206, 221]]], ["In a high gel adherence group, HIV incidence was statistically lower (54 % decrease), with 38 % and 28 % HIV reduction in intermediate gel adherence and low gel adherence groups respectively [10] .", [["HIV reduction", "DISEASE", 105, 118], ["HIV", "ORGANISM", 31, 34], ["HIV", "SPECIES", 31, 34], ["HIV", "SPECIES", 105, 108], ["HIV incidence", "PROBLEM", 31, 44], ["28 % HIV reduction", "TREATMENT", 100, 118], ["intermediate gel adherence", "TREATMENT", 122, 148], ["low gel adherence groups", "TREATMENT", 153, 177]]], ["The SPL7013 Gel (VivaGel) is a microbicide that inhibits HIV, herpes simplex virus-2, and human papillomavirus in vitro and in animal models.", [["SPL7013 Gel", "CHEMICAL", 4, 15], ["VivaGel", "CHEMICAL", 17, 24], ["herpes simplex", "DISEASE", 62, 76], ["human papillomavirus", "DISEASE", 90, 110], ["VivaGel", "CHEMICAL", 17, 24], ["SPL7013 Gel", "SIMPLE_CHEMICAL", 4, 15], ["VivaGel", "SIMPLE_CHEMICAL", 17, 24], ["HIV", "ORGANISM", 57, 60], ["herpes simplex virus-2", "ORGANISM", 62, 84], ["human", "ORGANISM", 90, 95], ["papillomavirus", "ORGANISM", 96, 110], ["HIV", "SPECIES", 57, 60], ["herpes simplex virus-2", "SPECIES", 62, 84], ["human", "SPECIES", 90, 95], ["papillomavirus", "SPECIES", 96, 110], ["HIV", "SPECIES", 57, 60], ["herpes simplex virus-2", "SPECIES", 62, 84], ["human papillomavirus", "SPECIES", 90, 110], ["a microbicide", "TREATMENT", 29, 42], ["HIV", "PROBLEM", 57, 60], ["herpes simplex virus", "PROBLEM", 62, 82], ["human papillomavirus in vitro", "TREATMENT", 90, 119]]], ["A phase 1 clinical trial demonstrated that VivaGel is well tolerated with no serious adverse events when used by sexually active women aged 18-24 years [11] .", [["VivaGel", "CHEMICAL", 43, 50], ["VivaGel", "CHEMICAL", 43, 50], ["VivaGel", "SIMPLE_CHEMICAL", 43, 50], ["women", "ORGANISM", 129, 134], ["women", "SPECIES", 129, 134], ["serious adverse events", "PROBLEM", 77, 99]]], ["Besides technological advances, simple strategies are also effective in HIV prevention.", [["HIV", "ORGANISM", 72, 75], ["HIV", "SPECIES", 72, 75], ["simple strategies", "TREATMENT", 32, 49], ["HIV prevention", "TREATMENT", 72, 86]]], ["Education programs providing information for individual protection against infection, such as information about routes of transmission, condom use, lubrication, blood risks, and safe and risky sexual practices, are of fundamental importance [12] .Diagnosis toolsIt is important to note that some infectious diseases are treatable.", [["blood", "ANATOMY", 161, 166], ["infection", "DISEASE", 75, 84], ["infectious diseases", "DISEASE", 296, 315], ["blood", "ORGANISM_SUBSTANCE", 161, 166], ["Education programs", "TREATMENT", 0, 18], ["infection", "PROBLEM", 75, 84], ["lubrication", "TREATMENT", 148, 159], ["some infectious diseases", "PROBLEM", 291, 315], ["infectious", "OBSERVATION", 296, 306]]], ["However, to achieve successful therapy rapid detection of the causative agent is a determinant factor.", [["successful therapy", "TREATMENT", 20, 38]]], ["Since the discovery of microbes as causative agents of several transmissible diseases in the late 1800s, the advent of recent genetic methodologies has transformed the field of medical microbiology.", [["transmissible diseases", "DISEASE", 63, 85], ["several transmissible diseases", "PROBLEM", 55, 85]]], ["Developed in 1983 by Kary Mullis, the polymerase chain reaction (PCR) is now an indispensable technique widely applied in medical and biological research [13] .", [["the polymerase chain reaction", "PROBLEM", 34, 63], ["PCR", "TEST", 65, 68]]], ["Initially, PCR was a qualitative test that could be used to detect the presence of a specific gene segment, interpreting that if the gene sequence was present the pathogen would be present also.", [["specific gene segment", "DNA", 85, 106], ["PCR", "TEST", 11, 14], ["a qualitative test", "TEST", 19, 37], ["a specific gene segment", "PROBLEM", 83, 106], ["the gene sequence", "TEST", 129, 146], ["the pathogen", "PROBLEM", 159, 171]]], ["Nowadays, PCR has diversified into various subtechniques with important applications.", [["PCR", "TEST", 10, 13], ["important applications", "TREATMENT", 62, 84]]], ["In fact, there are several commercial kits available for the diagnosis of important pathogens.", [["important pathogens", "PROBLEM", 74, 93]]], ["The principal advantage of PCR is that nucleic acid amplification allows the detection of lower levels of pathogen genetic material, emphasizing the high sensitivity of this technique [14] .", [["nucleic acid", "CHEMICAL", 39, 51], ["PCR", "TEST", 27, 30], ["nucleic acid amplification", "TEST", 39, 65], ["lower levels of pathogen genetic material", "PROBLEM", 90, 131]]], ["Post-amplification analysis, such the traditional Sanger sequencing, allows the identification of microorganism species or genetic variants that could be related to drug resistance [14] .", [["Post-amplification analysis", "TEST", 0, 27], ["the traditional Sanger sequencing", "TEST", 34, 67], ["microorganism species", "PROBLEM", 98, 119], ["genetic variants", "PROBLEM", 123, 139], ["microorganism species", "OBSERVATION", 98, 119]]], ["Genetic variant studies are now identifying new types and subtypes of important pathogens; these variations could represent a major determinant of microorganism pathogenesis [15] .Diagnosis toolsMultiplex PCR assays are a useful approach that enables simultaneous amplification of several target genes in the same reaction.", [["target genes", "DNA", 289, 301], ["Genetic variant studies", "TEST", 0, 23], ["important pathogens", "PROBLEM", 70, 89], ["microorganism pathogenesis", "PROBLEM", 147, 173], ["Diagnosis tools", "TEST", 180, 195], ["Multiplex PCR assays", "TEST", 195, 215], ["microorganism", "OBSERVATION", 147, 160]]], ["This technique has already been applied with success to the identification of influenza subtypes, the subtyping of dengue viruses, and the genotyping of rotaviruses, among others [16] [17] [18] [19] .", [["influenza", "DISEASE", 78, 87], ["dengue", "DISEASE", 115, 121], ["[16] [17] [18] [19]", "SIMPLE_CHEMICAL", 179, 198], ["dengue viruses", "SPECIES", 115, 129], ["This technique", "TREATMENT", 0, 14], ["influenza subtypes", "PROBLEM", 78, 96], ["dengue viruses", "PROBLEM", 115, 129], ["rotaviruses", "PROBLEM", 153, 164], ["influenza", "OBSERVATION", 78, 87], ["dengue viruses", "OBSERVATION", 115, 129]]], ["Multiplex PCR often requires posterior analysis methods; usually, post-amplification analysis includes methods such as sequencing, pyrosequencing, reverse hybridization, and Luminex analysis [14] .", [["Multiplex PCR", "TEST", 0, 13], ["posterior analysis methods", "TEST", 29, 55], ["post-amplification analysis", "TEST", 66, 93], ["methods", "TREATMENT", 103, 110], ["pyrosequencing", "TEST", 131, 145], ["reverse hybridization", "TREATMENT", 147, 168], ["Luminex analysis", "TEST", 174, 190], ["posterior", "ANATOMY_MODIFIER", 29, 38]]], ["Pyrosequencing is a high throughput DNA sequencing method based on the detection of pyrophosphate release after nucleotide incorporation [20] .", [["pyrophosphate", "CHEMICAL", 84, 97], ["nucleotide", "CHEMICAL", 112, 122], ["pyrophosphate", "CHEMICAL", 84, 97], ["nucleotide", "CHEMICAL", 112, 122], ["DNA", "CELLULAR_COMPONENT", 36, 39], ["pyrophosphate", "SIMPLE_CHEMICAL", 84, 97], ["nucleotide", "SIMPLE_CHEMICAL", 112, 122], ["pyrophosphate release", "TREATMENT", 84, 105], ["nucleotide incorporation", "TREATMENT", 112, 136]]], ["This technology has been used for the study of highly variable pathogens, allowing rapid characterization of evolving quasispecies [21] [22] [23] [24] .", [["[21] [22] [23] [24]", "SIMPLE_CHEMICAL", 131, 150], ["the study", "TEST", 34, 43], ["highly variable pathogens", "PROBLEM", 47, 72], ["evolving quasispecies", "PROBLEM", 109, 130]]], ["Moreover, pyrosequencing is a useful approach to identifying drugresistant strains [25] .", [["drugresistant strains", "PROBLEM", 61, 82]]], ["Widely applicable, real-time PCR is an important methodology for the molecular diagnosis of viral, bacterial, and even parasitic infections.", [["parasitic infections", "DISEASE", 119, 139], ["viral, bacterial", "PROBLEM", 92, 108], ["parasitic infections", "PROBLEM", 119, 139], ["viral", "OBSERVATION", 92, 97], ["parasitic", "OBSERVATION_MODIFIER", 119, 128], ["infections", "OBSERVATION", 129, 139]]], ["The main advantage of this technique is that real-time PCR allows the quantification of the target sequence, which is directly related to the quantity of infecting microorganisms.", [["this technique", "TREATMENT", 22, 36], ["the target sequence", "TEST", 88, 107], ["infecting microorganisms", "PROBLEM", 154, 178], ["main", "OBSERVATION_MODIFIER", 4, 8], ["infecting", "OBSERVATION_MODIFIER", 154, 163], ["microorganisms", "OBSERVATION", 164, 178]]], ["Also, real-time PCR can be multiplexed for the detection of up to 3-5 targets simultaneously.", [["real-time PCR", "TEST", 6, 19], ["the detection", "TEST", 43, 56]]], ["Real-time PCR is being applied in a large spectrum of infectious diseases, such as dengue fever, HIV, malaria, and several other major infectious diseases [26] [27] [28] .", [["infectious diseases", "DISEASE", 54, 73], ["dengue fever", "DISEASE", 83, 95], ["HIV, malaria", "DISEASE", 97, 109], ["infectious diseases", "DISEASE", 135, 154], ["HIV", "SPECIES", 97, 100], ["HIV", "SPECIES", 97, 100], ["time PCR", "TEST", 5, 13], ["infectious diseases", "PROBLEM", 54, 73], ["dengue fever", "PROBLEM", 83, 95], ["HIV", "PROBLEM", 97, 100], ["malaria", "PROBLEM", 102, 109], ["several other major infectious diseases", "PROBLEM", 115, 154], ["infectious", "OBSERVATION", 54, 64]]], ["PCR-related techniques revolutionized the field of disease diagnosis, and at the moment the sequencing of the genomes of pathogens is permitting the identification of individual genetic variants.", [["PCR", "TEST", 0, 3], ["disease diagnosis", "TEST", 51, 68], ["pathogens", "PROBLEM", 121, 130], ["individual genetic variants", "PROBLEM", 167, 194], ["disease", "OBSERVATION", 51, 58], ["genetic variants", "OBSERVATION", 178, 194]]], ["This rapid and reliable methodology is simplifying the identification of the genetic basis of drug resistance in several pathogens.Diagnosis toolsFor latent tuberculosis infection, the gold standard method is the tuberculin skin test; as an alternative, interferon gamma (IFN-\u03b3) release assays have been introduced.", [["skin", "ANATOMY", 224, 228], ["latent tuberculosis infection", "DISEASE", 150, 179], ["skin", "ORGAN", 224, 228], ["interferon gamma", "GENE_OR_GENE_PRODUCT", 254, 270], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 272, 277], ["interferon gamma", "PROTEIN", 254, 270], ["IFN", "PROTEIN", 272, 275], ["drug resistance", "PROBLEM", 94, 109], ["several pathogens", "PROBLEM", 113, 130], ["latent tuberculosis infection", "PROBLEM", 150, 179], ["the tuberculin skin test", "TEST", 209, 233], ["an alternative, interferon gamma (IFN-\u03b3)", "TREATMENT", 238, 278], ["drug resistance", "OBSERVATION", 94, 109], ["several", "OBSERVATION_MODIFIER", 113, 120], ["pathogens", "OBSERVATION", 121, 130], ["latent", "OBSERVATION_MODIFIER", 150, 156], ["tuberculosis", "OBSERVATION_MODIFIER", 157, 169], ["infection", "OBSERVATION", 170, 179], ["skin", "ANATOMY", 224, 228]]], ["Currently, two tests have been approved by the US Food and Drug Administration (FDA).", [["two tests", "TEST", 11, 20]]], ["These are: QuantiFERON\u00ae-TB Gold In-Tube test (QFT-GIT), which detects IFN-\u03b3 concentration released by patient T cells after incubation with a mixture of synthetic stimulatory peptides, and T-SPOT\u00ae.", [["T cells", "ANATOMY", 110, 117], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 70, 75], ["patient", "ORGANISM", 102, 109], ["T cells", "CELL", 110, 117], ["T-SPOT", "GENE_OR_GENE_PRODUCT", 189, 195], ["IFN", "PROTEIN", 70, 73], ["\u03b3", "PROTEIN", 74, 75], ["T cells", "CELL_TYPE", 110, 117], ["patient", "SPECIES", 102, 109], ["QuantiFERON", "TEST", 11, 22], ["Tube test", "TEST", 35, 44], ["IFN", "TEST", 70, 73], ["synthetic stimulatory peptides", "TREATMENT", 153, 183], ["GIT", "ANATOMY", 50, 53]]], ["TB test (T-Spot), which works on the same principle, but detects the number of IFN-\u03b3-producing cells instead of the concentration [29] .Diagnosis toolsSuccessful diagnostic tools often require high sensitivity, reliability, and short periods to process samples.", [["cells", "ANATOMY", 95, 100], ["IFN-\u03b3-", "GENE_OR_GENE_PRODUCT", 79, 85], ["cells", "CELL", 95, 100], ["IFN", "PROTEIN", 79, 82], ["\u03b3-producing cells", "CELL_TYPE", 83, 100], ["TB test", "TEST", 0, 7], ["diagnostic tools", "TEST", 162, 178], ["high sensitivity", "PROBLEM", 193, 209]]], ["In accordance with these requirements, biosensors are becoming a valuable, large, applicable technology.", [["large", "OBSERVATION_MODIFIER", 75, 80]]], ["Utilizing a classical antigen-antibody reaction, Mujika et al. [30] designed a magneto-resistive immunosensor, integrated into a microfluidic network, for the detection of Escherichia coli O157: H7 in food and clinical samples.", [["samples", "ANATOMY", 219, 226], ["Escherichia coli", "ORGANISM", 172, 188], ["O157: H7", "ORGANISM", 189, 197], ["Escherichia coli O157", "SPECIES", 172, 193], ["Escherichia coli O157: H7", "SPECIES", 172, 197], ["a classical antigen-antibody reaction", "TEST", 10, 47], ["a magneto-resistive immunosensor", "TREATMENT", 77, 109], ["a microfluidic network", "TREATMENT", 127, 149], ["Escherichia coli", "PROBLEM", 172, 188], ["H7", "PROBLEM", 195, 197], ["clinical samples", "TEST", 210, 226], ["Escherichia coli", "OBSERVATION", 172, 188]]], ["This device detects magnetic field oscillations caused by monitoring the presence of super paramagnetic beads bound to E. coli-immobilized antigens.", [["E. coli-immobilized antigens", "GENE_OR_GENE_PRODUCT", 119, 147], ["E. coli-immobilized antigens", "PROTEIN", 119, 147], ["This device", "TREATMENT", 0, 11], ["magnetic field oscillations", "PROBLEM", 20, 47], ["super paramagnetic beads bound", "PROBLEM", 85, 115]]], ["A significant advantage of this method is that the beads are strongly stable, permitting repetition of the assays several times [30] .", [["the assays", "TEST", 103, 113], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["stable", "OBSERVATION_MODIFIER", 70, 76]]], ["An electrochemical biosensor, which employs DNA probes for the 16S rRNA of the most common uropathogens, was tested in a prospective clinical study in patients with neurogenic bladder.", [["neurogenic bladder", "ANATOMY", 165, 183], ["neurogenic bladder", "DISEASE", 165, 183], ["DNA", "CELLULAR_COMPONENT", 44, 47], ["patients", "ORGANISM", 151, 159], ["bladder", "ORGAN", 176, 183], ["DNA probes", "DNA", 44, 54], ["16S rRNA", "DNA", 63, 71], ["patients", "SPECIES", 151, 159], ["An electrochemical biosensor", "TEST", 0, 28], ["DNA probes", "TREATMENT", 44, 54], ["the 16S rRNA", "PROBLEM", 59, 71], ["a prospective clinical study", "TEST", 119, 147], ["neurogenic bladder", "PROBLEM", 165, 183], ["most common", "OBSERVATION_MODIFIER", 79, 90], ["uropathogens", "OBSERVATION", 91, 103], ["neurogenic", "OBSERVATION", 165, 175], ["bladder", "ANATOMY", 176, 183]]], ["The authors report that the biosensor assay specificity and positive predictive values were of 100 % with a pathogen detection sensitivity of approximately 89 %, yielding a 76 % negative predictive value.", [["the biosensor assay specificity", "TEST", 24, 55], ["a pathogen detection sensitivity", "TEST", 106, 138]]], ["A positive aspect of this device is that it allows the samples to be tested within 1-2 h of collection; however, the test failed to detect pathogens at a concentration of 4-3 10 4 CFU/mL or less [31] .Diagnosis toolsAlthough the important advances in molecular diagnosis of infectious diseases are incontestable, serological techniques are still the principal application in infectious diseases.", [["samples", "ANATOMY", 55, 62], ["infectious diseases", "DISEASE", 274, 293], ["infectious diseases", "DISEASE", 375, 394], ["this device", "TREATMENT", 21, 32], ["the test", "TEST", 113, 121], ["pathogens", "PROBLEM", 139, 148], ["infectious diseases", "PROBLEM", 274, 293], ["serological techniques", "TEST", 313, 335], ["infectious diseases", "PROBLEM", 375, 394], ["positive", "OBSERVATION_MODIFIER", 2, 10], ["infectious", "OBSERVATION", 274, 284], ["infectious", "OBSERVATION", 375, 385]]], ["In this way, monoclonal antibody techniques gained an important role in the fields of microbiology and immunology.", [["monoclonal antibody", "PROTEIN", 13, 32], ["monoclonal antibody techniques", "TREATMENT", 13, 43]]], ["Monoclonal antibodies are now widely applied in serological techniques, such as enzyme-linked immunosorbent assay (ELISA), producing more sensitivity than traditional techniques in detecting and measuring antibodies to pathogens [1] .VaccinesAdditionally, after the implementation of control measures like sanitation, epidemiological vigilance, and therapy, vaccines are probably responsible for some of the world's greatest public health achievements.", [["Monoclonal antibodies", "PROTEIN", 0, 21], ["antibodies", "PROTEIN", 205, 215], ["Monoclonal antibodies", "TREATMENT", 0, 21], ["serological techniques", "TEST", 48, 70], ["enzyme", "TEST", 80, 86], ["immunosorbent assay", "TEST", 94, 113], ["ELISA", "TEST", 115, 120], ["traditional techniques", "TEST", 155, 177], ["measuring antibodies to pathogens", "PROBLEM", 195, 228], ["control measures", "TREATMENT", 284, 300], ["therapy", "TREATMENT", 349, 356], ["vaccines", "TREATMENT", 358, 366]]], ["Over the last few years there has been an explosion of potential new strategies for vaccine development.", [["vaccine development", "TREATMENT", 84, 103]]], ["Since the development of new techniques, especially those based on genetic engineering, the field of vaccinology has been exploring safer vaccines by the creation of recombinant immunogenic proteins, naked DNA vaccines, and viral recombinants/mutants [32] [33] [34] .", [["DNA", "CELLULAR_COMPONENT", 206, 209], ["recombinant immunogenic proteins", "PROTEIN", 166, 198], ["safer vaccines", "TREATMENT", 132, 146], ["recombinant immunogenic proteins", "TREATMENT", 166, 198], ["naked DNA vaccines", "TREATMENT", 200, 218], ["viral recombinants/mutants", "PROBLEM", 224, 250], ["new", "OBSERVATION_MODIFIER", 25, 28], ["techniques", "OBSERVATION", 29, 39]]], ["Several techniques for safe immunization have presented positive results; an interesting example is the vaccine against human papillomaviruses, which uses a system to generate virus-like particles by inserting the genes encoding the L1 proteins of oncogenic serotypes into baculovirus, producing highly immunogenic proteins via infected insect cells.", [["papillomaviruses", "ANATOMY", 126, 142], ["cells", "ANATOMY", 344, 349], ["human papillomaviruses", "DISEASE", 120, 142], ["human", "ORGANISM", 120, 125], ["papillomaviruses", "ORGANISM", 126, 142], ["baculovirus", "ORGANISM", 273, 284], ["insect cells", "CELL", 337, 349], ["L1 proteins", "PROTEIN", 233, 244], ["immunogenic proteins", "PROTEIN", 303, 323], ["infected insect cells", "CELL_TYPE", 328, 349], ["human", "SPECIES", 120, 125], ["human papillomaviruses", "SPECIES", 120, 142], ["baculovirus", "SPECIES", 273, 284], ["safe immunization", "TREATMENT", 23, 40], ["the vaccine", "TREATMENT", 100, 111], ["human papillomaviruses", "PROBLEM", 120, 142], ["a system", "TREATMENT", 155, 163], ["virus-like particles", "TREATMENT", 176, 196], ["oncogenic serotypes into baculovirus", "PROBLEM", 248, 284], ["infected insect cells", "PROBLEM", 328, 349], ["L1", "ANATOMY", 233, 235], ["oncogenic serotypes", "OBSERVATION", 248, 267], ["infected insect cells", "OBSERVATION", 328, 349]]], ["This vaccine is now licensed for use in humans [35] .VaccinesAn important obstacle that comes with recombinant protein immunization is that subunit vaccines are weak immunogens.", [["VaccinesAn", "CHEMICAL", 53, 63], ["humans", "ORGANISM", 40, 46], ["recombinant protein", "PROTEIN", 99, 118], ["humans", "SPECIES", 40, 46], ["humans", "SPECIES", 40, 46], ["This vaccine", "TREATMENT", 0, 12], ["VaccinesAn", "TREATMENT", 53, 63], ["recombinant protein immunization", "TREATMENT", 99, 131], ["subunit vaccines", "TREATMENT", 140, 156], ["weak immunogens", "PROBLEM", 161, 176]]], ["To overcome this obstacle, viral vector vaccines have been used against several pathogens.", [["this obstacle", "TREATMENT", 12, 25], ["viral vector vaccines", "TREATMENT", 27, 48], ["several pathogens", "PROBLEM", 72, 89]]], ["Viral vector vaccines are potentially safe, able to induce strong immune responses (by simulating a natural infection), and easy to handle.", [["infection", "DISEASE", 108, 117], ["Viral vector vaccines", "TREATMENT", 0, 21], ["a natural infection", "PROBLEM", 98, 117]]], ["Recombinant adenoviruses have emerged as promising viral vectors, with the potential to deliver genes of interest, inducing a protective immune response [36] .", [["adenoviruses", "ORGANISM", 12, 24], ["Recombinant adenoviruses", "TREATMENT", 0, 24], ["adenoviruses", "OBSERVATION", 12, 24]]], ["In fact, substantial protection in a pre-clinical study was provided against the pre-erythrocytic stages of malaria by vaccination first with an adenoviral and then with a modified vaccinia virus Ankara (MVA) poxviral vector encoding the same ME-TRAP transgene, heterologous prime and boost vaccination [37] .", [["malaria", "DISEASE", 108, 115], ["malaria", "ORGANISM", 108, 115], ["adenoviral", "ORGANISM", 145, 155], ["vaccinia virus Ankara", "ORGANISM", 181, 202], ["MVA", "ORGANISM", 204, 207], ["ME-TRAP", "GENE_OR_GENE_PRODUCT", 243, 250], ["ME-TRAP transgene", "DNA", 243, 260], ["vaccinia virus", "SPECIES", 181, 195], ["adenoviral", "SPECIES", 145, 155], ["vaccinia virus", "SPECIES", 181, 195], ["a pre-clinical study", "TEST", 35, 55], ["malaria", "PROBLEM", 108, 115], ["an adenoviral", "TREATMENT", 142, 155], ["a modified vaccinia virus Ankara (MVA) poxviral vector", "TREATMENT", 170, 224], ["TRAP transgene", "TREATMENT", 246, 260], ["heterologous prime", "TREATMENT", 262, 280], ["substantial", "OBSERVATION_MODIFIER", 9, 20], ["protection", "OBSERVATION", 21, 31], ["malaria", "OBSERVATION", 108, 115]]], ["This alternative, the use of viral vectors to augment the immunogenic potential recombinant proteins, has been employed successfully in numerous infectious animal models [38] [39] [40] [41] .", [["[38] [39] [40", "SIMPLE_CHEMICAL", 170, 183], ["recombinant proteins", "PROTEIN", 80, 100], ["viral vectors", "TREATMENT", 29, 42], ["the immunogenic potential recombinant proteins", "TREATMENT", 54, 100]]], ["Most importantly, viral vector vaccines are now being tested in phase III clinical trials, as illustrated by the RTS,S/AS malaria vaccine.", [["malaria", "DISEASE", 122, 129], ["viral vector vaccines", "TREATMENT", 18, 39], ["malaria vaccine", "TREATMENT", 122, 137]]], ["RTS,S/AS is a genetically engineered viral vector vaccine based on the hepatitis B surface antigen virus-like particle (VLP) expressing the circumsporozoite (CS) antigen (carboxy terminus amino acids 207-395) of the P. falciparum [42, 43] .", [["hepatitis B surface antigen virus-like particle", "CHEMICAL", 71, 118], ["carboxy terminus amino acids 207-395", "CHEMICAL", 171, 207], ["P. falciparum", "DISEASE", 216, 229], ["carboxy", "CHEMICAL", 171, 178], ["amino acids", "CHEMICAL", 188, 199], ["hepatitis B surface antigen virus-like particle", "ORGANISM", 71, 118], ["VLP", "ORGANISM", 120, 123], ["circumsporozoite (CS) antigen", "GENE_OR_GENE_PRODUCT", 140, 169], ["amino acids", "AMINO_ACID", 188, 199], ["207-395", "AMINO_ACID", 200, 207], ["P. falciparum", "ORGANISM", 216, 229], ["circumsporozoite (CS) antigen", "PROTEIN", 140, 169], ["carboxy terminus amino acids 207-395", "PROTEIN", 171, 207], ["P. falciparum", "SPECIES", 216, 229], ["hepatitis B", "SPECIES", 71, 82], ["P. falciparum", "SPECIES", 216, 229], ["a genetically engineered viral vector vaccine", "TREATMENT", 12, 57], ["the hepatitis B surface antigen virus", "TEST", 67, 104], ["the circumsporozoite (CS) antigen", "TEST", 136, 169], ["carboxy terminus amino acids", "TEST", 171, 199]]], ["In a phase 2a trial the RTS,S/AS malaria vaccine induced protection against challenge with infectious sporozoites in 40 % of the 80 subjects enrolled in the study.", [["malaria", "DISEASE", 33, 40], ["infectious sporozoites", "DISEASE", 91, 113], ["the RTS", "TEST", 20, 27], ["S/AS malaria vaccine", "TREATMENT", 28, 48], ["infectious sporozoites", "PROBLEM", 91, 113], ["the study", "TEST", 153, 162], ["infectious", "OBSERVATION_MODIFIER", 91, 101]]], ["Protective immunity was associated with CD4 + T cells frequency significantly higher in protected versus non-protected subjects [44] .VaccinesAnother phase III clinical trial vaccine is showing promising results.", [["CD4 + T cells", "ANATOMY", 40, 53], ["CD4", "GENE_OR_GENE_PRODUCT", 40, 43], ["CD4", "PROTEIN", 40, 43], ["T cells", "CELL_TYPE", 46, 53], ["CD4 + T cells frequency", "PROBLEM", 40, 63], ["Vaccines", "TREATMENT", 134, 142], ["Another phase III clinical trial vaccine", "TREATMENT", 142, 182]]], ["Among a cohort of healthy adults aged 16-65 years in China, the vaccine efficacy after three doses was 100.0 % with no vaccination-related serious adverse events [45] .", [["the vaccine efficacy", "TREATMENT", 60, 80], ["vaccination", "PROBLEM", 119, 130], ["serious adverse events", "PROBLEM", 139, 161]]], ["This recombinant hepatitis E virus (HEV) vaccine, denominated HEV 239, has a 26-amino acid extension from the N terminal of another peptide, E2, of the HEV capsid protein expressed in bacteria.", [["hepatitis E", "DISEASE", 17, 28], ["HEV 239", "CHEMICAL", 62, 69], ["amino acid", "CHEMICAL", 80, 90], ["E2", "CHEMICAL", 141, 143], ["amino acid", "CHEMICAL", 80, 90], ["N", "CHEMICAL", 110, 111], ["recombinant", "ORGANISM", 5, 16], ["hepatitis E virus", "ORGANISM", 17, 34], ["HEV", "ORGANISM", 36, 39], ["HEV 239", "ORGANISM", 62, 69], ["amino acid", "AMINO_ACID", 80, 90], ["E2", "GENE_OR_GENE_PRODUCT", 141, 143], ["HEV", "ORGANISM", 152, 155], ["N terminal", "PROTEIN", 110, 120], ["HEV capsid protein", "PROTEIN", 152, 170], ["hepatitis E virus", "SPECIES", 17, 34], ["hepatitis E virus", "SPECIES", 17, 34], ["HEV", "SPECIES", 36, 39], ["HEV", "SPECIES", 62, 65], ["HEV", "SPECIES", 152, 155], ["This recombinant hepatitis E virus (HEV) vaccine", "TREATMENT", 0, 48], ["denominated HEV", "TEST", 50, 65], ["a 26-amino acid extension", "PROBLEM", 75, 100], ["the HEV capsid protein", "TEST", 148, 170], ["bacteria", "PROBLEM", 184, 192], ["capsid protein", "OBSERVATION", 156, 170], ["bacteria", "OBSERVATION_MODIFIER", 184, 192]]], ["This vaccine was previously demonstrated to protect monkeys against HEV infection by inducing high levels of IgG anti-HEV serum antibody [46] .", [["serum", "ANATOMY", 122, 127], ["HEV infection", "DISEASE", 68, 81], ["monkeys", "ORGANISM", 52, 59], ["HEV", "ORGANISM", 68, 71], ["IgG", "GENE_OR_GENE_PRODUCT", 109, 112], ["serum", "ORGANISM_SUBSTANCE", 122, 127], ["IgG", "PROTEIN", 109, 112], ["HEV serum antibody", "PROTEIN", 118, 136], ["monkeys", "SPECIES", 52, 59], ["HEV", "SPECIES", 68, 71], ["HEV", "SPECIES", 118, 121], ["This vaccine", "TREATMENT", 0, 12], ["HEV infection", "PROBLEM", 68, 81], ["IgG anti-HEV serum antibody", "TEST", 109, 136], ["infection", "OBSERVATION", 72, 81]]], ["Moreover, a dengue tetravalent, live, attenuated vaccine (CYD-1-4), based on the backbone of the yellow fever vaccine 17D (YFV 17D), is presenting good safety and immunogenicity profiles.", [["dengue", "DISEASE", 12, 18], ["CYD-1-4", "CHEMICAL", 58, 65], ["yellow fever", "DISEASE", 97, 109], ["YFV 17D", "CHEMICAL", 123, 130], ["yellow fever vaccine 17D", "ORGANISM", 97, 121], ["YFV 17D", "ORGANISM", 123, 130], ["yellow fever vaccine", "SPECIES", 97, 117], ["dengue", "SPECIES", 12, 18], ["yellow fever vaccine 17D (YFV 17D", "SPECIES", 97, 130], ["a dengue tetravalent", "TREATMENT", 10, 30], ["attenuated vaccine", "TREATMENT", 38, 56], ["CYD", "TEST", 58, 61], ["the yellow fever vaccine", "PROBLEM", 93, 117]]], ["After a complete round of three immunizations, this formulation induces a strong immune response against all four dengue serotypes in a high proportion of the 6,000 vaccinated children [47] .", [["dengue", "DISEASE", 114, 120], ["children", "ORGANISM", 176, 184], ["children", "SPECIES", 176, 184], ["dengue", "SPECIES", 114, 120], ["three immunizations", "TREATMENT", 26, 45], ["this formulation", "TREATMENT", 47, 63], ["all four dengue serotypes", "PROBLEM", 105, 130]]], ["A recent randomized, double-blind efficacy field trial with 8,323 women demonstrated that a herpes simplex virus type 2 (HSV-2) subunit vaccine, containing glycoprotein D, was associated with an increased risk of local reactions and more importantly, the vaccine efficacy against genital herpes disease was only 20 % [48] .VaccinesOf the viral infections, HIV is actually the main cause of death in the world, accounting for 1.8 million deaths in 2011.", [["genital", "ANATOMY", 280, 287], ["herpes simplex virus", "DISEASE", 92, 112], ["genital herpes disease", "DISEASE", 280, 302], ["viral infections", "DISEASE", 338, 354], ["HIV", "DISEASE", 356, 359], ["death", "DISEASE", 390, 395], ["deaths", "DISEASE", 437, 443], ["women", "ORGANISM", 66, 71], ["herpes simplex virus type 2", "ORGANISM", 92, 119], ["HSV-2", "ORGANISM", 121, 126], ["glycoprotein D", "GENE_OR_GENE_PRODUCT", 156, 170], ["genital herpes", "ORGANISM", 280, 294], ["HIV", "ORGANISM", 356, 359], ["glycoprotein D", "PROTEIN", 156, 170], ["women", "SPECIES", 66, 71], ["herpes simplex virus", "SPECIES", 92, 112], ["HIV", "SPECIES", 356, 359], ["herpes simplex virus", "SPECIES", 92, 112], ["HSV", "SPECIES", 121, 124], ["HIV", "SPECIES", 356, 359], ["a herpes simplex virus type", "PROBLEM", 90, 117], ["HSV", "TEST", 121, 124], ["subunit vaccine", "TREATMENT", 128, 143], ["local reactions", "PROBLEM", 213, 228], ["the vaccine efficacy", "TREATMENT", 251, 271], ["genital herpes disease", "PROBLEM", 280, 302], ["the viral infections", "PROBLEM", 334, 354], ["HIV", "PROBLEM", 356, 359], ["death", "PROBLEM", 390, 395], ["increased", "OBSERVATION_MODIFIER", 195, 204], ["local reactions", "OBSERVATION", 213, 228], ["viral", "OBSERVATION_MODIFIER", 338, 343], ["infections", "OBSERVATION", 344, 354]]], ["Several groups have focused on developing an effective HIV vaccine, but without success so far.", [["HIV", "ORGANISM", 55, 58], ["HIV", "SPECIES", 55, 58], ["an effective HIV vaccine", "TREATMENT", 42, 66]]], ["At present, four distinct vaccine regimens have been tested in phase III or IIb efficacy trials in human volunteers; two of these involve the Vaxgen's gp120 alone, which is a bivalent vaccine consisting of a preparation of recombinant gp120 from two types of HIV.", [["human", "ORGANISM", 99, 104], ["volunteers", "ORGANISM", 105, 115], ["Vaxgen", "GENE_OR_GENE_PRODUCT", 142, 148], ["gp120", "GENE_OR_GENE_PRODUCT", 151, 156], ["gp120", "GENE_OR_GENE_PRODUCT", 235, 240], ["HIV", "ORGANISM", 259, 262], ["gp120", "PROTEIN", 151, 156], ["recombinant gp120", "PROTEIN", 223, 240], ["human", "SPECIES", 99, 104], ["HIV", "SPECIES", 259, 262], ["human", "SPECIES", 99, 104], ["HIV", "SPECIES", 259, 262], ["four distinct vaccine regimens", "TREATMENT", 12, 42], ["the Vaxgen's gp120", "TREATMENT", 138, 156], ["a bivalent vaccine", "TREATMENT", 173, 191], ["a preparation of recombinant gp120", "TREATMENT", 206, 240], ["HIV", "PROBLEM", 259, 262]]], ["The others consist of Merck's rAd5, a replication-defective recombinant adenovirus serotype 5, and ALVAC + gp120 (RV144), a recombinant canarypox vector carrying three synthetic HIV genes [49] [50] [51] .", [["Merck's rAd5", "ORGANISM", 22, 34], ["recombinant", "ORGANISM", 60, 71], ["adenovirus serotype 5", "ORGANISM", 72, 93], ["ALVAC + gp120", "GENE_OR_GENE_PRODUCT", 99, 112], ["RV144", "GENE_OR_GENE_PRODUCT", 114, 119], ["ALVAC", "PROTEIN", 99, 104], ["gp120", "PROTEIN", 107, 112], ["RV144", "PROTEIN", 114, 119], ["HIV genes", "DNA", 178, 187], ["HIV", "SPECIES", 178, 181], ["HIV", "SPECIES", 178, 181], ["Merck's rAd5", "TREATMENT", 22, 34], ["a replication-defective recombinant adenovirus serotype", "TREATMENT", 36, 91], ["ALVAC", "TEST", 99, 104], ["a recombinant canarypox vector", "TREATMENT", 122, 152]]], ["However, only ALVAC showed a modest degree of efficacy in preventing HIV-1 infection (31 % protective efficacy against HIV-1 acquisition) [52] .", [["ALVAC", "CHEMICAL", 14, 19], ["HIV-1 infection", "DISEASE", 69, 84], ["ALVAC", "SIMPLE_CHEMICAL", 14, 19], ["HIV-1", "ORGANISM", 69, 74], ["HIV-1", "ORGANISM", 119, 124], ["HIV-1", "SPECIES", 69, 74], ["HIV-1", "SPECIES", 119, 124], ["HIV-1", "SPECIES", 69, 74], ["HIV-1", "SPECIES", 119, 124], ["ALVAC", "TEST", 14, 19], ["HIV-1 infection", "PROBLEM", 69, 84], ["HIV", "TEST", 119, 122], ["modest", "OBSERVATION_MODIFIER", 29, 35]]], ["Additional important vaccines are available for the human population (Table 1) .", [["human", "ORGANISM", 52, 57], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57], ["Additional important vaccines", "TREATMENT", 0, 29]]], ["Although the list of diseases preventable by immunization is still limited, in recent years new vaccine candidates have been tested and it is expected that in the future they will become licensed.ConclusionA variety of molecular-based strategies are now improving our knowledge of microorganism biology, and of preventive and therapeutic tools, providing humankind with better control of infectious agents.", [["diseases", "PROBLEM", 21, 29], ["immunization", "TREATMENT", 45, 57], ["new vaccine candidates", "TREATMENT", 92, 114], ["humankind", "TREATMENT", 355, 364], ["infectious agents", "TREATMENT", 388, 405]]], ["In addition, the advancements in the fields of immunology, bioinformatics, and nanotechnology are expected to have an impact on our interpretation of interaction mechanisms between host and pathogenic microorganisms.", [["interaction mechanisms between host and pathogenic microorganisms", "PROBLEM", 150, 215]]], ["These advancements may lead to the discovery of new pathogens, new potential therapeutic targets, and", [["new pathogens", "PROBLEM", 48, 61], ["new", "OBSERVATION_MODIFIER", 48, 51], ["pathogens", "OBSERVATION", 52, 61]]]], "PMC7134829": [["The SARS scare death tollKwai died on March 13, Pollack on March 21 and Dougherty on March 29.", [["SARS", "DISEASE", 4, 8], ["death", "DISEASE", 15, 20], ["The SARS scare death", "PROBLEM", 0, 20]]], ["The chain of transmission that started with Kwai\u2019s mother caused 438 infections, including 39 other deaths, from what would come to be known as Severe Acute Respiratory Syndrome or SARS\u2014with every death other than Kwai\u2019s and his mother\u2019s traceable to that encounter in a crowded ED.The SARS scare death tollThe outbreak that paralyzed Toronto\u2014one episode in a worldwide epidemic that sickened 8,098 and killed 7741\u2014has assumed new importance as avian influenza H5N1 moves across the globe.", [["infections", "DISEASE", 69, 79], ["deaths", "DISEASE", 100, 106], ["Acute Respiratory Syndrome", "DISEASE", 151, 177], ["SARS", "DISEASE", 181, 185], ["death", "DISEASE", 197, 202], ["SARS", "DISEASE", 286, 290], ["death", "DISEASE", 297, 302], ["influenza H5N1", "DISEASE", 451, 465], ["avian influenza H5N1", "ORGANISM", 445, 465], ["avian influenza H5N1", "SPECIES", 445, 465], ["Severe Acute Respiratory Syndrome", "PROBLEM", 144, 177], ["SARS", "PROBLEM", 181, 185], ["every death", "PROBLEM", 191, 202], ["The SARS scare death", "PROBLEM", 282, 302], ["avian influenza H5N1", "PROBLEM", 445, 465], ["Severe", "OBSERVATION_MODIFIER", 144, 150], ["Acute", "OBSERVATION_MODIFIER", 151, 156], ["Respiratory Syndrome", "OBSERVATION", 157, 177], ["globe", "ANATOMY", 483, 488]]], ["In the rapid ramp-up of planning for a possible pandemic, public health authorities and emergency physicians view EDs with disquiet, fearing they will be swamped at least and amplifiers of the epidemic at worst.The SARS scare death toll\u201cWhen you think about the tremendous influx of patients that could conceivably result from a pandemic, it is almost overwhelming, and certainly frightening to the average emergency physician,\u201d said Dr. J. Patrick O\u2019Neal, who retired as chief of emergency medicine at DeKalb County Medical Center near Atlanta and now directs health care pandemic planning for the Georgia Division of Public Health.At the breaking pointFears of a pandemic\u2019s impact on EDs begin with the basic facts of life of emergency medicine: many EDs are crowded most of the time.", [["SARS", "DISEASE", 215, 219], ["death", "DISEASE", 226, 231], ["patients", "ORGANISM", 283, 291], ["patients", "SPECIES", 283, 291]]], ["According to American Hospital Association data, 48% of EDs describe themselves as crowded on most days, and 46% regularly go on diversion.2", [["diversion", "TREATMENT", 129, 138], ["diversion", "OBSERVATION", 129, 138]]]], "PMC7275168": [["INTRODUCTIONWe describe the third reported case of transverse myelitis in a patient with the onset of coronavirus disease 2019 (Covid-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).", [["transverse myelitis", "DISEASE", 51, 70], ["coronavirus disease", "DISEASE", 102, 121], ["acute respiratory syndrome coronavirus", "DISEASE", 168, 206], ["patient", "ORGANISM", 76, 83], ["coronavirus", "ORGANISM", 102, 113], ["SARS-CoV-2", "ORGANISM", 210, 220], ["patient", "SPECIES", 76, 83], ["severe acute respiratory syndrome coronavirus", "SPECIES", 161, 206], ["SARS-CoV-2", "SPECIES", 210, 220], ["transverse myelitis", "PROBLEM", 51, 70], ["coronavirus disease", "PROBLEM", 102, 121], ["Covid", "TEST", 128, 133], ["the disease", "PROBLEM", 139, 150], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 161, 206], ["CoV", "TEST", 215, 218], ["transverse", "OBSERVATION_MODIFIER", 51, 61], ["myelitis", "OBSERVATION", 62, 70], ["coronavirus", "OBSERVATION", 102, 113], ["severe", "OBSERVATION_MODIFIER", 161, 167], ["acute", "OBSERVATION_MODIFIER", 168, 173], ["respiratory syndrome", "OBSERVATION", 174, 194]]], ["Although it is a well-known fact now that strains of SARS-CoV-2 can cause neurological manifestations such as anosmia and dysgeusia, recent literature has found complex neurological disease associations such as Guillain\u2013Barr\u00e9 syndrome and early-onset large-vessel strokes [1, 2, 3].", [["neurological", "ANATOMY", 74, 86], ["neurological", "ANATOMY", 169, 181], ["vessel", "ANATOMY", 257, 263], ["SARS", "DISEASE", 53, 57], ["anosmia", "DISEASE", 110, 117], ["dysgeusia", "DISEASE", 122, 131], ["Guillain\u2013Barr\u00e9 syndrome", "DISEASE", 211, 234], ["vessel strokes", "DISEASE", 257, 271], ["SARS-CoV-2", "ORGANISM", 53, 63], ["Guillain\u2013Barr\u00e9", "ORGANISM", 211, 225], ["vessel", "MULTI-TISSUE_STRUCTURE", 257, 263], ["SARS-CoV", "SPECIES", 53, 61], ["SARS", "PROBLEM", 53, 57], ["neurological manifestations", "PROBLEM", 74, 101], ["anosmia", "PROBLEM", 110, 117], ["dysgeusia", "PROBLEM", 122, 131], ["complex neurological disease associations", "PROBLEM", 161, 202], ["Guillain\u2013Barr\u00e9 syndrome", "PROBLEM", 211, 234], ["early-onset large-vessel strokes", "PROBLEM", 239, 271], ["complex", "OBSERVATION_MODIFIER", 161, 168], ["neurological disease", "OBSERVATION", 169, 189], ["Barr\u00e9 syndrome", "OBSERVATION", 220, 234], ["onset", "OBSERVATION_MODIFIER", 245, 250], ["large", "OBSERVATION_MODIFIER", 251, 256], ["-", "OBSERVATION_MODIFIER", 256, 257], ["vessel", "ANATOMY", 257, 263], ["strokes", "OBSERVATION", 264, 271]]], ["It has become apparent that Covid-19 causes an inflammatory cascade that results in multiple organ system being affected.", [["organ system", "ANATOMY", 93, 105], ["Covid-19", "CHEMICAL", 28, 36], ["Covid-19", "GENE_OR_GENE_PRODUCT", 28, 36], ["organ", "ORGAN", 93, 98], ["Covid", "TEST", 28, 33], ["an inflammatory cascade", "PROBLEM", 44, 67], ["multiple organ system", "PROBLEM", 84, 105], ["inflammatory", "OBSERVATION", 47, 59], ["multiple", "OBSERVATION_MODIFIER", 84, 92], ["organ system", "ANATOMY", 93, 105]]], ["In this case, inflammatory complications affecting the myelin in spinal cord occurred without the classic Covid-19 symptoms.CASEOn April 3, 2020, a 61-year-old female presented with a chief complaint of generalized weakness.", [["myelin", "ANATOMY", 55, 61], ["spinal cord", "ANATOMY", 65, 76], ["weakness", "DISEASE", 215, 223], ["myelin", "GENE_OR_GENE_PRODUCT", 55, 61], ["spinal cord", "ORGAN", 65, 76], ["female", "ORGANISM", 160, 166], ["inflammatory complications", "PROBLEM", 14, 40], ["the myelin in spinal cord", "PROBLEM", 51, 76], ["the classic Covid-19 symptoms", "PROBLEM", 94, 123], ["generalized weakness", "PROBLEM", 203, 223], ["inflammatory", "OBSERVATION_MODIFIER", 14, 26], ["complications", "OBSERVATION", 27, 40], ["myelin", "OBSERVATION", 55, 61], ["spinal cord", "ANATOMY", 65, 76], ["generalized", "OBSERVATION_MODIFIER", 203, 214], ["weakness", "OBSERVATION", 215, 223]]], ["She stated that her symptoms initially started with rhinorrhea and chills a week ago.", [["rhinorrhea", "DISEASE", 52, 62], ["chills", "DISEASE", 67, 73], ["her symptoms", "PROBLEM", 16, 28], ["rhinorrhea", "PROBLEM", 52, 62], ["chills", "PROBLEM", 67, 73], ["chills", "OBSERVATION", 67, 73]]], ["She was suspicious that she had coronavirus because she had been exposed to several symptomatic coworkers potentially with Covid-19, so she was constantly checking her temperature; however, she was afebrile throughout.", [["coronavirus", "DISEASE", 32, 43], ["She", "ORGANISM", 0, 3], ["coronavirus", "PROBLEM", 32, 43], ["Covid", "TEST", 123, 128], ["her temperature", "TEST", 164, 179], ["afebrile", "PROBLEM", 198, 206]]], ["Three days afterward, she started also developing numbness and tingling in her hands and feet.", [["numbness", "DISEASE", 50, 58], ["feet", "ORGANISM_SUBDIVISION", 89, 93], ["numbness", "PROBLEM", 50, 58], ["tingling in her hands and feet", "PROBLEM", 63, 93], ["numbness", "OBSERVATION", 50, 58], ["tingling", "OBSERVATION", 63, 71], ["hands", "ANATOMY", 79, 84], ["feet", "ANATOMY", 89, 93]]], ["Over the next 48 hours, this progressed to severe weakness in her lower extremities bilaterally.", [["lower extremities", "ANATOMY", 66, 83], ["weakness", "DISEASE", 50, 58], ["lower extremities", "ORGANISM_SUBDIVISION", 66, 83], ["severe weakness in her lower extremities bilaterally", "PROBLEM", 43, 95], ["severe", "OBSERVATION_MODIFIER", 43, 49], ["weakness", "OBSERVATION", 50, 58], ["lower extremities", "ANATOMY", 66, 83], ["bilaterally", "ANATOMY_MODIFIER", 84, 95]]], ["She began having difficulty with ambulation and standing, further stating that the numbness had ascended to the level of her abdomen and with associated symptoms of constipation and difficulty voiding.CASEInitial labs revealed a positive nasopharyngeal swab for SARS-CoV-2, serum lymphocytopenia, and mild elevation of her proinflammatory markers.", [["abdomen", "ANATOMY", 125, 132], ["nasopharyngeal swab", "ANATOMY", 238, 257], ["serum", "ANATOMY", 274, 279], ["numbness", "DISEASE", 83, 91], ["constipation", "DISEASE", 165, 177], ["lymphocytopenia", "DISEASE", 280, 295], ["abdomen", "ORGANISM_SUBDIVISION", 125, 132], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 262, 272], ["serum", "ORGANISM_SUBSTANCE", 274, 279], ["proinflammatory markers", "PROTEIN", 323, 346], ["SARS-CoV", "SPECIES", 262, 270], ["difficulty with ambulation", "PROBLEM", 17, 43], ["the numbness", "PROBLEM", 79, 91], ["associated symptoms", "PROBLEM", 142, 161], ["constipation", "PROBLEM", 165, 177], ["difficulty voiding", "PROBLEM", 182, 200], ["CASEInitial labs", "TEST", 201, 217], ["a positive nasopharyngeal swab", "PROBLEM", 227, 257], ["SARS", "PROBLEM", 262, 266], ["CoV", "TEST", 267, 270], ["serum lymphocytopenia", "PROBLEM", 274, 295], ["mild elevation of her proinflammatory markers", "PROBLEM", 301, 346], ["numbness", "OBSERVATION", 83, 91], ["abdomen", "ANATOMY", 125, 132], ["constipation", "OBSERVATION", 165, 177], ["nasopharyngeal", "ANATOMY", 238, 252], ["lymphocytopenia", "OBSERVATION", 280, 295], ["mild", "OBSERVATION_MODIFIER", 301, 305], ["elevation", "OBSERVATION_MODIFIER", 306, 315], ["proinflammatory markers", "OBSERVATION", 323, 346]]], ["On physical exam, she was noted to have bilateral upper extremity weakness graded 4/5, and bilateral lower extremity weakness graded 3/5.", [["extremity", "ANATOMY", 56, 65], ["lower extremity", "ANATOMY", 101, 116], ["upper extremity", "ORGANISM_SUBDIVISION", 50, 65], ["lower extremity", "ORGANISM_SUBDIVISION", 101, 116], ["physical exam", "TEST", 3, 16], ["bilateral upper extremity weakness", "PROBLEM", 40, 74], ["bilateral lower extremity weakness graded", "PROBLEM", 91, 132], ["bilateral", "ANATOMY_MODIFIER", 40, 49], ["upper extremity", "ANATOMY", 50, 65], ["weakness", "OBSERVATION", 66, 74], ["bilateral", "ANATOMY_MODIFIER", 91, 100], ["lower extremity", "ANATOMY", 101, 116], ["weakness", "OBSERVATION", 117, 125]]], ["Notably, she also had decreased ankle reflexes, with pathological extensor plantar responses bilaterally.", [["ankle", "ANATOMY", 32, 37], ["extensor plantar", "ANATOMY", 66, 82], ["decreased ankle reflexes", "DISEASE", 22, 46], ["ankle", "ORGANISM_SUBDIVISION", 32, 37], ["extensor plantar", "ORGANISM_SUBDIVISION", 66, 82], ["decreased ankle reflexes", "PROBLEM", 22, 46], ["decreased", "OBSERVATION_MODIFIER", 22, 31], ["ankle reflexes", "ANATOMY", 32, 46], ["extensor plantar", "ANATOMY", 66, 82], ["bilaterally", "ANATOMY_MODIFIER", 93, 104]]], ["Magnetic Resonance Imaging (MRI) with gadolinium of the cervico-thoraco-lumbar spine revealed extensive intramedullary disease throughout the entire length of the cervical spinal cord, with an ill-defined patchy hyperintense signal on the T2-weighted images with mild enlargement of the caliber of the cord without pathological contrast enhancement.", [["cervico-thoraco-lumbar spine", "ANATOMY", 56, 84], ["cervical spinal cord", "ANATOMY", 163, 183], ["cord", "ANATOMY", 302, 306], ["gadolinium", "CHEMICAL", 38, 48], ["gadolinium", "CHEMICAL", 38, 48], ["lumbar spine", "PATHOLOGICAL_FORMATION", 72, 84], ["cervical", "ORGAN", 163, 171], ["spinal cord", "ORGAN", 172, 183], ["cord", "ORGAN", 302, 306], ["Magnetic Resonance Imaging (MRI) with gadolinium of the cervico-thoraco-lumbar spine", "TEST", 0, 84], ["extensive intramedullary disease", "PROBLEM", 94, 126], ["an ill-defined patchy hyperintense signal", "PROBLEM", 190, 231], ["the T2-weighted images", "TEST", 235, 257], ["mild enlargement of the caliber of the cord", "PROBLEM", 263, 306], ["pathological contrast enhancement", "PROBLEM", 315, 348], ["lumbar spine", "ANATOMY", 72, 84], ["extensive", "OBSERVATION_MODIFIER", 94, 103], ["intramedullary disease", "OBSERVATION", 104, 126], ["entire", "ANATOMY_MODIFIER", 142, 148], ["length", "ANATOMY_MODIFIER", 149, 155], ["cervical spinal cord", "ANATOMY", 163, 183], ["ill", "OBSERVATION_MODIFIER", 193, 196], ["patchy", "OBSERVATION_MODIFIER", 205, 211], ["hyperintense", "OBSERVATION", 212, 224], ["mild", "OBSERVATION_MODIFIER", 263, 267], ["enlargement", "OBSERVATION", 268, 279], ["caliber", "OBSERVATION_MODIFIER", 287, 294], ["cord", "ANATOMY", 302, 306], ["without", "UNCERTAINTY", 307, 314], ["pathological", "OBSERVATION_MODIFIER", 315, 327], ["contrast enhancement", "OBSERVATION", 328, 348]]], ["Cerebrospinal fluid (CSF) analysis revealed elevated protein and albumin with a white-cell count of one per cubic millimeter, which were mature appearing lymphocytes on cytology.", [["Cerebrospinal fluid", "ANATOMY", 0, 19], ["white-cell", "ANATOMY", 80, 90], ["lymphocytes", "ANATOMY", 154, 165], ["Cerebrospinal fluid", "ORGANISM_SUBSTANCE", 0, 19], ["CSF", "ORGANISM_SUBSTANCE", 21, 24], ["albumin", "GENE_OR_GENE_PRODUCT", 65, 72], ["cell", "CELL", 86, 90], ["lymphocytes", "CELL", 154, 165], ["albumin", "PROTEIN", 65, 72], ["lymphocytes", "CELL_TYPE", 154, 165], ["Cerebrospinal fluid (CSF) analysis", "TEST", 0, 34], ["elevated protein", "PROBLEM", 44, 60], ["albumin", "TEST", 65, 72], ["a white-cell count", "TEST", 78, 96], ["cytology", "TEST", 169, 177], ["fluid", "OBSERVATION", 14, 19], ["elevated protein", "OBSERVATION", 44, 60], ["cubic millimeter", "OBSERVATION_MODIFIER", 108, 124], ["mature", "OBSERVATION_MODIFIER", 137, 143], ["appearing", "OBSERVATION_MODIFIER", 144, 153], ["lymphocytes", "OBSERVATION", 154, 165]]], ["The autoimmune encephalopathy panel was negative as well as a real-time polymerase-chain-reaction assay of the CSF for SARS-CoV-2.", [["autoimmune encephalopathy", "DISEASE", 4, 29], ["CSF", "GENE_OR_GENE_PRODUCT", 111, 114], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 119, 129], ["CSF", "PROTEIN", 111, 114], ["SARS-CoV", "SPECIES", 119, 127], ["The autoimmune encephalopathy panel", "TEST", 0, 35], ["the CSF", "TEST", 107, 114], ["SARS", "PROBLEM", 119, 123], ["CoV", "TEST", 124, 127], ["autoimmune", "OBSERVATION", 4, 14]]], ["Results of studies and additional laboratory findings are shown in Table 1.", [["studies", "TEST", 11, 18], ["additional laboratory findings", "TEST", 23, 53]]], ["Electromyography findings were consistent with a distal and motor, axonal-loss predominant, polyneuropathy impacting the lower extremities with evidence of ongoing active denervation.", [["axonal", "ANATOMY", 67, 73], ["lower extremities", "ANATOMY", 121, 138], ["axonal-loss", "DISEASE", 67, 78], ["polyneuropathy", "DISEASE", 92, 106], ["lower extremities", "ORGANISM_SUBDIVISION", 121, 138], ["Electromyography findings", "TEST", 0, 25], ["a distal and motor, axonal-loss predominant", "PROBLEM", 47, 90], ["polyneuropathy impacting the lower extremities", "PROBLEM", 92, 138], ["ongoing active denervation", "PROBLEM", 156, 182], ["consistent with", "UNCERTAINTY", 31, 46], ["distal", "OBSERVATION_MODIFIER", 49, 55], ["motor", "OBSERVATION_MODIFIER", 60, 65], ["axonal", "OBSERVATION_MODIFIER", 67, 73], ["loss", "OBSERVATION_MODIFIER", 74, 78], ["predominant", "OBSERVATION_MODIFIER", 79, 90], ["polyneuropathy", "OBSERVATION", 92, 106], ["lower extremities", "ANATOMY", 121, 138], ["evidence of", "UNCERTAINTY", 144, 155], ["ongoing", "OBSERVATION_MODIFIER", 156, 163], ["active", "OBSERVATION_MODIFIER", 164, 170], ["denervation", "OBSERVATION", 171, 182]]], ["There was sparing of all sensory nerves tested.", [["sensory nerves", "ANATOMY", 25, 39], ["sensory nerves", "MULTI-TISSUE_STRUCTURE", 25, 39], ["sparing", "OBSERVATION_MODIFIER", 10, 17], ["all", "ANATOMY_MODIFIER", 21, 24], ["sensory nerves", "ANATOMY", 25, 39]]], ["No evidence of demyelination was found.CASEThe patient received a five-day course of methylprednisolone with no improvement in her symptoms.", [["demyelination", "DISEASE", 15, 28], ["methylprednisolone", "CHEMICAL", 85, 103], ["methylprednisolone", "CHEMICAL", 85, 103], ["patient", "ORGANISM", 47, 54], ["methylprednisolone", "SIMPLE_CHEMICAL", 85, 103], ["patient", "SPECIES", 47, 54], ["demyelination", "PROBLEM", 15, 28], ["methylprednisolone", "TREATMENT", 85, 103], ["her symptoms", "PROBLEM", 127, 139], ["evidence of", "UNCERTAINTY", 3, 14], ["demyelination", "OBSERVATION", 15, 28]]], ["Her weakness continued to worsen at which point she underwent five sessions of plasmapheresis, with mild improvements.", [["Her weakness", "PROBLEM", 0, 12], ["plasmapheresis", "TREATMENT", 79, 93], ["weakness", "OBSERVATION", 4, 12], ["mild", "OBSERVATION_MODIFIER", 100, 104], ["improvements", "OBSERVATION", 105, 117]]], ["Prior to the plasma exchange therapy, she had repeated nasopharyngeal testing for SARS-CoV-2 that tested negative.", [["plasma", "ANATOMY", 13, 19], ["nasopharyngeal", "ANATOMY", 55, 69], ["SARS", "DISEASE", 82, 86], ["plasma", "ORGANISM_SUBSTANCE", 13, 19], ["nasopharyngeal", "ORGAN", 55, 69], ["SARS-CoV", "SPECIES", 82, 90], ["the plasma exchange therapy", "TREATMENT", 9, 36], ["repeated nasopharyngeal testing", "TEST", 46, 77], ["SARS", "PROBLEM", 82, 86], ["CoV", "TEST", 87, 90], ["nasopharyngeal", "ANATOMY", 55, 69]]], ["She also had a repeat lumbar puncture done for further CSF analysis which again showed no pleocytosis, elevated protein, and negative cultures (Table 1).", [["lumbar", "ANATOMY", 22, 28], ["pleocytosis", "DISEASE", 90, 101], ["CSF", "ORGANISM_SUBSTANCE", 55, 58], ["a repeat lumbar puncture", "TEST", 13, 37], ["further CSF analysis", "TEST", 47, 67], ["pleocytosis", "PROBLEM", 90, 101], ["elevated protein", "PROBLEM", 103, 119], ["lumbar", "ANATOMY", 22, 28], ["no", "UNCERTAINTY", 87, 89], ["pleocytosis", "OBSERVATION", 90, 101]]], ["She did not develop any respiratory decompensation throughout her hospitalization and subsequently was transitioned to inpatient rehabilitation.CASEUnfortunately, the patient is still undergoing inpatient physical rehabilitation, requiring an intensive degree of interdisciplinary therapies.", [["respiratory", "ANATOMY", 24, 35], ["respiratory decompensation", "DISEASE", 24, 50], ["patient", "ORGANISM", 167, 174], ["patient", "SPECIES", 167, 174], ["any respiratory decompensation", "PROBLEM", 20, 50], ["inpatient rehabilitation", "TREATMENT", 119, 143], ["inpatient physical rehabilitation", "TREATMENT", 195, 228], ["interdisciplinary therapies", "TREATMENT", 263, 290], ["respiratory", "ANATOMY", 24, 35], ["decompensation", "OBSERVATION", 36, 50]]], ["She is suffering paraplegia, neurogenic bladder, and subsequent impairments in mobility and the ability to complete activities of daily living.", [["neurogenic bladder", "ANATOMY", 29, 47], ["paraplegia", "DISEASE", 17, 27], ["neurogenic bladder", "DISEASE", 29, 47], ["bladder", "ORGAN", 40, 47], ["paraplegia", "PROBLEM", 17, 27], ["neurogenic bladder", "PROBLEM", 29, 47], ["subsequent impairments in mobility", "PROBLEM", 53, 87], ["paraplegia", "OBSERVATION", 17, 27], ["neurogenic", "OBSERVATION", 29, 39], ["bladder", "ANATOMY", 40, 47]]], ["However, she has significant improvement in her sensation and fewer muscle spasms are appreciated.", [["muscle", "ANATOMY", 68, 74], ["muscle spasms", "DISEASE", 68, 81], ["muscle", "ORGAN", 68, 74], ["her sensation", "PROBLEM", 44, 57], ["fewer muscle spasms", "PROBLEM", 62, 81], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["improvement", "OBSERVATION_MODIFIER", 29, 40], ["muscle", "ANATOMY", 68, 74], ["spasms", "OBSERVATION", 75, 81]]], ["She continues to receive three hours of therapy daily, five days per week.DISCUSSIONInflammation of the spinal cord, otherwise known as transverse myelitis, has been well documented as a result of viral infections, bacterial infections, and immune system disorders [4].", [["spinal cord", "ANATOMY", 104, 115], ["immune system", "ANATOMY", 241, 254], ["transverse myelitis", "DISEASE", 136, 155], ["viral infections", "DISEASE", 197, 213], ["bacterial infections", "DISEASE", 215, 235], ["immune system disorders", "DISEASE", 241, 264], ["spinal cord", "ORGAN", 104, 115], ["therapy", "TREATMENT", 40, 47], ["DISCUSSIONInflammation of the spinal cord", "PROBLEM", 74, 115], ["transverse myelitis", "PROBLEM", 136, 155], ["viral infections", "PROBLEM", 197, 213], ["bacterial infections", "PROBLEM", 215, 235], ["immune system disorders", "PROBLEM", 241, 264], ["spinal cord", "ANATOMY", 104, 115], ["transverse", "OBSERVATION_MODIFIER", 136, 146], ["myelitis", "OBSERVATION", 147, 155], ["viral", "OBSERVATION_MODIFIER", 197, 202], ["infections", "OBSERVATION", 203, 213], ["bacterial infections", "OBSERVATION", 215, 235]]], ["There is no cure for transverse myelitis.", [["myelitis", "DISEASE", 32, 40], ["transverse myelitis", "PROBLEM", 21, 40], ["no cure for", "UNCERTAINTY", 9, 20], ["transverse", "OBSERVATION_MODIFIER", 21, 31], ["myelitis", "OBSERVATION", 32, 40]]], ["Typical treatments are only aimed at preventing or minimizing permanent neurological deficits.", [["neurological", "ANATOMY", 72, 84], ["neurological deficits", "DISEASE", 72, 93], ["Typical treatments", "TREATMENT", 0, 18], ["minimizing permanent neurological deficits", "PROBLEM", 51, 93]]], ["These treatments include corticosteroid and other therapies that suppress the immune system, such as plasmapheresis if there is poor response to initial treatment.", [["immune system", "ANATOMY", 78, 91], ["corticosteroid", "SIMPLE_CHEMICAL", 25, 39], ["These treatments", "TREATMENT", 0, 16], ["corticosteroid", "TREATMENT", 25, 39], ["other therapies", "TREATMENT", 44, 59], ["the immune system", "TREATMENT", 74, 91], ["plasmapheresis", "TREATMENT", 101, 115], ["initial treatment", "TREATMENT", 145, 162]]], ["Most patients partially recover within three months to two years after initial diagnosis.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13]]], ["Some degree of disability may remain, but physical therapy has been shown to improve outcomes.", [["disability", "DISEASE", 15, 25], ["disability", "PROBLEM", 15, 25], ["physical therapy", "TREATMENT", 42, 58], ["degree", "OBSERVATION_MODIFIER", 5, 11], ["disability", "OBSERVATION", 15, 25]]], ["Scattered reports since the 1980s have suggested certain coronavirus genotypes, which include SARS-CoV in 2003, have neurotropic properties, and sometimes neurologically devastating results such as encephalomyelitis, Guillain-Barre, seizure, and loss of neurofunctional status [5].", [["SARS-CoV", "DISEASE", 94, 102], ["encephalomyelitis", "DISEASE", 198, 215], ["Guillain-Barre, seizure", "DISEASE", 217, 240], ["coronavirus", "ORGANISM", 57, 68], ["SARS-CoV", "ORGANISM", 94, 102], ["SARS-CoV", "SPECIES", 94, 102], ["certain coronavirus genotypes", "PROBLEM", 49, 78], ["SARS", "PROBLEM", 94, 98], ["encephalomyelitis", "PROBLEM", 198, 215], ["seizure", "PROBLEM", 233, 240], ["loss of neurofunctional status", "PROBLEM", 246, 276]]], ["The first case of SARS-CoV-2 causing acute myelitis was published in March 2020 from a center in Wuhan, China where the outbreak first began, and the second case being reported April 2020 from Harvard [6, 7].", [["SARS", "DISEASE", 18, 22], ["acute myelitis", "DISEASE", 37, 51], ["SARS-CoV-2", "ORGANISM", 18, 28], ["SARS-CoV", "SPECIES", 18, 26], ["SARS", "PROBLEM", 18, 22], ["acute myelitis", "PROBLEM", 37, 51], ["acute", "OBSERVATION_MODIFIER", 37, 42], ["myelitis", "OBSERVATION", 43, 51]]], ["Some ways by which our case differs is that our patient was afebrile throughout her presentation and course, never developed flaccid paralysis or respiratory distress, and symptoms progressed to urinary/fecal incontinence.", [["flaccid", "ANATOMY", 125, 132], ["respiratory", "ANATOMY", 146, 157], ["urinary", "ANATOMY", 195, 202], ["fecal", "ANATOMY", 203, 208], ["flaccid paralysis", "DISEASE", 125, 142], ["respiratory distress", "DISEASE", 146, 166], ["urinary/fecal incontinence", "DISEASE", 195, 221], ["patient", "ORGANISM", 48, 55], ["urinary", "ORGANISM_SUBDIVISION", 195, 202], ["fecal", "ORGANISM_SUBSTANCE", 203, 208], ["patient", "SPECIES", 48, 55], ["afebrile", "PROBLEM", 60, 68], ["flaccid paralysis", "PROBLEM", 125, 142], ["respiratory distress", "PROBLEM", 146, 166], ["symptoms", "PROBLEM", 172, 180], ["urinary/fecal incontinence", "PROBLEM", 195, 221], ["flaccid", "OBSERVATION_MODIFIER", 125, 132], ["paralysis", "OBSERVATION", 133, 142], ["respiratory distress", "OBSERVATION", 146, 166], ["urinary", "ANATOMY", 195, 202], ["fecal", "ANATOMY", 203, 208], ["incontinence", "OBSERVATION", 209, 221]]], ["This is important to highlight the atypical presentations of Covid-19.", [["Covid", "TEST", 61, 66], ["atypical", "OBSERVATION_MODIFIER", 35, 43]]], ["It is also worth noting that the first case and the recently reported cases of Guillain\u2013Barr\u00e9 syndrome due to SARS-CoV-2, have all had negative polymerase-chain-reaction assay of the CSF for SARS-CoV-2 [3].", [["Guillain\u2013Barr\u00e9 syndrome", "DISEASE", 79, 102], ["SARS", "DISEASE", 110, 114], ["Guillain\u2013Barr\u00e9", "ORGANISM", 79, 93], ["SARS-CoV-2", "ORGANISM", 110, 120], ["CSF", "GENE_OR_GENE_PRODUCT", 183, 186], ["CSF", "PROTEIN", 183, 186], ["SARS-CoV", "SPECIES", 110, 118], ["SARS-CoV", "SPECIES", 191, 199], ["Guillain\u2013Barr\u00e9 syndrome", "PROBLEM", 79, 102], ["SARS", "PROBLEM", 110, 114], ["CoV", "TEST", 115, 118], ["the CSF", "TEST", 179, 186], ["SARS", "PROBLEM", 191, 195], ["CoV", "TEST", 196, 199]]], ["Although the CSF studies in this patient indicated a pathology such as atypical Guillain\u2013Barr\u00e9 syndrome, the MRI studies revealed the true pathological process at hand (Figure 1).", [["hand", "ANATOMY", 163, 167], ["Guillain\u2013Barr\u00e9 syndrome", "DISEASE", 80, 103], ["CSF", "GENE_OR_GENE_PRODUCT", 13, 16], ["patient", "ORGANISM", 33, 40], ["hand", "ORGANISM_SUBDIVISION", 163, 167], ["patient", "SPECIES", 33, 40], ["the CSF studies", "TEST", 9, 24], ["a pathology", "TEST", 51, 62], ["atypical Guillain\u2013Barr\u00e9 syndrome", "PROBLEM", 71, 103], ["the MRI studies", "TEST", 105, 120], ["the true pathological process", "PROBLEM", 130, 159], ["Barr\u00e9 syndrome", "OBSERVATION", 89, 103]]], ["One proposed mechanism for the neurologic disease has been the presence of ACE2 receptors that are expressed on the membrane of spinal cord neurons [6].", [["neurologic", "ANATOMY", 31, 41], ["membrane", "ANATOMY", 116, 124], ["spinal cord neurons", "ANATOMY", 128, 147], ["neurologic disease", "DISEASE", 31, 49], ["ACE2", "GENE_OR_GENE_PRODUCT", 75, 79], ["membrane", "CELLULAR_COMPONENT", 116, 124], ["spinal cord neurons", "CELL", 128, 147], ["ACE2 receptors", "PROTEIN", 75, 89], ["spinal cord neurons", "CELL_TYPE", 128, 147], ["the neurologic disease", "PROBLEM", 27, 49], ["ACE2 receptors", "PROBLEM", 75, 89], ["mechanism for", "UNCERTAINTY", 13, 26], ["spinal cord", "ANATOMY", 128, 139]]], ["There is a need for more evidence to understand the pathogenesis and subsequent neurological sequelae of active or recent infections with SARS-CoV-2.CONCLUSIONThis case demonstrates the importance of keeping a broad differential at a time when the body of evidence regarding Covid-19 continues to grow.", [["neurological", "ANATOMY", 80, 92], ["infections", "DISEASE", 122, 132], ["the pathogenesis", "PROBLEM", 48, 64], ["recent infections", "PROBLEM", 115, 132], ["Covid", "TEST", 275, 280], ["active", "OBSERVATION_MODIFIER", 105, 111], ["infections", "OBSERVATION", 122, 132]]], ["While we learn more about the pandemic caused by SARS-CoV-2, we must be vigilant of the critical neurological illnesses that could be affecting our patients.CONSENTPatient provided written consent for the case study per the institutions Research Compliance Office.", [["neurological", "ANATOMY", 97, 109], ["SARS", "DISEASE", 49, 53], ["neurological illnesses", "DISEASE", 97, 119], ["SARS-CoV-2", "ORGANISM", 49, 59], ["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 148, 156], ["SARS-CoV", "SPECIES", 49, 57], ["the critical neurological illnesses", "PROBLEM", 84, 119], ["the case study", "TEST", 201, 215]]]], "9303dfc17a994c50b072843fd0ead25f16545722": [["Since its detection in China in December 2019, coronavirus disease 2019 (COVID-19) rapidly spread throughout the world becoming a Public Health Emergency of International Concern.", [["coronavirus disease", "DISEASE", 47, 66], ["COVID-19", "CHEMICAL", 73, 81], ["coronavirus disease", "PROBLEM", 47, 66], ["COVID", "TEST", 73, 78], ["coronavirus disease", "OBSERVATION", 47, 66]]], ["On February 21, 2020, the first case of COVID-19 had been reported in Northern Italy (Codogno, Lombardy), becoming the beginning of the COVID-19 pandemic and humanitarian crises in Italy.", [["pandemic", "DISEASE", 145, 153], ["COVID", "TEST", 40, 45]]], ["The COVID-19 outbreak in Northern Italy has been the cause of the healthcare system crisis with a massive influx of patients to the Emergency Departments, particularly in Piacenza due to its proximity to Codogno.", [["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 116, 124], ["The COVID", "TEST", 0, 9], ["massive", "OBSERVATION_MODIFIER", 98, 105], ["influx", "OBSERVATION_MODIFIER", 106, 112]]], ["In few days, the COVID-19 epidemic paralysed our public health system and hospital organization, becoming a challenge for our Emergency Department.", [["the COVID", "TEST", 13, 22]]], ["At the beginning of the Italian COVID-19 outbreak, we based the suspicion of COVID-19 infection upon the epidemiological risk: the exposure to confirmed COVID-19 case or prolonged contact with people in the geographical area with confirmed COVID-19 cases in the past 14 days.", [["infection", "DISEASE", 86, 95], ["people", "ORGANISM", 193, 199], ["people", "SPECIES", 193, 199], ["COVID-19 infection", "PROBLEM", 77, 95], ["infection", "OBSERVATION", 86, 95]]], ["Unfortunately, with the global and severe spread of COVID-19 and the dramatically increased number of infected patients in Piacenza, despite being a relatively small city, our hospital became one of the epicentres of the Italian epidemic with 2276 cases and 447 deaths at this moment.", [["deaths", "DISEASE", 262, 268], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["COVID", "TEST", 52, 57], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["spread", "OBSERVATION_MODIFIER", 42, 48], ["dramatically", "OBSERVATION_MODIFIER", 69, 81], ["increased", "OBSERVATION_MODIFIER", 82, 91], ["number", "OBSERVATION_MODIFIER", 92, 98], ["infected", "OBSERVATION_MODIFIER", 102, 110], ["relatively", "OBSERVATION_MODIFIER", 149, 159], ["small", "OBSERVATION_MODIFIER", 160, 165]]], ["The situation quickly turned critically with overcrowded Emergency Department and Intensive Care Unit, nearing collapse.", [["nearing collapse", "PROBLEM", 103, 119], ["collapse", "OBSERVATION", 111, 119]]], ["As consequence, our own hospital became a quite totally dedicated COVID-19 hospital with 80% of beds reserved for ill COVID-19 patients.", [["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 127, 135]]], ["We felt deeply concerned both by the alarming levels of spread and severity, and by the number of critically ill patients who required an immediate hospitalization in the Intensive Care Unit.", [["critically ill", "DISEASE", 98, 112], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121]]], ["To avoid the complete collapse of our healthcare system because of the lack of expertise in epidemics and the presence of limited human resources, we needed to change our perspectives and develop a long-term plan against catastrophic consequences to warrant a \"COVID-19-free way\" in the Emergency Room and prevent COVID-19 spread in \"COVID-19-free wards\" in our hospital.", [["human", "ORGANISM", 130, 135], ["human", "SPECIES", 130, 135], ["human", "SPECIES", 130, 135], ["catastrophic consequences", "PROBLEM", 221, 246], ["a \"COVID", "TREATMENT", 258, 266], ["COVID", "TEST", 314, 319], ["collapse", "OBSERVATION", 22, 30]]]]}